Journal of Pharmaceutical Sciences

A publication of the American Pharmaceutical Association

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 61
JANUARY TO DECEMBER, 1972

Published monthly under the supervision of the Committee on Publications with the approval of the Board of Trustees

EDWARD G. FELDMANN
Editor

MARY H. FERGUSON
Associate Editor

SHELLY ELLIOTT
Production Editor

CHRISTINE L. BAILEY
Contributing Editor

L. LUAN CORRIGAN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

COMMITTEE ON PUBLICATIONS

CHARLES F. DAHL
Chairman
WILLIAM S. APPLE
GROVER C. BOWLES, JR.
RALPH S. LEVI
KENNETH E. TIEMANN

EDITORIAL ADVISORY BOARD

LYNN R. BRADY
RAYMOND E. COUNSELL
GERHARD LEVY
CARL J. LINTNER, JR.
G. VICTOR ROSSI
EUGENE E. VOGIN

© Copyright 1972 by the American Pharmaceutical Association

AUTHOR INDEX

A

Abate, K., *see* Schulman, S. G., 1576
Aboul-Enein, M. N., Morgan, L., and Sam, J., piperidinecarboxamides with potential CNS and cardiovascular properties, 127
Abraham, D. J., *see* Messmer, W. M., 1858
——*see* Tin-Wa, M., 1846
Abruzzo, C. W., *see* Kaplan, S. A., 773
Acel, K., *see* Tuckerman, M. M., 448
Adams, H. J., Kronberg, G. H., and Takman, B. H., local anesthetic activity and acute toxicity of (±)-2-(*N*-ethylpropylamino)-2′,6′-butyroxylidide, a new long-acting agent, 1829
Agarwal, S. P., Walash, M. I., and Blake, M. I., spectrophotometric titration of sulfonamides with bromate–bromide solution, 779
——*see* Walash, M. I., 277
Ahuja, S., *see* Spiegel, D., 1630
Adam, A. S., and Parrott, E. L., effect of adjuvants on tackiness of polyvinylpyrrolidone film coating, 265
Ali, B., *see* Parmar, S. S., 179, 1366
Alkalay, D., Khemani, L., and Bartlett, M. F., spectrophotofluorometric determination of methyltestosterone in plasma or serum, 1746
Allen, D. J., DeMarco, J. D., and Kwan, K. C., free films I: apparatus and preliminary evaluation, 106
Allen, D. R., *see* Nelson, W. L., 1640
Allen, J. E., *see* Levy, G., 143
Allen, L. M., and Creaven, P. J., effect of microsomal activation on interaction between isophosphamide and DNA, 2009
Allen, R. C., *see* Cammarata, A., 1670
Allwardt, W. H., Babcock, P. A., Segelman, A. B., and Cross, J. M., photochemical studies of marijuana (Cannabis) constituents, 1994
Altman, R. E., Jr., and Honigberg, I. L., dicinnamides as potential hypocholesterolemic agents, 610
Alton, M., *see* Pitman, I. H., 918
Amann, A. H., *see* Swarbrick, J., 1645
Ambrogi, V., Bloch, K., Daturi, S., Logemann, W., and Parenti, M. A., synthesis of pyrazine derivatives as potential hypoglycemic agents, 1483
Amidon, G. L., *see* Yalkowsky, S. H., 983
Amsel, L. P., and Davison, C., simultaneous metabolism of aspirin and acetaminophen in man, 1474
Amshey, J. W., Jr., *see* Steinberg, G. M., 1735
Anderson, L. J., *see* Kandeel, E. M., 1231
Andrews, P. R., binding of CNS active drugs to the peptide bond: a model system and mode of action hypothesis, 1717
Anuforo, D. C., *see* Lee, K. H., 626
Appelt, G. D., *see* Kosh, J. W., 1963
——*see* Reyes, E., 562
Araujo, O. E., thixotropy measured using a weight-actuated viscometer, 1848
Arison, B. H., *see* Smith, G. B., 708
Arora, V., *see* Garg, H. G., 130
Arret, B., *see* Rippere, R. A., 449
Arrigoni, E., *see* Benzi, G., 348
Ary, T. E., *see* Galpin, D. R., 963
Aszalos, A., Kirschbaum, J., Ratych, O. T., Kraemer, N., Kocy, O., Frost, D., and Casey, J. P., reversible dissociation of L-asparaginase of *Escherichia coli* B, 791
Atwell, L., *see* Perrine, T. D., 86
Auen, E., *see* Windheuser, J. J., 301
Augustine, M. A., and Swarbrick, J., correlations between *in vitro* transport in a three-phase model cell and *in vivo* absorption of a series of sulfanilamides, 1656
Autian, J., *see* Hung, G. W. C., 1094
——*see* Lawrence, W. H., 19, 1712
——*see* Nasim, K., 1775
——*see* Serota, D. G., 416
——*see* Singh, A. R., 51
Awataguchi, M., *see* Naito, S.-I., 198
Axelson, J. E., and Gibaldi, M., absorption and excretion of riboflavin in the rat: an unusual example of nonlinear pharmacokinetics, 404
Aynehchi, Y., Mojtabaii, M., and Yazdizadeh, K., chemical examination of *Euphorbia myrsinitis* Linn., 292
Aynilian, G., Farnsworth, N. R., Lyon, R. L., and Fong, H. H. S., Catharanthus alkaloids XXVI: isolation of cathanneine, a new alkaloid from *Catharanthus lanceus*, 298

B

Babcock, P. A., *see* Allwardt, W. H., 1994
Back, N., *see* Finnegan, R. A., 1599
Backer, R. C., Bianchi, E., and Cole, J. R., a phytochemical investigation of *Yucca schottii* (Liliaceae), 1665
Badawi, M. A., *see* Nabih, I., 1500
Baer, J. E., role of drug metabolism in drug research and development: basic considerations, 1674
Bafna, S. L., Patel, D. J., and Mehta, J. D., separation of ascorbic acid and 2-keto-L-gulonic acid, 1333
Bailey, K., and Verner, D., correlation between potency and UV spectra of hallucinogenic amphetamines, 480
Baker, S. A., *see* Reda, F., 1970
Baker, T., *see* Notari, R. E., 244
Banker, G. S., *see* Woodruff, C. W., 1916, 1956
Bansal, P., *see* Repta, A. J., 1069
Barile, R. G., *see* Smolen, V. F., 467
Barry, B. W., and Grace, A. J., sensory testing of spreadability: investigation of rheological conditions operative during application of topical preparations, 335
——and Russell, G. F. J., interaction of amaranth with some alkyltrimethylammonium salts: a coacervation phenomenon, 502
Barry, H., III, Marcus, F., and Colaizzi, J. L., value of repeated tests in a percutaneous absorption study, 172
——*see* Krimmer, E. C., 1611
——*see* Kubena, R. K., 144
——*see* Lucarotti, R. L., 903
Bartholomay, A. C., *see* Cressman, W. A., 1170
Bartlett, M. F., *see* Alkalay, D., 1746
Batchelder, M., Tarlin, H. I., and Williamson, G., chromatographic separation and determination of methyl *p*-hydroxybenzoate, 252
Bates, T. R., *see* Johns, W. H., 730, 735
——*see* Stupak, E. I., 400
Bauduin, H., *see* Vanhaelen, M., 1165
Bavitz, J. F., *see* Rosolia, A. M., 1638
Beal, D. K., *see* McChesney, J. D., 310
Belote, J., *see* Manley, E. S., Jr., 1401
Benedict, R. G., and Brady, L. R., antimicrobial activity of mushroom metabolites, 1820
——*see* Brady, L. R., 318
Benet, L. Z., general treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics, 536
Benzi, G., De Bernardi, M., Manzo, L., Ferrara, A., Panceri, P., Arrigoni, E., and Berté, F., effect of lysergide and nimergoline on glucose metabolism investigated on the dog brain isolated *in situ*, 348
Bercz, C. V., and Ice, R. D., synthesis of 1-carbethoxy-4-cyano-4-phenylpiperidine, 1316
Berkowitz, L. M., *see* Steinberg, G. M., 527
Bernardo, P. D., *see* Shami, E. G., 1318
Bertagni, P., Marcucci, F., Mussini, E., and Garattini, S., biliary excretion of conjugated hydroxyl benzodiazepines after administration of several benzodiazepines to rats, guinea pigs, and mice, 965
Berté, F., *see* Benzi, G., 348
Bevelle, C., *see* Messmer, W. M., 1858
Bhansali, K. G., use of 1-nitroso-2-naphthol in quantitative determination of medicinal phenolic compounds, 146
Bhargava, H. B., *see* Tsai, C. S., 228
Bhattacharya, S. K., Ghosal, S., Chaudhuri, R. K., and Sanyal, A. K., *Canscora decussata* (Gentianaceae) xanthones III: pharmacological studies, 1838
——*see* Ghosal, S., 808, 1274
Bhatti, M., *see* Bhatti, W., 307
Bhatti, W., Bhatti, M., Imbler, P., Lee, A., and Lorenzen, B., preparation of pure *meso*-tetraphenylporphine and two derivatives, 307
——*see* Fong, H. H. S., 1818
Bianchi, E., *see* Backer, R. C., 1665
Biandrate, P., *see* Frigerio, A., 1144
Bican-Fister, T., *see* Tuckerman, M. M., 448
Biggs, D. F., Coutts, R. T., Selley, M. L., and Towill, G. A., potential hypotensive compounds: substituted 3-aminopropionates and 3-aminoproplonohydroxamic acids, 1739
Billow, J., *see* Tuckerman, M. M., 448
Birner, J., determination of *p*-hydroxyphenoxyacetic acid in phenoxymethyl penicillin fermentations, 933
Bishara, R. H., Born, G. S., and Christian, J. E., radiotracer distribution and excretion study of chlorophenothane in rats, 1912
Blake, M. I., *see* Agarwal, S. P., 779
Blank, M. L., *see* Piantadosi, C., 607
Blaug, S. M., and Hajratwala, B., kinetics of aerobic oxidation of ascorbic acid, 556
——and Huang, W.-T., interaction of dextroamphetamine sulfate with spray-dried lactose, 1770
Bloch, K., *see* Ambrogi, V., 1483
Block, J. H., *see* Kandeel, E. M., 1231
Blois, D. W., and Swarbrick, J., interaction of quaternary ammonium bactericides with biological materials I: conductometric studies with cephalin, 390
——and Swarbrick, J., interaction of quaternary ammonium bactericides with biological materials II: insoluble monolayer studies, 393
Blount, J. F., *see* Shefter, E., 872
Blum, K., *see* Wallace, J. E., 1397
Bobbink, S. R., *see* Galpin, D. R., 963
Bobrin, L. J., *see* Sinsheimer, J. E., 314
Bodin, J. I., *see* Rabinowitz, M. P., 1974
Bonardi, G., *see* Coppi, G., 1460
Boost, G., *see* Runkel, R., 703
Bopp, R. J., Murphy, H. W., Nash, J. F., and Novotny, C. R., GLC determination of chlormadinone acetate in plasma, 1441
——Schirmer, R. E., and Meyers, D. B., determination of mycophenolic acid and its glucuronide metabolite in plasma, 1750
Boreham, D. R., Cummings, A. J., Dell, D., and Martin, B. K., elimination of 4-*n*-butoxyphenylacethydroxamic acid (bufexamac) in man, 164
Born, G. S., *see* Bishara, R. H., 1912
——*see* Larsen, R. V., 2004
Bottari, F., Giannaccini, B., Nannipieri, E., and Sacttone, M. F., thermal dissociation of sulfonylureas II: dissociation of four *N*- and *N′*-substituted sulfonylureas in different media, 602
Bouche, R., anthraquinone, a new chemical oxidation product of amitriptyline, 986
Boughton, O. D., Brown, R. D., Bryant, R., Burger, F. J., and Combs, C. M., assay of cyclophosphamide, 97
Bowman, F. W., Knoll, E. W., White, M., and Mislivec, P., survey of microbial contamination of ophthalmic ointments, 532
Bradshaw, J. W., Rhodes, C. T., and Richardson, G., effect of nonionic surfactant on bactericidal activity of cetylpyridinium chloride, 1163
Brady, L. R., and Benedict, R. G., occurrence of bisnoryangonin in *Pholiota squarrosoadiposa*, 318
——*see* Benedict, R. G., 1820
Brake, N. W., *see* Fike, W. W., 615
Braude, M. C., *see* Rosenkrantz, H., 1106
Braun, R. J., and Parrott, E. L., effect of various parameters upon diffusion-con-

trolled dissolution of benzoic acid, 592
——and Parrott, E. L., influence of viscosity and solubilization on dissolution rate, 175
Brennan, T. F., *see* Shefter, E., 872
Brenner, G. S., *see* Smith, G. B., 708
Brochmann-Hanssen, E., opium alkaloids XII: quantitative determination of morphine in opium by isotope dilution, 1118
Brofazi, F. R., *see* Spiegel, D., 1630
Brown, L. W., and Forist, A. A., *in vitro* and *in vivo* hydrolysis of salicylanilide *N*-methylcarbamate and 4-biphenylyl *N*-methylcarbamate, 858
Brown, R. D., *see* Boughton, O. D., 97
Brown, R. G., *see* Reed, F. D., Jr., 1571
Brusco, D., *see* Maulding, H. V., 1197
——*see* Turi, P., 1811
Bryant, R., *see* Boughton, O. D., 97
Bubeva-Ivanova, L., *see* Zheleva, A., 1643
Buckley, J. P., physiological effects of environmental stimuli, 1175
——*see* Krimmer, E. C., 1611
——*see* Tadepalli, A. S., 1844
Burch, H. A., *see* Schwan, T. J., 1506
Burckhalter, J. H., *see* De Leenheer, A., 273, 1659
Burger, F. J., *see* Boughton, O. D., 97
Burkman, A. M., and Cannon, J. G., screening nornuciferine derivatives for apomorphine-like activity, 813
Burks, T. F., nonspecific intestinal spasmolytic actions of a piperazine antimalarial drug, 482
Byrd, B. G., *see* Frank, S. G., 1762

C

Cadwallader, D. E., *see* Javaid, K. A., 1370
——*see* Underwood, T. W., 239
Caldwell, H. C., and Westlake, W. J., magnesium lauryl sulfate—soluble lubricant, 984
Cammarata, A., and Allen, R. C., conformational stabilization by *o*-methyl groups of a sulfanilamide, 1670
——and Yau, S. J., molecular estimates for molar attraction constants, 723
Cammarato, L. V., *see* Willette, R. E., 122
Campisi, J., *see* Gruber, M. P., 1147
Cannon, J. G., *see* Burkman, A. M., 813
Carpenter, O. S., *see* Flynn, G. L., 312
Carrano, R. A., and Malbica, J. O., primary screening approach for anti-inflammatory agents utilizing an *in vivo* and a new *in vitro* method, 1450
Carstensen, J. T., and Musa, M. N., decomposition of benzoic acid derivatives in solid state, 1112
——and Musa, M. N., dissolution rate patterns of log-normally distributed powders, 223
——and Su, K. S. E., solvation of montmorillonite, 139
——Stremming, K. P., and Pothisiri, P., sedimentation kinetics of flocculated suspensions III: effect of ζ-potential, 1999
——*see* McVean, D. E., 1609
——*see* Steiner, G., 2009
——*see* Su, K. S. E., 420
Casey, J. P., *see* Aszalos, A., 791
Cereijido, M., *see* Vilallonga, F. A., 1720
Chae, K., *see* Piantadosi, C., 971
Chafetz, L., Tsilifonis, D. C., and Riedl, J. M., facile differential UV determination of steroids with conjugated ketone chromophores *via* lithium borohydride reduction, 148
——*see* Daly, R. E., 927
Chalvet, O., *see* Peradejordi, F., 909
Chaplin, M., *see* Runkel, R., 703
Charles, R. L., *see* Valentine, J. L., 796
Chasin, M., *see* Weinryb, I., 1556
Chaturvedi, A. K., Chaudhari, A., and Parmar, S. S., substituted 3,4,5-trimethoxybenzamides: correlation between inhibition of pyruvic acid oxidation and anticonvulsant activity, 1157
——*see* Parmar, S. S., 78
Chaudhari, A., *see* Chaturvedi, A. K., 1157
——*see* Parmar, S. S., 78, 1322
Chaudhuri, R. K., *see* Bhattacharya, S. K., 1838
Chaudry, I. A., and King, R. E., migration of potent drugs in wet granulations, 1121
Chen, C.-H., and Soine, T. O., synthesis and NMR spectral characteristics of bisnorargemonine isomers, 55
Cheng, C. C., inhibitors of t-RNA *O*-methyltransferase as possible antineoplastic agents, 645
——and Zee-Cheng, K.-Y., some antineoplastic antibiotics, 485
——*see* Zee-Cheng, K.-Y., 969
Chin, M. L., *see* Notari, R. E., 1189
Chmielewicz, Z. F., *see* Shefter, E., 872
Choulis, N. H., conductimetric studies of interactions of optically active ions I: interactions of amphetamine with mandelic and tartaric acids, 293
——examination of molecular associations *via* thin-layer electrophoresis II: interactions of amphetamine isomers with optically active and racemic acids, 1325
——*see* Tryfiates, G. P., 465
Chow, Y. P., and Repta, A. J., complexation of acetaminophen with methyl xanthines, 1454
Christenson, G. L., *see* McVean, D. E., 1609
Christenson, K., *see* Shearer, C. M., 1627
Christian, J. E., *see* Bishara, R. H., 1912
——*see* Larsen, R. V., 2004
——*see* Morris, C. H., 815
Chu-Fong, I., *see* Lau-Cam, C. A., 1303
Chun, A. H. C., *see* Wiegand, R. G., 425
Cihonski, C. D., *see* Siuda, J. F., 1856
Clark, M. L., *see* Kaul, P. N., 581, 1753
Clarke, F. H., role of drug metabolism in drug research and development: view of a medicinal chemist, 1678
Coffey, J. J., effects of protein binding of drugs on areas under plasma concentration–time curves, 138
Cohen, P., *see* O'Neill, H. J., 863, 1292
Colaizzi, J. L., *see* Barry, H., III, 172
——*see* Lucarotti, R. L., 903
Cole, E. T., *see* Rees, J. E., 1313
Cole, J. R., *see* Backer, R. C., 1665
——*see* McDoniel, P. B., 1992
——*see* Sheth, K., 1819
Combs, C. M., *see* Boughton, O. D., 97
Cometti, A., *see* Maggi, N., 924
Connors, K. A., *see* Munson, J. W., 211
Conway, M. W., *see* Kaul, P. N., 581
Cooke, G. G., *see* Schirmer, R. E., 428
Cooper, J., and Rees, J. E., tableting research and technology, 1511
Coppi, G., Vidi, A., and Bonardi, G., quantitative determination of D-dopa present in levodopa samples, 1460
Cornish, H. H., *see* Rao, G. S., 1822
Cosyns, L., *see* Kraml, M., 408
Cotler, S., *see* Kaplan, S. A., 1361
Coutts, R. T., *see* Biggs, D. F., 1739
Craine, E. M., and Ray, W. H., metabolites of furazolidone in urine of chickens, 1495
Creaven, P. J., *see* Allen, L. M., 2009
Cressman, W. A., Renzi, N. L., and Bartholomay, A. C., effect of volume of distribution on plasma levels of total radioactivity, 1170
Crevar, G. E., Wilken, L. O., Jr., Mora, E. C., and Daron, H. H., analyses of *Ludwigia alternifolia* L. for fatty acids, 1336
Cross, J. M., *see* Allwardt, W. H., 1994
Crouthamel, W. G., *see* Kojima, S., 1061
Cummings, A. J., *see* Boreham, D. R., 164

D

Dagcioglu, M., *see* Sadée, W., 1126
Daly, R. E., Moran, C., and Chafetz, L., acetaminophen colorimetry as 2-nitro-4-acetamidophenol, 927
Daron, H. H., *see* Crevar, G. E., 1336
Daturi, S., *see* Ambrogi, V., 1483
Daudel, R., *see* Peradejordi, F., 909
Davies, W. L., and Gloor, W. T., Jr., batch production of pharmaceutical granulations in a fluidized bed II: effects of various binders and their concentrations on granulations and compressed tablets, 618
Davis, S. S., *see* Rytting, J. H., 816
Davison, C., *see* Amsel, L. P., 1474
Dayal, S., *see* Higuchi, T., 695
Dearden, J. C., nature of acetaminophen–antipyrine complex, 1661
De Bernardi, M., *see* Benzi, G., 348
De Fabrizio, F., assay procedure for spectrophotometric determination of dextroamphetamine sulfate and amobarbital formulated into timed-release capsules, 101
De Leenheer, A., and Heyndrickx, A., methotrimeprazine and its sulfoxide and desmethyl metabolites in urine of psychiatric patients, 914
——Sinsheimer, J. E., and Burckhalter, J. H., chromatographic studies of 9-acridine derivatives, 1659
——Sinsheimer, J. E., and Burckhalter, J. H., photochemical cyclization of *N*-butyl-*N'*-(9-acridinyl)thiourea, 273
Delgado, J. N., *see* Reed, F. D., Jr., 1571
Dell, D., *see* Boreham, D. R., 164
DeMarco, J. D., *see* Allen, D. J., 106
De Moerloose, P., *see* Haemers, A., 1803
DeYoung, J. L., *see* Notari, R. E., 135
Dickerson, T. L., *see* Stubbins, J. F., 470
Diecke, F. P. J., *see* Greenberg, S., 1471
Digenis, G. A., and Whitlock, H. W., Jr., oxidative fragmentation of 9-aminomethylacridan, 206
Dillingham, E. O., *see* Lawrence, W. H., 19
DiSanto, A. R., and Wagner, J. G., pharmacokinetics of highly ionized drugs I: methylene blue—whole blood, urine, and tissue assays, 598
——and Wagner, J. G., pharmacokinetics of highly ionized drugs II: methylene blue—absorption, metabolism, and excretion in man and dog after oral administration, 1086
——and Wagner, J. G., pharmacokinetics of highly ionized drugs III: methylene blue—blood levels in the dog and tissue levels in the rat following intravenous administration, 1090
——and Wagner, J. G., potential erroneous assignment of nonlinear data to the classical linear two-compartment open model, 552
Doerge, R. F., *see* Kallay, K. R., 949
——*see* Spencer, L. A., 1331
Doluisio, J. T., *see* Kojima, S., 1061
Doorenbos, N. J., *see* Slatkin, D. J., 1825
Doskotch, R. W., Malik, M. Y., Hufford, C. D., Malik, S. N., Trent, J. E., and Kubelka, W., antitumor agents V: cytotoxic cardenolides from *Cryptostegia grandiflora* (Roxb.) R. Br., 570
Douglas, A. W., *see* Smith, G. B., 708
Dressler, W. E., Rossi, G. V., and Orzechowski, R. F., effect of several anticonvulsant drugs and procainamide against ouabain-induced cardiac arrhythmias in rabbits, 133
Driscoll, J. S., *see* Paull, K. D., 1481
Dubash, D. D., and Moore, W. E., preliminary studies on oxidative decomposition of dipyrone solutions, 386
Dunn, W. J., III, *see* Hansch, C., 1
Dutta, S. K., *see* Ghosal, S., 1274
Dvornik, D., *see* Kraml, M., 408
Dwivedi, C., *see* Parmar, S. S., 179, 1366

E

Eaves, T., and Jones, T. M., effect of moisture on tensile strength of bulk solids I: sodium chloride and effect of particle size, 256
——and Jones, T. M., effect of moisture on tensile strength of bulk solids II: fine particle-size materials with varying inherent coherence, 342
Ebert, A. G., *see* Moy, P. L., 804
Ebian, A. R., *see* Khalil, S. A., 1615
Ecanow, B., *see* Stanaszek, W. F., 860
El-Hawary, F., *see* Nabih, I., 1327
Eling, T. E., *see* Ritschel, W. A., 1267
Emele, J. F., *see* Langford, F. D., 75
Engle, R. R., *see* Paull, K. D., 1481
Ennals, T. R., *see* Weber, D. J., 689
Epstein, S. S., *see* Friedman, M. A., 1492
Epstein, W. L., *see* Shah, V. P., 634
Euler, K. L., *see* Gupta, V. D., 1458
Eyolfson, J. L., *see* Hamon, N. W., 2006

F

Fanelli, R., *see* Frigerio, A., 1144
Farnsworth, N. R., anomalous isolation of an active antitumor alkaloid from a fraction of *Catharanthus lanceus* devoid of anticancer activity, 1840
——*see* Aynilian, G., 298
——*see* Fong, H. H. S., 1818
——*see* Krmpotic, E., 1508
——*see* Kubena, R. K., 144
——*see* Messmer, W. M., 1858
——*see* Tin-Wa, M., 1846
Fayez, M. B. E., and Negm, S. A. R., mass spectrometric behavior of cardiac steroid

aglycones of the cardenolide type, 765
Felmeister, A., relationships between surface activity and biological activity of drugs, 151
——Tsai, D., and Weiner, N. D., interaction of 3,4-benzpyrene with monomolecular films, 1065
Ferguson, G. G., action of alkaloidal extract of *Banisteriopsis quitensis* on rabbit ileum, 623
Ferrara, A., *see* Benzi, G., 348
Fetterman, P. S., and Turner, C. E., constituents of *Cannabis sativa* L. I: propyl homologs of cannabinoids from an Indian variant, 1476
Fike, W. W., and Brake, N. W., modified method for determining tetracycline, 4-epitetracycline, and anhydrotetracyclines in tetracycline base or hydrochloride, 615
Finnegan, R. A., and Merkel, K. E., constituents of *Mammea americana* L. IX: oxidation of mammein and mammeisin, 1603
——Merkel, K. E., and Back, N., constituents of *Mammea americana* L. VIII: novel structural variations on the mammein theme and antitumor activity of mammein and related coumarin and phloroglucinol derivatives, 1599
Flynn, G. L., and Smith, R. W., membrane diffusion III: influence of solvent composition and permeant solubility on membrane transport, 61
——and Yalkowsky, S. H., correlation and prediction of mass transport across membranes I: influence of alkyl chain length on flux-determining properties of barrier and diffusant, 838
——Carpenter, O. S., and Yalkowsky, S. H., total mathematical resolution of diffusion layer control of barrier flux, 312
——*see* Kramer, S. F., 1896
——*see* Yalkowsky, S. H., 852, 983
Fong, D. T. K., *see* Polli, G. P., 1078
Fong, H. H. S., Bhatti, W., and Farnsworth, N. R., antitumor activity of certain plants due to tannins, 1818
——*see* Aynilian, G., 298
——*see* Messmer, W. M., 1858
——*see* Tin-Wa, M., 1846
Fontani, F., Massarani, E., Nardi, D., and Tajana, A., determination of nifurpipone in urine, 1502
Forchielli, E., *see* Runkel, R., 703
Forist, A. A., *see* Brown, L. W., 858
Fox, R. M., *see* McChesney, J. D., 310
Foxx, M. E., *see* Gruber, M. P., 1147
Foye, W. O., and Lo, J.-R., metal-binding abilities of antibacterial heterocyclic thiones, 1209
Frank, S. G., and Byrd, B. G., phase transitions in binary mixtures of cholesteryl esters, 1762
Free, C. A., *see* Weinryb, I., 1556
Friedman, H. L., and Wang, R. I. H., oral absorption of ^{14}C-labeled mepenzolate bromide in humans, 1663
Friedman, M. A., Greene, E. J., and Epstein, S. S., rapid gastric absorption of sodium nitrite in mice, 1492
Frigerio, A., Fanelli, R., Biandrate, P., Passerini, G., Morselli, P. L., and Garattini, S., mass spectrometric characterization of carbamazepine-10,11-epoxide, a carbamazepine metabolite isolated from human urine, 1144
Frost, D., *see* Aszalos, A., 791
Fukui, K., *see* Naito, S.-I., 1791
Fung, H.-L., and Ow, Y.-H., functional group contribution in ion-pair extraction of tricyclic amines, 1967
Furukawa, H., *see* Lee, K.-H., 629

G

Galpin, D. R., Bobbink, S. R., and Ary, T. E., *cis*- and *trans*-3-methylamino-2-phenyltetrahydropyran, 963
Gang, D. M., and Shaikh, K. Z., turbidimetric method for assay of nitrofuran compounds, 462
Ganse, G., *see* Tansy, M. F., 1141
Garattini, S., *see* Bertagni, P., 965
——*see* Frigerio, A., 1144
Gardner, T. D., *see* Mason, W. D., 1301
Garg, H. G., and Arora, V., chemistry and biological activity of N^1-acyl-4-arylazopyrazoles, 130
——and Prakash, C., potential antidiabetics XII: N^1-phenylcarbamoyl-4-arylazo(3- and/or 5-substituted)pyrazoles and their biological activities, 957
Garrett, E. R., and Hermann, T. W., prediction of stability in pharmaceutical preparations XVII: design of a nonprecipitating injectable potassium canrenoate solution, 717
——and Tsau, J., application of ion-pair methods to drug extraction from biological fluids I: quantitative determination of biguanides in urine, 1404
——and Tsau, J., solvolyses of cytosine and cytidine, 1052
——and Weber, D. J., metal complexes of thiouracils III: polarographic studies and correlations among complex stabilities, thiouracil structures, and biological activities, 1241
——Tsau, J., and Hinderling, P. H., application of ion-pair methods to drug extraction from biological fluids II: quantitative determination of biguanides in biological fluids and comparison of protein binding estimates, 1411
——*see* Heman-Ackah, S. M., 545
——*see* Vilallonga, F. A., 1720
Garteiz, D. A., and Walle, T., electron impact fragmentation studies of β-blocking drugs and their metabolites by GC–mass spectroscopy, 1728
Gautieri, R. F., *see* Sherman, W. T., 878
Geissman, T. A., *see* Huang, E.-S., 1960
Gerraughty, R. J., *see* Mauger, J. W., 94
Ghosal, S., Bhattacharya, S. K., and Mehta, R., naturally occurring and synthetic β-carbolines as cholinesterase inhibitors, 808
——Dutta, S. K., and Bhattacharya, S. K., erythrina—chemical and pharmacological evaluation II: alkaloids of *Erythrina variegata* L., 1274
——*see* Bhattacharya, S. K., 1838
Giannaccini, B., *see* Bottari, F., 602
Gibaldi, M., and Grundhofer, B., drug transport VI: functional integrity of the rat everted small intestine with respect to passive transfer, 116
——and Levy, G., dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics, 567
——and Perrier, D., drug elimination and apparent volume of distribution in multicompartment systems, 952
——*see* Axelson, J. E., 404
——*see* Jusko, W. J., 1270
——*see* Levy, G., 798
Gibbs, I. S., *see* Tuckerman, M. M., 448
Gibson, M. R., *see* Gupta, M. P., 1257
Gibson, P. F., and Wright, N., ethchlorvynol in biological fluids: specificity of assay methods, 169
Gidwani, R. N., *see* Sciarra, J. J., 754
Gillette, J. R., *see* Stripp, B., 1682
Gisvold, O., acetyldigoxin and acetyldigitoxin from *Digitalis lanata*, 1320
Glave, W. R., and Hansch, C., relationship between lipophilic character and anesthetic activity, 589
Glenn, E. M., *see* Kaiser, D. G., 1908
Gloor, W. T., Jr., *see* Davies, W. L., 618
Goldenberg, H., *see* Weinryb, I., 1556
Goldwitz, B. A., *see* Turczan, J. W., 613, 1309
Gopal, H., and Gupta, R. K., chemical constituents of *Salmalia malabarica* Schott and Endl. flowers, 807
Goto, S., Tsuzuki, O., and Iguchi, S., relationship between enhancement of plasma level of aminopyrine by barbital and stomach emptying pattern, 945
Grabowski, B. F., and Haney, W. G., Jr., characterization of silver deposits in tissue resulting from dermal application of a silver-containing pharmaceutical, 1488
——*see* Parimoo, P., 974
Grace, A. J., *see* Barry, B. W., 335
Graham, G., and Rowland, M., application of salivary salicylate data to biopharmaceutical studies of salicylates, 1219
Granatek, A. P., *see* Prasad, V. K., 1579
Grattan, J. F., *see* Luts, H. A., 1504
Greenberg, S., Diecke, F. P. J., and Long, J. P., *in vitro* model for studying effects of morphine and nalorphine on ^{45}Ca–ganglioside binding, 1471
Greene, E. J., *see* Friedman, M. A., 1492
Grifantini, M., Martelli, S., and Stein, M. L., structure–activity relationships in reactivators of organophosphorus-inhibited acetylcholinesterase V: quaternary salts of hydroxyiminomethylimidazoles, 631
Groff, W. A., *see* Sidell, F. R., 1136, 1765
Grogan, J. L., and Honigberg, I. L., potential hypocholesterolemic agents: dicinnamoyl esters as analogs of cynarin, 802
Gropper, E., *see* Tingstad, J., 1985
Gruber, C. M., Jr., *see* Rubin, A., 739
Gruber, M. P., Klein, R. W., Foxx, M. E., and Campisi, J., rapid analysis of iodochlorhydroxyquin and related halogenated 8-hydroxyquinolines *via* GLC of their trimethylsilyl ethers, 1147
Grundhofer, B., *see* Gibaldi, M., 116
Gualtieri, F., Johnson, H., Maibach, H., Skidmore, D., and Skinner, W., topical mosquito repellents IV: alicyclic, bicyclic, and unsaturated acetals, aminoacetals, and carboxamide acetals, 577
Guilford, J., *see* Sinsheimer, J. E., 314
Guillory, J. K., *see* Yang, S. S., 26
Gupta, M. P., and Gibson, M. R., protein–alkaloid relationship in *Datura stramonium* var. *tatula*, 1257
Gupta, R. K., *see* Gopal, H., 807
Gupta, T. K., *see* Parmar, S. S., 1322
Gupta, V. D., quantitative determination of salicylic acid and benzoic acid in ointments, 1625
——and Euler, K. L., desorption of belladonna alkaloids from antacids for analysis, 1458
Guttman, D. E., *see* Hayton, W. L., 356

H

Haataja, M., Nieminen, L., and Möttönen, M., effect of levodopa upon plasma levels of 17-hydroxycorticosterone, 481
Haddad, H. M., *see* Loucas, S. P., 985
Haemers, A., and De Moerloose, P., column chromatographic determination of polymyxin B sulfate, 1803
Hajratwala, B., *see* Blaug, S. M., 556
Hakim, A. A., chymotrypsin inhibition of muscular contraction, 352
Hall, N. A., *see* Martis, L., 1757
Hamilton, H. E., *see* Wallace, J. E., 1397
Hamlin, W. E., and Shah, A. C., pharmaceutical sciences—1971: literature review of pharmaceutics, 989
Hammer, R. H., *see* Pancorbo, S., 954
Hamon, N. W., and Eyolfson, J. L., biosynthesis of tropic acid in *Datura innoxia* root tissue, 2006
Handorf, C. R., *see* Mathison, I. W., 637
Haney, W. G., Jr., *see* Grabowski, B. F., 1488
——*see* Parimoo, P., 974
Hansch, C., and Dunn, W. J., III, linear relationships between lipophilic character and biological activity of drugs, 1
——*see* Glave, W. R., 589
Hansen, W. G., *see* Morris, C. H., 815
Hardegree, M. C., *see* O'Neill, H. J., 863, 1292
Harris, D. N., *see* Weinryb, I., 1556
Harris, P. A., *see* Rowland, M., 379
Hartman, C. W., *see* Javaid, K. A., 900
Harwood, R. J., Niebergall, P. J., Sugita, E. T., and Schnaare, R. L., effect of copper (II)–glycine chelates on degradation of penicillin in mildly acid solution, 82
Havemeyer, R. N., *see* Pelzmann, K. S., 110
Hayton, W. L., and Levy, G., effect of complex formation on drug absorption XII: enhancement of intestinal absorption of prednisone and prednisolone by dialkylpropionamides in rats, 362
——and Levy, G., effect of complex formation on drug absorption XIII: effect of constant concentrations of *N,N*-di-*n*-propylpropionamide on prednisolone absorption from the rat small intestine, 367
——and Levy, G., effect of complex formation on drug absorption XV: structural requirements for enhancement of intestinal absorption of steroids by *N,N*-di-*n*-propylpropionamide, 649
——Guttman, D. E., and Levy, G., effect of complex formation on drug absorption XI: complexation of prednisone and prednisolone with dialkylpropionamides and its effect on prednisone transfer through an artificial lipoid barrier, 356
——Levy, G., and Regårdh, C.-G., effect of complex formation on drug absorption

XIV: effect of *N,N*-di-*n*-propylpropionamide on intestinal absorption of certain nonsteroid drugs in the rat, 473
——*see* Schwartz, M. A., 906
Heimlich, K. R., role of drug metabolism in drug research and development: pharmaceutical chemistry aspects, 1686
Helgren, P. F., Thomas, M. A., and Theivagt, J. G., GLC determination of sorbitol in irrigating solutions, 103
Hem, S. L., *see* Lindsay, R. E., 202
Heman-Ackah, S. M., and Garrett, E. R., kinetics and mechanisms of action of drugs on microorganisms XV: effect of erythromycin on the action of lincomycin (phase II) and the 7(S)-chloro analogs of lincomycin against *Escherichia coli*, 545
Hemnani, K. L., *see* Huang, C. L., 119
Hermann, T. W., *see* Garrett, E. R., 717
Hersey, J. A., *see* Rees, J. E., 1313
Hess, S. M., *see* Weinryb, I., 1556
Hester, J. B., *see* Lemke, T. L., 275
Heyndrickx, A., *see* De Leenheer, A., 914
Hiestand, E. N., physical properties of coarse suspensions, 268
Higgins, D. M., and Skauen, D. M., influence of power on quality of emulsions prepared by ultrasound, 1567
Higuchi, T., Dayal, S., and Pitman, I. H., effects of solute–solvent complexation reactions on dissolution kinetics: testing of a model by using a concentration jump technique, 695
——*see* Hussain, A., 371
——*see* Pitman, I. H., 918
——*see* Rytting, J. H., 816
Higuchi, W. I., *see* Ho, N. F. H., 192
——*see* Sjuib, F., 1374, 1381
——*see* Stehle, R. G., 1922, 1931
——*see* Surpuriya, V., 375
——*see* Turi, J. S., 1618
——*see* Vora, K. R. M., 1785
——*see* Yeh, K. C., 1648
Hinderling, P. H., *see* Garrett, E. R., 1411
Ho, B. T., monoamine oxidase inhibitors, 821
Ho, N. F. H., Higuchi, W. I., and Turi, J., theoretical model studies of drug absorption and transport in the GI tract III, 192
——*see* Turi, J. S., 1618
——*see* Vora, K. R. M., 1785
Hodge, W. R., and Schneider, L. E., a new antibacterial mode of action for sulfonamides, 142
Hoinowski, A. M., *see* Smith, G. B., 708
Holak, W., analysis of cacodylate injections by NMR spectroscopy, 1635
Holmes, P. A., *see* Langford, F. D., 75
Honigberg, I. L., *see* Altman, R. E., Jr., 610
——*see* Grogan, J. L., 802
Hopkins, L. V., Vacik, J. P., and Shelver, W. H., kinetics of the addition of diethyl phosphonate to various *p*-substituted benzylideneanilines, 114
Hornemann, K. M. K., Neal, J. M., and McLaughlin, J. L., cactus alkaloids XII: β-phenethylamine alkaloids of the genus Coryphantha, 41
Hossie, R. D., *see* Mattok, G. L., 460
Hou, J. P., and Poole, J. W., measurement of β-lactamase activity and rate of inactivation of penicillins by a pH-stat alkalimetric titration method, 1594
Hsu, P. L., *see* Jun, H. W., 1835
Huang, C. L., and Mir, G. N., toxicological and pharmacological studies on sea anemone, *Calliactis polypus* (Hormathiidae), 66
——Mir, G. N., Liu, S. J., Hemnani, K. L., and Yau, E. T., distribution and excretion of ^{3}H-venoms of *Crotalus adamanteus*, *Crotalus atrox*, and *Agkistrodon piscivorus* and ^{3}H-serum of *Lampropeltis getulus* in rats, 119
Huang, E.-S., Lee, K.-H., Piantadosi, C., Geissman, T. A., and Pagano, J. S., rapid microtiter method for cytotoxicity screening, 1960
——*see* Lee, K.-H., 626, 629
Huang, H.-C., *see* Lee, K.-H., 629
Huang, W.-T., *see* Blaug, S. M., 1770
Hucker, H. B., Stauffer, S. C., and White, S. E., effect of halofenate on binding of various drugs to human plasma proteins and on the plasma half-life of antipyrine in monkeys, 1490
Hudgins, P. M., *see* Stubbins, J. F., 470
Huebner, C. F., *see* Lin, S.-L., 1418
Hufford, C. D., *see* Doskotch, R. W., 570
Hughes, D. W., *see* Radecka, C., 430
Hung, G. W. C., and Autian, J., use of thermal gravimetric analysis in sorption studies II: evaluation of diffusivity and solubility of a series of aliphatic alcohols in polyurethan, 1094
Hurwitz, A., *see* Hussain, A., 371
——*see* Patel, R. M., 1806
Hussain, A., prediction of dissolution rates of slightly water-soluble powders from simple mathematical relationships, 811
——Higuchi, T., Hurwitz, A., and Pitman, I. H., rates of hydrolysis of *N*-chlorinated molecules, 371
Hussain, M. H., *see* Kapadia, G. J., 1172

I

Ice, R. D., *see* Bercz, C. V., 1316
Iguchi, S., *see* Goto, S., 945
Iizuka, K., *see* Kikugawa, K., 1904
Imbler, P., *see* Bhatti, W., 307
Indeherberg, J., *see* Vanhaelen, M., 1165
Isaacson, E. I., *see* Reed, F. D., Jr., 1571
Ishaq, K. S., *see* Piantadosi, C., 607, 971
Israsena, S., *see* Wormser, H. C., 1168
Izushi, F., *see* Naito, S.-I., 198

J

Jacobson, A. E., *see* Perrine, T. D., 86
Jaffe, J. H., *see* Kaistha, K. K., 305, 679
Jalal, I. M., Malinowski, H. J., and Smith, W. E., tablet granulations composed of spherical-shaped particles, 1466
James, T., fluorometric determination of ethinyl estradiol in tablets, 1306
Jato, J., *see* Windheuser, J. J., 1669
Javaid, K. A., and Cadwallader, D. E., dissolution of aspirin from tablets containing various buffering agents, 1370
——and Hartman, C. W., blood levels of sulfamethizole in dogs following administration of timed-release tablets employing lipase–lipid–drug systems, 900
Johns, W. H., and Bates, T. R., drug–cholestyramine interactions I: physicochemical factors affecting *in vitro* binding of sodium fusidate to cholestyramine, 730
——and Bates, T. R., drug–cholestyramine interactions II: influence of cholestyramine on GI absorption of sodium fusidate, 735
Johnson, B. J., conformation dependency of antibodies to poly(L-tyrosyl-L-glutamyl-L-alanylglycyl)glycine-1-^{14}C ethyl ester, 1654
——immunochemical studies on linear antigenic polypeptides with a known primary structure, 806
——immunochemical studies on linear antigenic polypeptides with a known repeating sequence of amino acids, 1990
Johnson, H., *see* Gualtieri, F., 577
Jolad, S., *see* Sheth, K., 1819
Jones, S. C., *see* Sadée, W., 1129, 1132
Jones, T. M., *see* Eaves, T., 256, 342
Judis, J., binding of sulfonylureas to serum proteins, 89
Jun, H. W., Luzzi, L. A., and Hsu, P. L., phenylbutazone–sodium warfarin binding using a fluorescent probe technique, 1835
——Whitworth, C. W., and Luzzi, L. A., decomposition of aspirin in polyethylene glycols, 1160
Juneau, R. J., *see* Yakatan, G. J., 749
Jusko, W. J., and Gibaldi, M., effects of change in elimination on various parameters of the two-compartment open model, 1270

K

Kaiser, D. G., and Glenn, E. M., correlation of plasma 4,5-bis(*p*-methoxyphenyl)-2-phenylpyrrole-3-acetonitrile levels with biological activity, 1908
Kaistha, K. K., drug abuse screening programs: detection procedures, development costs, street-sample analysis, and field tests, 655
——and Jaffe, J. H., reliability of identification techniques for drugs of abuse in a urine screening program and drug excretion data, 305
——and Jaffe, J. H., TLC techniques for identification of narcotics, barbiturates, and CNS stimulants in a drug abuse urine screening program, 679
Kallay, K. R., and Doerge, R. F., *p*-substituted 1,2-diphenylindolizines as anti-inflammatory agents, 949
Kaminskis, A., *see* Sidell, F. R., 1136, 1765
Kandeel, E. M., Anderson, L. J., Block, J. H., White, A. I., and Martin, A. R., substituted tetralins IV: synthesis and stereochemistry of 4,4-disubstituted 1,2,3,4-tetrahydro-2-naphthoic acids, 1231
Kapadia, G. J., Hussain, M. H., and Rao, G. S., peyote and related alkaloids XIV: mescaloxylic acid and mescaloruvic acid, the novel amino acid analogs of mescaline, 1172
Kaplan, S. A., and Cotler, S., use of cannulated everted intestinal sac for serial sampling as a drug absorbability (permeability) screen, 1361
——Weinfeld, R. E., Abruzzo, C. W., and Lewis, M., pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man, 773
Kapoor, A. L., *see* Sciarra, J. J., 219
Karim, A., Ranney, R. E., and Kraychy, S., species differences in the biotransformation of a new antiarrhythmic agent: disopyramide phosphate, 888
Kashiwagi, M., *see* Norton, T. R., 1814
Kaul, P. N., Conway, M. W., Ticku, M. K., and Clark, M. L., chlorpromazine metabolism II: determination of nonconjugated metabolites in blood of schizophrenic patients, 581
——Ticku, M. K., and Clark, M. L., chlorpromazine metabolism V: disposition of free and conjugated metabolites in blood fractions of schizophrenic patients, 1753
Keller, W. J., and McLaughlin, J. L., cactus alkaloids III: isolation of (−)-normacromerine from *Coryphantha macromeris* var. *runyonii*, 147
Kendall, F. M., *see* Tansy, M. F., 1507
Khalil, S. A., Moustafa, M. A., Ebian, A. R., and Motawi, M. M., GI absorption of two crystal forms of sulfameter in man, 1615
Khanna, K. L., *see* Rao, G. S., 1822
Khemani, L., *see* Alkalay, D., 1746
Kho, B. T., *see* Prue, D. G., 249
Kier, L. B., a molecular theory of sweet taste, 1394
Kikugawa, K., and Iizuka, K., inhibition of platelet aggregation by bisulfite–sulfite, 1904
Kildsig, D. O., *see* Krause, P. D., 281, 1478
——*see* Nedich, R. L., 214
——*see* Shively, C. D., 1589
King, R. E., *see* Chaudry, I. A., 1121
Kirk, W. F., *in vitro* method of comparing clouds produced from inhalation aerosols for efficiency in penetration of airways, 262
Kirsch, L. E., *see* Larsen, R. V., 2004
Kirschbaum, J., *see* Aszalos, A., 791
Kirsten, E. B., and Ross, S. M., circuit for simulation of multiple-dosing kinetics, 1468
Klein, R. W., *see* Gruber, M. P., 1147
Knapp, J. E., *see* Slatkin, D. J., 1825
Knoll, E. W., *see* Bowman, F. W., 532
Kocialski, A. B., Marozzi, F. J., Jr., and Malone, M. H., effects of certain nonsteroid anti-inflammatory drugs, tolbutamide, and tetrahydroalstonine on blood glucose and carrageenin-induced pedal edema in rats, 1202
Kocy, O., *see* Aszalos, A., 791
Kojima, S., Smith, R. B., Crouthamel, W. G., and Doluisio, J. T., drug absorption VI: water flux and drug absorption in an *in situ* rat gut preparation, 1061
Kondo, Y., *see* Waters, J. A., 321
Kopple, K. D., synthesis of cyclic peptides, 1345
Kornet, M. J., and Tan, H. S. I., synthesis of novel analgesic agents I: pyrazolidines with an oxygenated phenyl substituent, 188
——and Tan, H. S. I., synthesis of novel analgesic agents II: pyrazolidines with nonoxygenated phenyl substituents, 235
——and Tan, H. S. I., synthesis of novel analgesic agents III: 1,2-dialkyl-4-aryl and 1,2,4-trialkyl-4-aryl piperidazines, 1781
——and Tan, H. S. I., synthesis of novel analgesic agents IV: 1,2-dialkyl-3-aryl

piperidazines and 1,2,3-trialkyl-3-aryl piperidazines, 1936
Kosh, J. W., and Appelt, G. D., selected pharmacological studies of succinic semialdehyde, 1963
Koss, R., *see* Shargel, L., 1445
Kraemer, N., *see* Aszalos, A., 791
Kram, T. C., separation of sulfa drugs by high speed liquid chromatography, 254
Kramer, S. F., and Flynn, G. L., solubility of organic hydrochlorides, 1896
Kraml, M., Dvornik, D., and Cosyns, L., colorimetric determination of C-10 hydroxylated metabolites of cyheptamide: application to absorption and enzyme induction studies in the rat, 408
Krause, P. D., and Kildsig, D. O., mechanism of dissolution II: experimental determination of surface tension of a solid, 281
——and Kildsig, D. O., mechanism of dissolution III: relationship between solid–liquid interfacial energies and dissolution rates in organic solvents, 1478
Kraychy, S., *see* Karim, A., 888
Krimmer, E. C., Barry, H., III, and Buckley, J. P., acute and chronic effects of 3,4-dimethoxyphenylacetamide on plasma glucose and cholesterol in rats, 1611
Krmpotic, E., Farnsworth, N. R., and Messmer, W. M., cryptopleurine, an active antiviral alkaloid from *Boehmeria cylindrica* (L.) Sw. (Urticaceae), 1508
Kronberg, G. H., *see* Adams, H. J., 1829
Kubelka, W., *see* Doskotch, R. W., 570
Kubena, R. K., Barry, H., III, Segelman, A. B., Theiner, M., and Farnsworth, N. R., biological and chemical evaluation of a 43-year-old sample of Cannabis fluidextract, 144
Kuchinskas, E. J., and Levy, G. N., comparative stabilities of ampicillin and hetacillin in aqueous solution, 727
Kuehn, P. B., *see* Thakkar, A. L., 1841
Kupferberg, H. J., GLC determination of carbamazepine in plasma, 284
Kwan, K. C., *see* Allen, D. J., 106

L

Lach, J. L., *see* Monkhouse, D. C., 1430, 1435
Lachman, L., *see* Lin, S.-L., 1418
——*see* Tingstad, J., 1985
Lalezari, I., Rezvani, N., and Malekzadeh, F., synthesis and antimicrobial activity of thiocarbohydrazide-1,5-dicarboxylic acid diester, 1486
Langford, F. D., Holmes, P. A., and Emele, J. F., objective method for evaluation of analgesic/anti-inflammatory activity, 75
Larsen, R. V., Kirsch, L. E., Shaw, S. M., Christian, J. E., and Born, G. S., excretion and tissue distribution of uniformly labeled ^{14}C-pentachlorophenol in rats, 2004
Lau-Cam, C. A., and Chu-Fong, I., TLC of coumarin anticoagulants, 1303
Lawrence, R. C., *see* Watson, J. R., 929
Lawrence, W. H., Dillingham, E. O., Turner, J. E., and Autian, J., toxicity profile of chloroacetaldehyde, 19
——Malik, M., Turner, J. E., and Autian, J., toxicity profile of epichlorohydrin, 1712
——*see* Singh, A. R., 51
Lee, A., *see* Bhatti, W., 307
Lee, K.-H., Anuforo, D. C., Huang, E.-S., and Piantadosi, C., antitumor agents I: angustibalin, a new cytotoxic sesquiterpene lactone from *Balduina angustifolia* (Pursh.) Robins, 626
——Huang, H.-C., Huang, E.-S., and Furukawa, H., antitumor agents II: eupatolide, a new cytotoxic principle from *Eupatorium formosanum* HAY., 629
——*see* Huang, E.-S., 1960
Lemberger, L., role of drug metabolism in drug research and development: importance of drug metabolism in clinical pharmacological evaluation of new drugs, 1690
Lemke, T. L., Hester, J. B., and Rudzik, A. D., a new 2,6-difluorobenzodiazepinone, 275
Leong, A., *see* Smith, R. V., 316
Levy, G., and Rao, B. K., enhanced intestinal absorption of riboflavin from sodium alginate solution in man, 279
——Gibaldi, M., and Procknal, J. A., effect of an anticholinergic agent on riboflavin absorption in man, 798
——Mosovich, L. L., Allen, J. E., and Yaffe, S. J., biliary excretion of riboflavin in man, 143
——*see* Gibaldi, M., 567
——*see* Hayton, W. L., 356, 362, 367, 473, 649
——*see* Tsuchiya, T., 541, 586, 624, 800
Levy, G. N., *see* Kuchinskas, E. J., 727
Levy, R. H., and Rowland, M., development of a system for studying subcutaneous absorption kinetics of local anesthetic amines, 1263
——*see* Martis, L., 1341
——*see* Simons, K. J., 1252
Lewis, M., *see* Kaplan, S. A., 773
Lin, R.-T., *see* Roe, D. A., 1081
Lin, S.-L., preformulation investigation II: dissolution kinetics and thermodynamic parameters of polymorphs of an experimental antihypertensive, 1423
——Lachman, L., Swartz, C. J., and Huebner, C. F., preformulation investigation I: relation of salt forms and biological activity of an experimental antihypertensive, 1418
Lindsay, R. E., and Hem, S. L., effect of ionic strength on chemical stability of potassium penicillin G, 202
Lindstrom, R. E., *see* Swarbrick, J., 1645
Liu, S. J., *see* Huang, C. L., 119
Lo, E. K. F., *see* Yung, D. K., 1953
Lo, J.-R., *see* Foye, W. O., 1209
Logemann, W., *see* Ambrogi, V., 1483
Long, J. P., *see* Greenberg, S., 1471
Lorenzen, B., *see* Bhatti, W., 307
Loucas, S. P., and Haddad, H. M., solid-state ophthalmic dosage systems in effecting prolonged release of pilocarpine in the cul-de-sac, 985
Lowell, G. J., determination of the isomeric composition of amphetamine mixtures from melting points of monohydrogen succinate salts, 1976
Lowenthal, W., mechanism of action of starch as a tablet disintegrant V: effect of starch grain deformation, 455
——mechanism of action of tablet disintegrants: correlation of tablet mean pore diameter and porosity, 303
Lu, M. Y., *see* Weiner, N. D., 1098
Lucarotti, R. L., Colaizzi, J. L., Barry, H., III, and Poust, R. I., enhanced pseudoephedrine absorption by concurrent administration of aluminum hydroxide gel in humans, 903
Luts, H. A., and Grattan, J. F., new compounds: physiologically active amines and amine salts, 1504
Luzzi, L. A., *see* Jun, H. W., 1160, 1835
——*see* Madan, P. L., 1586
——*see* Shepherd, R. E., 1152
Lyle, R. E., *see* Wu, M. T., 141, 477
Lyon, R. L., *see* Aynilian, G., 298

M

Macy, L. R., *see* Winkler, V. W., 1462
Madan, P. L., Luzzi, L. A., and Price, J. C., factors influencing microencapsulation of a waxy solid by complex coacervation, 1586
Maddox, J. P., *see* Steinberg, G. M., 527
Magarian, R. A., Melton, S., and Natarelli, G., 1,1 - dichloro - *trans* - 2,3 - diphenylcyclopropane, 1216
Maggi, N., and Cometti, A., colorimetric assay of levodopa, 924
Mahn, F. P., *see* Manius, G., 1831
Maibach, H., *see* Gualtieri, F., 577
Malbica, J. O., *see* Carrano, R. A., 1450
Malekzadeh, F., *see* Lalezari, I., 1486
Malik, M., *see* Lawrence, W. H., 1712
Malik, M. Y., *see* Doskotch, R. W., 570
Malik, S. N., *see* Doskotch, R. W., 570
Malinowski, H. J., *see* Jalal, I. M., 1466
Malone, M. H., *see* Kocialski, A. B., 1202
Manius, G., Mahn, F. P., Venturella, V. S., and Senkowski, B. Z., GLC determination of sorbitol and mannitol in aqueous solutions, 1831
Manley, E. S., Jr., and Belote, J., comparative depressant activity and interaction of ethanol and pentobarbital in goldfish, 1401
Manzo, L., *see* Benzi, G., 348
Marcucci, F., *see* Bertagni, P., 965
Marcus, F., *see* Barry, H., III, 172
Margosis, M., and Tanner, J. T., determination of mercury in pharmaceutical products by neutron activation analysis, 936
Marozzi, F. J., Jr., *see* Kocialski, A. B., 1202
Marrelli, L. P., colorimetric estimation of cephalexin, cephaloglycin, and related compounds, 1647
Martelli, S., *see* Grifantini, M., 631
Martin, A. N., *see* Peradejordi, F., 909
Martin, A. R., *see* Kandeel, E. M., 1231
Martin, B. K., *see* Boreham, D. R., 164
Martis, L., and Levy, R. H., determination of meprobamate in dissolution studies: shortcomings of direct GLC and development of a new assay, 1341
——Hall, N. A., and Thakkar, A. L., micelle formation and testosterone solubilization of sodium glycocholate, 1757
Mason, W. D., Gardner, T. D., and Stewart, J. T., determination of ascorbic acid in pharmaceutical dosage forms based on oxidation at the tubular carbon electrode, 1301
Massarani, E., *see* Fontani, F., 1502
Master, R. E., and Rost, W. J., carbamates and ureas with potential chemotherapeutic properties, 125
Mathison, I. W., Morgan, P. H., Tidwell, R. R., and Handorf, C. R., steric and physicochemical studies of decahydroisoquinolines possessing antiarrhythmic activity, 637
Matin, S. B., and Rowland, M., electron-capture sensitivity comparison of various derivatives of primary and secondary amines, 1235
Matsui, F., *see* Watson, J. R., 929
Mattocks, A. M., and Penzotti, S. C., acceleration of peritoneal dialysis with minimum amounts of dioctyl sodium sulfosuccinate, 475
Mattok, G. L., and McGilveray, I. J., comparison of bioavailabilities and dissolution characteristics of commercial tablet formulations of sulfamethizole, 746
——McGilveray, I. J., and Hossie, R. D., technical problems of the USP/NF dissolution test, 460
Mauger, J. W., Paruta, A. N., and Gerraughty, R. J., solubilities of sulfadiazine, sulfisomidine, and sulfadimethoxine in several normal alcohols, 94
Maulding, H. V., Brusco, D., Polesuk, J., Nazareno, J., and Michaelis, A. F., hydrolysis of certain 5-aminodibenzo[*a,d*]cycloheptanes, 1197
——Nazareno, J., Polesuk, J., and Michaelis, A., investigations of hydrolytic products of butalbital, 1389
——*see* Turi, P., 1811
May, E. L., *see* Perrine, T. D., 86
McBride, R. J., *see* Richards, R. M. E., 1075
McChesney, J. D., Beal, D. K., and Fox, R. M., rapid qualitative identification of barbiturates by mass spectrometry, 310
McConnell, P. M. J., *see* Watson, J. R., 929
McCormick, D. B., *see* Roe, D. A., 1081
McDoniel, P. B., and Cole, J. R., antitumor activity of *Bursera schlechtendalii* (Burseraceae): isolation and structure determination of two new lignans, 1992
McGilveray, I. J., *see* Mattok, G. L., 460, 746
McLaughlin, J. L., *see* Hornemann, K. M. K., 41
——*see* Keller, W. J., 147
McMahon, K. A., and O'Reilly, W. J., pharmacokinetics of sulfanilic acid and 1-naphthylamine-4-sulfonic acid in the rabbit, 524
——and O'Reilly, W. J., pharmacokinetics of three sulfonamides in the rabbit, 518
McVean, D. E., Tuerck, P. A., Christenson, G. L., and Carstensen, J. T., inadequacies in leakage test procedures for flame-sealed ampuls, 1609
Mednick, M. L., *see* Steinberg, G. M., 1735
Medwick, T., *see* Turczan, J., 434
Mehta, J. D., *see* Bafna, S. L., 1333
Mehta, R., *see* Ghosal, S., 808
Meiling, M. S., *see* Wormser, H. C., 1168
Melton, S., *see* Magarian, R. A., 1216

Merkel, K. E., *see* Finnegan, R. A., 1599, 1603
Messmer, W. M., Tin-Wa, M., Fong, H. H. S., Bevelle, C., Farnsworth, N. R., Abraham, D. J., and Trojánek, J., fagaronine, a new tumor inhibitor isolated from *Fagara zanthoxyloides* Lam. (Rutaceae), 1858
——*see* Krmpotic, E., 1508
Metzler, C. M., *see* Oesterling, T. O., 287
Meyer, M. C., *see* Nasim, K., 1775
——*see* Serota, D. G., 416
Meyers, D. B., *see* Bopp, R. J., 1750
Mezei, M., and Ryan, K. J., effect of surfactants on epidermal permeability in rabbits, 1329
Michaelis, A. F., *see* Maulding, H. V., 1197, 1389
——*see* Turi, P., 1811
Michel, I. M., *see* Weinryb, I., 1556
Mikawa, T., *see* Naito, S.-I., 1212
Mir, G. N., *see* Huang, C. L., 66, 119
Mislivec, P., *see* Bowman, F. W., 532
Misra, R. S., *see* Parmar, S. S., 78, 1322
Mitchner, H., *see* Weber, D. J., 689
Mittal, K. L., determination of CMC of polysorbate 20 in aqueous solution by surface tension method, 1334
——*see* Vold, R. D., 769
Miya, T. S., *see* Morris, C. H., 815
Mizutani, M., *see* Naito, S.-I., 1212
Mojtabaii, M., *see* Aynehchi, Y., 292
Mollica, J. A., and Strusz, R. F., analysis of corticosteroid creams and ointments by high pressure liquid chromatography, 444
Moniot, J. L., *see* Shamma, M., 295
Monkhouse, D. C., and Lach, J. L., use of adsorbents in enhancement of drug dissolution I, 1430
——and Lach, J. L., use of adsorbents in enhancement of drug dissolution II, 1435
Montgomery, J. A., *see* Temple, C., Jr., 1297
Moore, W. E., *see* Dubash, D. D., 386
Mora, E. C., *see* Crevar, G. E., 1336
Moran, C., *see* Daly, R. E., 927
Morgan, L., *see* Aboul-Enein, M. N., 127
Morgan, P. H., *see* Mathison, I. W., 637
Morozowich, W., *see* Oesterling, T. O., 1861
Morris, C. H., Christian, J. E., Miya, T. S., and Hansen, W. G., effect of aspirin and ethanol on the gastric mucosa of the rat, 815
Morselli, P. L., *see* Frigerio, A., 1144
Mosovich, L. L., *see* Levy, G., 143
Motawi, M. M., *see* Khalil, S. A., 1615
Mottonen, M., *see* Haataja, M., 481
Moustafa, M. A., *see* Khalil, S. A., 1615
Moy, P. L., and Ebert, A. G., microbial degradation of 2,3,5-triiodobenzoic acid in soil, 804
Mukerjee, P., thermodynamic aspects of solubility of small particles, 478
Mukherji, A., *see* Shearer, C. M., 1627
Munson, J. W., and Connors, K. A., spectrophotometric determination of acid hydrazides *via* nickel (II)-catalyzed hydroxamic acid formation, 211
Murphy, D. C., *see* Stubbins, J. F., 470
Murphy, H. W., *see* Bopp, R. J., 1441
Murphy, J. G., direct synthesis of a glucuronide: specific complexing of copper among biological cations, 810
Musa, M. N., *see* Carstensen, J. T., 223, 1112
Mussini, E., *see* Bertagni, P., 965

N

Nabih, I., and Zoorog, H., structure and activity of schistosomicidal agents of the pyrimidine type, 967
——El-Hawary, F., and Zoorob, H., structure and activity in thiazole-type schistosomicidal agents, 1327
——Nasr, M., and Badawi, M. A., synthesis of (heterocyclicamino)aminoalkylnaphthols and reduced tetrahydro derivatives for possible antimalarial activity, 1500
Naito, S.-I., and Fukui, K., biopharmaceutical studies on aminoethanesulfonylphenetidine and related compounds III: drug in blood, 1791
——and Umetsu, K., biopharmaceutical studies on 2-(aminoethanesulfonylamino)-pyridine and related compounds I: absorption, excretion, metabolism, and preliminary pharmacological investigation, 884
——Mizutani, M., Osumi, S., Mikawa, T., Sekishiro, K., Nakao, K., and Wakita, H., biopharmaceutical studies on guaiacol glyceryl ether and related compounds V, 1212
——Sekishiro, K., Awataguchi, M., and Izushi, F., biopharmaceutical studies on aminoethanesulfonylpiperidine and related compounds I: absorption, excretion, metabolism, and some pharmacological activities, 198
Nakao, K., *see* Naito, S.-I., 1212
Nannipieri, E., *see* Bottari, F., 602
Nardi, D., *see* Fontani, F., 1502
Nash, J. F., *see* Bopp, R. J., 1441
Nasim, K., Meyer, M. C., and Autian, J., permeation of aromatic organic compounds from aqueous solutions through polyethylene, 1775
Nasr, M., *see* Nabih, I., 1500
Natarelli, G., *see* Magarian, R. A., 1216
Nazareno, J., *see* Maulding, H.V., 1197, 1389
Neal, J. M., *see* Hornemann, K. M. K., 41
Nedich, R. L., and Kildsig, D. O., mechanism of dissolution I: mathematical interpretation of concentration gradients developed during dissolution of a solid, 214
Negm, S. A. R., *see* Fayez, M. B. E., 765
Nelson, D. A., *see* Perrin, J. H., 1667
Nelson, K. G., the Kelvin equation and solubility of small particles, 479
Nelson, W. L., Allen, D. R., and Vincenzi, F. F., muscarinic receptors: 2-trimethylammonium - 7 - oxabicyclo[2.2.1]heptane iodide epoxides and 2-trimethylammoniumbicyclo[2.2.1]heptane iodides, 1640
Niebergall, P. J., Schnaare, R. L., and Sugita, E. T., spectral determination of microdissociation constants, 232
——*see* Harwood, R. J., 82
Nieminen, L., *see* Haataja, M., 481
Nightingale, C. H., Tse, M., and Stupak, E. I., structure–toxicity relationships of substituted phenothiazines, 1498
Nobles, W. L., *see* Varma, R. S., 112
Norton, T. R., and Kashiwagi, M., purification of a potent antitumor agent from a Tahitian sea anemone and methods of administration studies with Ehrlich ascites tumor in mice, 1814
Notari, R. E., and Baker, T., hydroxamic acids IV: hydroxide effect in hydroxylaminolysis of ethyl acetate, 244
——Chin, M. L., and Wittebort, R., arabinosylcytosine stability in aqueous solutions: pH profile and shelflife predictions, 1189
——DeYoung, J. L., and Reuning, R. H., effect of parallel first-order drug loss from site of administration on calculated values for absorption rate constants, 135
Novotny, C. R., *see* Bopp, R. J., 1441
Nuessle, N. O., *see* Woodruff, C. W., 787

O

O'Connell, J. R., *see* Rosolia, A. M., 1638
Oesterling, T. O., and Metzler, C. M., kinetics of alkaline isomerization and hydrolysis of lincomycin monoesters, 287
——Morozowich, W., and Roseman, T. J., prostaglandins, 1861
O'Neill, H. J., Yamauchi, T. N., Cohen, P., and Hardegree, M. C., characterization of adjuvant mineral oils, 1292
——Yamauchi, T. N., Cohen, P., and Hardegree, M. C., characterization of mannide monooleate, 863
O'Reilly, W. J., *see* McMahon, K. A., 518, 524
Orzechowski, R. F., *see* Dressler, W. E., 133
Osumi, S., *see* Naito, S.-I., 1212
Ow, Y.-H., *see* Fung, H.-L., 1967

P

Padden, J. J., *see* Shaler, R. C., 1851
Pagano, J. S., *see* Huang, E.-S., 1960
Paik, V. S., *see* Weinryb, I., 1556
Panceri, P., *see* Benzi, G., 348
Pancorbo, S., and Hammer, R. H., preliminary phytochemical investigation of *Euphorbia millii*, 954
Papariello, G. J., *see* Shearer, C. M., 1627
Parenti, M. A., *see* Ambrogi, V., 1483
Parimoo, P., Grabowski, B. F., and Haney, W. G., Jr., potential antihistamines with increased receptor specificity, 974
Parmar, S. S., Chaturvedi, A. K., Chaudhari, A., and Misra, R. S., relationship between MAO inhibitory and anticonvulsant properties of substituted cinnamides, 78
——Dwivedi, C., and Ali, B., selective inhibition of xanthine oxidase by 3-hydroxy-1-nitrophenyl - 1*H* - pyrazolo[4,3 - *c*]pyridines, 179
——Dwivedi, C., and Ali, B., substituted carbamides: interrelationship between anticonvulsant activity and inhibition of nicotinamide adenine dinucleotide-dependent pyruvic acid oxidation, 1366
——Misra, R. S., Chaudhari, A., and Gupta, T. K., 2-alkyl 1-(4'-benzhydrazide)aminomethylbenzimidazoles as MAO inhibitors, 1322
——*see* Chaturvedi, A. K., 1157
Parrott, E. L., *see* Alam, A. S., 265
——*see* Braun, R. J., 175, 592
Paruta, A. N., *see* Mauger, J. W., 94
Passerini, G., *see* Frigerio, A., 1144
Patel, D. J., *see* Bafna, S. L., 1333
Patel, J. M., *see* Sciarra, J. J., 219
Patel, R. M., and Hurwitz, A., eutectic temperature determination of preformulation systems and evaluation by controlled freeze drying, 1806
Patel, S., Perrin, J. H., and Windheuser, J. J., GLC analysis of aspirin from solid dosage forms, 1794
Paull, K. D., Engle, R. R., Twanmoh, L.-M., Wood, H. B., Jr., and Driscoll, J. S., synthesis of 9-(3,4-dimethoxyphenoxy)-1,2,-10-trimethoxyaporphine, 1481
Payte, J. T., *see* Wallace, J. E., 1397
Peck, G. E., *see* Woodruff, C. W., 1916, 1956
Pelzmann, K. S., and Havemeyer, R. N., concurrent water and drug absorption in the rat intestine, 110
Penzotti, S. C., *see* Mattocks, A. M., 475
Peradejordi, F., Martin, A. N., Chalvet, O., and Daudel, R., molecular orbital calculations on some nitrogen derivatives of conjugated hydrocarbons: base strength of benzacridines and their amino derivatives, 909
Perlman, D., *see* Wormser, H. C., 1168
Perrier, D., *see* Gibaldi, M., 952
Perrin, J. H., Nelson, D. A., and Tyson, I. B., binding of ^{99m}technetium to various human serum albumins, 1667
——*see* Patel, S., 1794
——*see* Thakkar, A. L., 1841
Perrine, T. D., Atwell, L., Tice, I. B., Jacobson, A. E., and May, E. L., analgesic activity as determined by the Nilsen method, 86
Pfeffer, M., and Schor, J. M., intestinal sorption of anisotropine methylbromide in the rat, 1223
Phillips, M., *see* Weinryb, I., 1556
Piantadosi, C., Chae, K., Ishaq, K. S., and Snyder, F., synthesis of acyl dihydroxyacetone phosphates and related derivatives, 971
——Ishaq, K. S., Blank, M. L., and Snyder, F., synthesis of 1-*O*-alkyl-3-*O*-phosphorylethanolamine-2-propanone and related derivatives, 607
——*see* Huang, E.-S., 1960
——*see* Lee, K.-H., 626
Piccolo, J., *see* Tawashi, R., 1857
Pitman, I. H., Higuchi, T., Alton, M. and Wiley, R., deuterium isotope effects on degradation of hydrocortisone in aqueous solution, 918
——*see* Higuchi, T., 695
——*see* Hussain, A., 371
Polesuk, J., *see* Maulding, H, V., 1197, 1389
Polli, G. P., Fong, D. T. K., and Shoop, C. E., sterile topical dosage forms I: laboratory phase, 1078
Poole, J. W., *see* Hou, J. P., 1594
Postma, E., *see* Schwartz, M. A., 123
Pothisiri, P., *see* Cartensen, J. T., 1999
——*see* Steiner, G., 2009
Poust, R. I., *see* Lucarotti, R. L., 903
——*see* Smolen, V. F., 1102
Powell, R. G., Weisleder, D., and Smith, C. R., Jr., antitumor alkaloids from *Cephalotaxus harringtonia:* structure and activity, 1227
Prakash, C., *see* Garg, H. G., 957
Prasad, V. K., Ricci, R. A., and Granatek,

A. P., kinetics of solvolysis of intrazole, 1579
Price, J. C., *see* Madan, P. L., 1586
——*see* Shepherd, R. E., 1152
Procknal, J. A., *see* Levy, G., 798
Prue, D. G., Warner, C. R., and Kho, B. T., pulse polarographic determination of disulfiram, 249

Q

R

Rabinowitz, M. P., Reisberg, P., and Bodin, J. I., GLC assay of meprobamate and related carbamates, 1974
Radecka, C., Wilson, W. L., and Hughes, D. W., determination of erythromycin in pharmaceutical preparations by direct densitometry after TLC, 430
Ranney, R. E., *see* Karim, A., 888
Rao, B. K., *see* Levy, G., 279
Rao, G. S., Khanna, K. L., and Cornish, H. H., mass spectrometric identification of methylxanthines and methyluric acids, the possible metabolites of caffeine, 1822
——*see* Kapadia, G. J., 1172
Rattie, E. S., *see* Shami, E. G., 1318
Ratych, O. T., *see* Aszalos, A., 791
Ravin, L. J., *see* Shami, E. G., 1318
Ray, W. H., *see* Craine, E. M., 1495
Reda, F., and Baker, S. A., influence of gibberellic acid on growth, flowering, and alkaloidal content of *Atropa belladonna* L. grown in Egypt, 1970
Reed, F. D., Jr., Brown, R. G., Delgado, J. N., and Isaacson, E. I., synthesis of 2-diphenylmethylene-1-acyl-1-alkyl hydrazines as potential psychotropic agents, 1571
Rees, J. E., Hersey, J. A., and Cole, E. T., simulation device for preliminary tablet compression studies, 1313
——*see* Cooper, J., 1511
Regårdh, C.-G., *see* Hayton, W. L., 473
Regnier, F. E., *see* Winkler, V. W., 1462
Reier, G. E., *see* Wadke, D. A., 868
Reisberg, P., *see* Rabinowitz, M. P., 1974
Renzi, N. L., *see* Cressman, W. A., 1170
Repta, A. J., and Bansal, P., phase solubility analysis employing solubility product relationships: purity determination of monobasic amines and their salts, 1069
——*see* Chow, Y. P., 1454
Restaino, F. A., *see* Rosolia, A. M., 1638
Reuning, R. H., *see* Notari, R. E., 135
Reyes, E., and Appelt, G. D., pharmacological aspects of concurrent administration of furosemide and skeletal muscle relaxants, 562
Rezvani, N., *see* Lalezari, I., 1486
Rhodes, C. T., *see* Bradshaw, J. W., 1163
——*see* Short, M. P., 1732
Ricci, R. A., *see* Prasad, V. K., 1579
Richards, R. M. E., and McBride, R. J., cross-resistance in *Pseudomonas aeruginosa* resistant to phenylethanol, 1075
Richardson, G., *see* Bradshaw, J. W., 1163
Ridolfo, A. S., *see* Rubin, A., 739
Riedl, J. M., *see* Chafetz, L., 148
Riegelman, S., *see* Rowland, M., 379
——*see* Sadée, W., 1126, 1129, 1132
——*see* Shah, V. P., 634
——*see* Wan, S. H., 1278, 1284, 1288
Rippere, R. A., and Arret, B., automated turbidimetric microbiological assay readout system, 449
Ritschel, W. A., Ritschel-Beurlin, G., and Eling, T. E., enzyme induction of organic nitrates I: nitroglycerin *in vivo* experiments, 1267
Ritschel-Beurlin, G., *see* Ritschel, W. A., 1267
Roberts, F. E., Jr., *see* Smith, G. B., 708
Robertson, J. H., and Tsuji, K., GLC determination of erythromycin in enteric-coated tablets, 1633
Rodda, B. E., *see* Rubin, A., 739
Roe, D. A., McCormick, D. B., and Lin, R.-T., effects of riboflavin on boric acid toxicity, 1081
Roos, R. W., separation and determination of barbiturates in pharmaceuticals by high speed liquid chromatography, 1979
Rose, J. D., *see* Temple, C., Jr., 1297
Roseman, T. J., release of steroids from a silicone polymer, 46
——*see* Oesterling, T. O., 1861
Rosenkrantz, H., Thompson, G. R., and Braude, M. C., oral and parenteral formulations of marijuana constituents, 1106
Rosoff, M., *see* Weiner, N. D., 1098
Rosolia, A. M., O'Connell, J. R., Bavitz, J. F., Restaino, F. A., and Schwartz, J. B., variation in dissolution data using an apparatus meeting USP–NF requirements, 1638
Ross, S. M., *see* Kirsten, E. B., 1468
Rossi, G. V., *see* Dressler, W. E., 133
Rost, W. J., *see* Masters, R. E., 125
Roth, R. P., and Tansy, M. F., atraumatic recording of gastric contractions in conscious, unrestrained rats, 1357
Rowe, E. L., automated drop volume apparatus for surface tension measurement, 781
Rowland, M., influence of route of administration on drug availability, 70
——Riegelman, S., Harris, P. A., and Sholkoff, S. D., absorption kinetics of aspirin in man following oral administration of an aqueous solution, 379
——*see* Graham, G., 1219
——*see* Levy, R. H., 1263
——*see* Matin, S. B., 1235
Rubin, A., Rodda, B. E., Warrick, P., Ridolfo, A. S., and Gruber, C. M., Jr., physiological disposition of fenoprofen in man II: plasma and urine pharmacokinetics after oral and intravenous administration, 739
Rudzik, A. D., *see* Lemke, T. L., 275
Runkel, R., Chaplin, M., Boost, G., Segre, E., and Forchielli, E., absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects, 703
Rupprecht, H. H., influence of solvents on adsorption of ionic surfactants on highly dispersed silicas, 700
Russell, G. F. J., *see* Barry, B. W., 502
Ryan, K. J., *see* Mezei, M., 1329
Rytting, J. H., Davis, S. S., and Higuchi, T., suggested thermodynamic standard state for comparing drug molecules in structure–activity studies, 816

S

Sackman, B. F., *see* Shefter, E., 872
Sackman, P., *see* Shefter, E., 872
Sadée, W., Dagcioglu, M., and Riegelman, S., fluorometric microassay for spironolactone and its metabolites in biological fluids, 1126
——Riegelman, S., and Jones, S. C., disposition of tritium-labeled spirolactones in the dog, 1132
——Riegelman, S., and Jones, S. C., plasma levels of spirolactones in the dog, 1129
Saenz, R. V., and Sowell, J. W., new compounds: amides derived from [(10,11-dihydro-5*H*-dibenzo[*a,d*]cycloheptен-5-yl)-thio]acetic acid, 978
Saettone, M. F., *see* Bottari, F., 602
Sam, J., *see* Aboul-Enein, M. N., 127
Samaniego, S., *see* Weinryb, I., 1556
Sangekar, S. A., Sarli, M., and Sheth, P. R., effect of moisture on physical characteristics of tablets prepared from direct compression excipients, 939
Sanyal, A. K., *see* Bhattacharya, S. K., 1838
Sarli, M., *see* Sangekar, S. A., 939
Sarrif, A., *see* Windheuser, J. J., 1311
Schiff, P. L., Jr., *see* Slatkin, D. J., 1825
Schirmer, R. E., Zemer, R. E., and Cooke, G. G., NMR stability assay for amyl nitrite ampuls, 428
——*see* Bopp, R. J., 1750
Schnaare, R. L., *see* Harwood, R. J., 82
——*see* Niebergall, P. J., 232
Schneider, L. E., *see* Hodge, W. R., 142
Schor, J. M., *see* Pfeffer, M., 1223
Schott, H., and Young, C. Y., electrokinetic studies of bacteria I: effect of nature, ionic strength, and pH of buffer solutions on electrophoretic mobility of *Streptococcus faecalis* and *Escherichia coli*, 182
——and Young, C. Y., electrokinetic studies of bacteria II: effect of cetyltrimethylammonium bromide on *Streptococcus faecalis*, 762
Schteingart, D. E., *see* Sinsheimer, J. E., 314
Schulman, S. G., and Abate, K., application of fluorescence spectroscopy to study of intramolecular hydrogen bonding in pamaquine, 1576
——*see* Yakatan, G. J., 749
Schwan, T. J., and Burch, H. A., new compounds: resolution of *d,l*-α-benzamido-4-hydroxy-3-methoxydihydrocinnamic acid, a precursor of *l*-3,4-dihydroxyphenylalanine, 1506
Schwartz, J. B., *see* Rosolia, A. M., 1638
Schwartz, M. A., and Hayton, W. L., relative stability of hetacillin and ampicillin in solution, 906
——and Postma, E., metabolites of demoxepam, a chlordiazepoxide metabolite, in man, 123
Sciarra, J. J., and Gidwani, R. N., evaluation of selected physical constants of polymeric films and proposed kinetics of drug release, 754
——Patel, J. M., and Kapoor, A. L., synthesis and formulation of several epinephrine salts as an aerosol dosage form, 219
Segelman, A. B., *see* Allwardt, W. H., 1994
——*see* Kubena, R. K., 144
Segre, E., *see* Runkel, R., 703
Sekishiro, K., *see* Naito, S.-I., 198, 1212
Selley, M. L., *see* Biggs, D. F., 1739
Senkowski, B. Z., *see* Manius, G., 1831
Serota, D. G., Meyer, M. C., and Autian, J., effects of structure on permeability of substituted anilines from aqueous solutions through polyethylene, 416
Shah, A. C., *see* Hamlin, W. E., 989
Shah, N. B., and Sheth, B. B., a method for study of timed-release films, 412
Shah, U. S., *see* Tsai, C. S., 228
Shah, V. P., Riegelman, S., and Epstein, W. L., determination of griseofulvin in skin, plasma, and sweat, 634
Shaikh, K. Z., *see* Gang, D. M., 462
Shaler, R. C., and Padden, J. J., identification of hallucinogens in illicit seizures I: 2,5-dimethoxyamphetamine, 1851
Shami, E. G., Bernardo, P. D., Rattie, E. S., and Ravin, L. J., kinetics of polymorphic transformation of sulfathiazole form I, 1318
——*see* Tingstad, J., 1985
Shamma, M., and Moniot, J. L., a new benzylisoquinoline alkaloid: *N*-methylpalaudinium chloride, 295
Shargel, L., and Koss, R., determination of fluorinated hydrocarbon propellants in blood of dogs after aerosol administration, 1445
Sharkey, P., *see* Short, M. P., 1732
Shaw, S. M., *see* Larsen, R. V., 2004
Shearer, C. M., Christenson, K., Mukherji, A., and Papariello, G. J., peak voltammetry at glassy carbon electrode of acetaminophen dosage forms, 1627
Shefter, E., Chmielewicz, Z. F., Blount, J. F., Brennan, T. F., Sackman, B. F., and Sackman, P., biological implications of molecular and crystal structures of sulfadimethoxine, sulfadoxine, and sulfisoxazole, 872
Shelver, W. H., *see* Hopkins, L. V., 114
——*see* Tsai, C. S., 228
Shepherd, R. E., Price, J. C., and Luzzi, L. A., dissolution profiles for capsules and tablets using a magnetic basket dissolution apparatus, 1152
Sherman, W. T., and Gautieri, R. F., effect of certain drugs on perfused human placenta X: norepinephrine release by bradykinin, 878
Sheth, B. B., *see* Shah, N. B., 412
Sheth, K., Jolad, S., Wiedhopf, R., and Cole, J. R., tumor-inhibitory agent from *Hyptis emoryi* (Labiatae), 1819
Sheth, P. R., *see* Sangekar, S. A., 939
Shipman, C., Jr., *see* Turi, J. S., 1618
Shively, C. D., and Kildsig, D. O., mechanism of dissolution IV: verification of effective interfacial concentration during dissolution of a solid, 1589
Sholkoff, S. D., *see* Rowland, M., 379
Shoop, C. E., *see* Polli, G. P., 1078
Short, M. P., Sharkey, P., and Rhodes, C. T., dissolution of hydrocortisone, 1732
Sidell, F. R., Groff, W. A., and Kaminskis, A., pralidoxime methanesulfonate: plasma levels and pharmacokinetics after oral administration to man, 1136
——Groff, W. A., and Kaminskis, A., toxogonin and pralidoxime: kinetic com-

parison after intravenous administration to man, 1765
Silber, R. H., *see* VandenHeuvel, W. J. A., 1997
Simonelli, A. P., *see* Sjuib, F., 1374, 1381
Simons, K. J., and Levy, R. H., GLC determination of sulthiame in plasma, 1252
Singh, A. R., Lawrence, W. H., and Autian, J., teratogenicity of phthalate esters in rats, 51
Sinsheimer, J. E., Guilford, J., Bobrin, L. J., and Schteingart, D. E., identification of *o,p'*-dichlorodiphenyl acetic acid as a urinary metabolite of 1-(*o*-chlorophenyl)-1-(*p*-chlorophenyl)-2,2-dichloroethane, 314
——*see* De Leenheer, A., 273, 1659
Siuda, J. F., and Cihonski, C. D., new compounds: carbamate derivatives of mafenide (homosulfanilamide), 1856
Sjuib, F., Simonelli, A. P., and Higuchi, W. I., release rates of solid drug mixtures dispersed in inert matrixes III: binary mixture of acid drugs released into alkaline media, 1374
——Simonelli, A. P., and Higuchi, W. I., release rates of solid drug mixtures dispersed in inert matrixes IV: binary mixture of amphoteric drugs released into reactive media, 1381
Skauen, D. M., *see* Higgins, D. M., 1567
Skidmore, D., *see* Gualtieri, F., 577
Skinner, W., *see* Gualtieri, F., 577
Slatkin, D. J., Doorenbos, N. J., Knapp, J. E., and Schiff, P. L., Jr., chemical constituents of *Cocculus carolinus* D.C. (Menispermaceae), 1825
Slunick, T. G., *see* Yalkowsky, S. H., 852
Smith, C. R., Jr., *see* Powell, R. G., 1227
Smith, G. B., Weinstock, L. M., Roberts, F. E., Jr., Brenner, G. S., Hoinowski, A. M., Arison, B. H., and Douglas, A. W., kinetics of equilibration of bisulfite and dexamethasone-21-phosphate in aqueous solution, 708
Smith, J. L., *see* VandenHeuvel, W. J. A., 1997
Smith, P. B., *see* Wade, A. E., 1205
Smith, R. B., *see* Kojima, S., 1061
Smith, R. V., and Leong, A., methods for the preparation of *trans*-3-methyl-2-hexenoic acid, the malodorous component of schizophrenics' sweat, 316
Smith, R. W., *see* Flynn, G. L., 61
Smith, W. B., *see* Jalal, I. M., 1466
——*see* Zaro, J. J., Jr., 814
Smolen, V. F., and Poust, R. I., interaction of hexachlorophene with human epidermis II: comparison of kinetic and equilibrium *in vivo* results obtained by direct and bioelectrometric methods, 1102
——and Williams, E. J., electrometric determination of the fixed-charge density of colloid surfaces: further confirmation of the method, 921
——Barile, R. G., and Theofanous, T. G., relationship between dose, effect, time, and biophasic drug levels, 467
——Turrie, B. D., and Weigand, W. A., drug input optimization: bioavailability-effected time-optimal control of multiple, simultaneous, pharmacological effects and their interrelationships, 1941
——*see* Theofanous, T. G., 980
——*see* Williams, E. J., 639
Snyder, F., *see* Piantadosi, C., 607, 971
Soine, T. O., *see* Chen, C.-H., 55
——*see* Zheleva, A., 1643
Sowell, J. W., *see* Saenz, R. V., 978
Spencer, L. A., and Doerge, R. F., substituted hippuramides as CNS depressants, 1331
Spiegel, D., Ahuja, S., and Brofazi, F. R., stability-indicating method for analysis of homatropine methylbromide in pharmaceutical formulations, 1630
Spitz, H. D., ghosting of ethylene glycol in GC, 1339
Stanaszek, W. F., and Ecanow, B., anesthetic gas absorption properties of surfactant systems, 860
Stauffer, S. C., *see* Hucker, H. B., 1490
Stehle, R. G., and Higuchi, W. I., *in vitro* model for transport of solutes in three-phase system I: theoretical principles, 1922
——and Higuchi, W. I., *in vitro* model for transport of solutes in three-phase system II: experimental considerations, 1931
Stein, M. L., *see* Grifantini, M., 631
Steinberg, G. M., Berkowitz, L. M., Thomas, N. C., Maddox, J. P., and Szafraniec, L. L., oxime acetates: substrates for acetylcholinesterase, 527
——Thomas, N. C., Mednick, M. L., and Amshey, J. W., Jr., acetylcholinesterase substrates: acetoxymethylpyridines and benzyl acetate, 1735
Steiner, G., Pothisiri, P., and Carstensen, J. T., surface area term in Myhill–Piper equation, 2009
Stewart, J. T., and Story, J. L., GLC determination of pentylenetetrazol in biological fluids, 1651
——and Story, J. L., *in vitro* binding of pentylenetetrazol to plasma proteins, 652
——and Wilkin, R. E., determination of sulfonamides and local anesthetics with 9-chloroacridine by quenching fluorometry, 432
——*see* Mason, W. D., 1301
Stohs, S. J., *see* Talcott, R. E., 296
Story, J. L., *see* Stewart, J. T., 652, 1651
Stremming, K. P., *see* Carstensen, J. T., 1999
Stripp, B., and Gillette, J. R., role of drug metabolism in drug research and development: factors affecting metabolism of drugs and their pharmacological and toxicological activity, 1682
Strusz, R. F., *see* Mollica, J. A., 444
Stubbins, J. F., Hudgins, P. M., Murphy, D. C., and Dickerson, T. L., anticholinergic agents based on Ariens' dual receptor site theory: nonester antagonists, 470
Stupak, E. I., and Bates, T. R., enhanced absorption and dissolution of reserpine from reserpine–polyvinylpyrrolidone coprecipitates, 400
——*see* Nightingale, C. H., 1498
Su, K. S. E., and Carstensen, J. T., nature of bonding in montmorillonite adsorbates II: bonding as an ion–dipole interaction, 420
——*see* Carstensen, J. T., 139
Sugita, E. T., *see* Harwood, R. J., 82
——*see* Niebergall, P. J., 232
Surpuriya, V., and Higuchi, W. I., interfacially controlled transport of micelle-solubilized sterols across an oil/water interface in two ionic surfactant systems, 375
Sutter, J. L., *see* Windheuser, J. J., 301, 1311
Swarbrick, J., Amann, A. H., and Lindstrom, R. E., factors affecting water vapor transmission through free polymer films, 1645
——*see* Augustine, M. A., 1656
——*see* Blois, D. W., 390, 393
Swartz, C. J., *see* Lin, S.-L., 1418
Szafraniec, L. L., *see* Steinberg, G. M., 527

T

Tadepalli, A. S., and Buckley, J. P., effects of nylidrin in endotoxin shock, 1844
Tajana, A., *see* Fontani, F., 1502
Takman, B. H., *see* Adams, H. J., 1829
Talcott, R. E., and Stohs, S. J., metabolism of aniline and hexobarbital by liver homogenates of spironolactone-pretreated male rats, 296
Tan, H. S. I., *see* Kornet, M. J., 188, 235, 1781, 1936
Tang, T. Y., *see* Wright, G. E., 299
Tanner, J. T., *see* Margosis, M., 936
Tansy, M. F., and Ganse, G., regional variations in responses of rat GI tract to local anesthetics, 1141
——and Kendall, F. M., existence of a vagosympathetic pressor reflex in the dog, 1507
——*see* Roth, R. P., 1357
Tarlin, H. I., *see* Batchelder, M., 252
Tartarini, S., dehistaminization of organ extracts by ion-exchange chromatography, 960
Tausendfreund, R. A., *see* Turi, P., 1811
Tawashi, R., and Piccolo, J., inhibited dissolution of drug crystals by certified water-soluble dyes: *in vivo* effect, 1857
Temple, C., Jr., Rose, J. D., and Montgomery, J. A., new synthesis of α-(disubstituted aminomethyl)-9-phenanthrenemethanols, 1297
Thakkar, A. L., Kuehn, P. B., Perrin, J. H., and Wilham, W. L., cycloheptaamylose–barbiturate inclusion complexes: solubility and circular dichroism studies, 1841
——*see* Martis, L., 1757
Theiner, M., *see* Kubena, R. K., 144
Theivagt, J. G., *see* Helgren, P. F., 103
Theofanous, T. G., and Smolen, V. F., multiple-dose kinetics of pharmacological effects of indirect anticoagulants, 980
——*see* Smolen, V. F., 467
Thomas, M. A., *see* Helgren, P. F., 103
Thomas, N. C., *see* Steinberg, G. M., 527, 1735
Thompson, E. B., effects of practolol, a new adrenergic receptor blocking agent on cardiovascular responses, 573
Thompson, G. R., *see* Rosenkrantz, H., 1106
Tice, I. B., *see* Perrine, T. D., 86
Ticku, M. K., *see* Kaul, P. N., 581, 1753
Tidwell, R. R., *see* Mathison, I. W., 637
Tingstad, J., Gropper, E., Lachman, L., and Shami, E., dissolution rate studies II: modified column apparatus and its use in evaluating isosorbide dinitrate tablets, 1985
Tin-Wa, M., Fong, H. H. S., Abraham, D. J., Trojánek, J., and Farnsworth, N. R., structure of sanguidimerine, a new major alkaloid from *Sanguinaria canadensis* (Papaveraceae), 1846
——*see* Messmer, W. M., 1858
Topham, J. D., a rising sphere rheometer, 783
Towill, G. A., *see* Biggs, D. F., 1739
Trent, J. E., *see* Doskotch, R. W., 570
Trojánek, J., *see* Messmer, W. M., 1858
——*see* Tin-Wa, M., 1846
Tryfiates, G. P., and Choulis, N. H., effect of benzene on rat liver ribonucleic acid, 465
Tsai, C. S., Shah, U. S., Bhargava, H. B., Zaylskie, R. G., and Shelver, W. H., synthesis of 2-dialkylaminomethyl-1,4-benzoxathians, 228
Tsai, D., *see* Felmeister, A., 1065
Tsau, J., *see* Garrett, E. R., 1052, 1404, 1411
Tse, M., *see* Nightingale, C. H., 1498
Tsilifonis, D. C., *see* Chafetz, L., 148
Tsuchiya, T., and Levy, G., biotransformation of salicylic acid to its acyl and phenolic glucuronides in man, 800
——and Levy, G., drug adsorption efficacy of commercial activated charcoal tablets *in vitro* and in man, 624
——and Levy, G., relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics, 541
——and Levy, G., relationship between effect of activated charcoal on drug absorption in man and its drug adsorption characteristics *in vitro*, 586
Tsuji, K., *see* Robertson, J. H., 1633
Tsuzuki, O., *see* Goto, S., 945
Tuckerman, M. M., Acel, K., Bican-Fister, T., Billow, J., and Gibbs, I. S., assay of official injections of amine salts, 448
Tuerck, P. A., *see* McVean, D. E., 1609
Turczan, J. W., and Goldwitz, B. A., determination of chloral hydrate in soft gelatin capsules by NMR, 613
——and Goldwitz, B. A., determination of pentylenetetrazol in tablets and injectables by NMR, 1309
——and Medwick, T., identification of sulfonamides by NMR spectroscopy, 434
Turi, J. S., Higuchi, W. I., Shipman, C., Jr., and Ho, N. F. H., systems approach to study of solute transport across membranes using suspension cultures of mammalian cells II: experimental procedures and uptake studies with cholesterol, 1618
——*see* Ho, N. F. H., 192
Turi, P., Brusco, D., Maulding, H. V., Tausendfreund, R. A., and Michaelis, A. F., rapid determination of color stability of tablet formulations, 1811
Turner, C. E., *see* Fetterman, P. S., 1476
Turner, J. E., *see* Lawrence, W. H., 19, 1712
Turrie, B. D., *see* Smolen, V. F., 1941
Twanmoh, L.-M., *see* Paull, K. D., 1481
Tyson, I. B., *see* Perrin, J. H., 1667

U

Umetsu, K., *see* Naito, S.-I., 884
Underwood, T. W., and Cadwallader, D. E., influence of various starches on dissolution rate of salicylic acid from tablets, 239

V

Vacik, J. P., *see* Hopkins, L. V., 114
Vaidhyanathan, V. S., influence of complex formation on drug transport, 894
——significance of coupling terms in passive transport of drugs affected by complex formation reactions, 2001
Valentine, J. L., Wiegert, P. E., and Charles, R. L., GLC determination of methadone in human urine, 796
VandenHeuvel, W. J. A., Smith, J. L., and Silber, R. H., β-(2-methoxyphenoxy)lactic acid, the major urinary metabolite of glyceryl guaiacolate in man, 1997
Vanhaelen, M., Indeherberg, J., and Bauduin, H., further chemical and pharmacological characterization of *Bersama yangambiensis* Toussaint (Melianthaceae), 1165
Varma, R. S., and Nobles, W. L., substituted 3-aminomethylbenzoxazoline-2-thiones as potential antibacterial agents, 112
Venturella, V. S., *see* Manius, G., 1831
Verner, D., *see* Bailey, K., 480
Vidi, A., *see* Coppi, G., 1460
Vilallonga, F. A., Garrett, E. R., and Cereijido, M., kinetics and mechanisms of monolayer interactions I: cetyl sulfate and cetrimonium ions interacting with dipalmitoyl lecithin and dipalmitoyl glycerol, 1720
Vincenzi, F. F., *see* Nelson, W. L., 1640
Vohra, M. M., *see* Yung, D. K., 1953
Vold, R. D., and Mittal, K. L., effect of age on ultracentrifugal stability of liquid petrolatum–water emulsions, 769
Von Lehmann, B., *see* Wan, S. H., 1288
Vora, K. R. M., Higuchi, W. I., and Ho, N. F. H., analysis of human buccal absorption of drugs by physical model approach, 1785

W

Wade, A. E., Wu, B., and Smith, P. B., effects of ascorbic acid deficiency on kinetics of drug hydroxylation in male guinea pigs, 1205
Wadke, D. A., and Reier, G. E., use of intrinsic dissolution rates to determine thermodynamic parameters associated with phase transitions, 868
Wagner, J. G., *see* DiSanto, A. R., 552, 598, 1086, 1090
Wakita, H., *see* Naito, S.-I., 1212
Walash, M. I., and Agarwal, S. P., characterization of sulfonamides by TLC using metal ions, 277
——*see* Agarwal, S. P., 779
Walkenstein, S. S., role of drug metabolism in drug research and development, 1673
Wallace, J. E., Hamilton, H. E., Payte, J. T., and Blum, K., sensitive spectrophotometric method for determining methadone in biological specimens, 1397
Walle, T., *see* Garteiz, D. A., 1728
Wan, L. S. C., anionic surfactant effect on viscosity of salicylic acid–cetrimide system, 642
Wan, S. H., and Riegelman, S., renal contribution to overall metabolism of drugs I: conversion of benzoic acid to hippuric acid, 1278
——and Riegelman, S., renal contribution to overall metabolism of drugs II: biotransformation of salicylic acid to salicyluric acid, 1284
——Von Lehmann, B., and Riegelman, S., renal contribution to overall metabolism of drugs III: metabolism of *p*-aminobenzoic acid, 1288
Wang, R. I. H., *see* Friedman, H. L., 1663
Warner, C. R., *see* Prue, D. G., 249
Warrick, P., *see* Rubin, A., 739
Waters, J. A., Kondo, Y., and Witkop, B., photochemistry of steroids, 321
Watson, J. R., Matsui, F., McConnell, P. M. J., and Lawrence, R. C., rapid GLC quantitation of salicylic acid in multicomponent codeine and propoxyphene analgesic formulations, 929
Weber, D. J., high pressure liquid chromatography of benzodiazepines: analysis of ketazolam, 1797
——Ennals, T. R., and Mitchner, H., versatile system for partition chromatography of corticosteroids and prediction of their elution curves, 689
——*see* Garrett, E. R., 1241
Weigand, W. A., *see* Smolen, V. F., 1941
Weiner, N. D., Lu, M. Y., and Rosoff, M., interactions of dimethyl sulfoxide with lipid and protein monolayers, 1098
——*see* Felmeister, A., 1065
Weinfeld, R. E., *see* Kaplan, S. A., 773
Weinryb, I., Chasin, M., Free, C. A., Harris, D. N., Goldenberg, H., Michel, I. M., Paik, V. S., Phillips, M., Samaniego, S., and Hess, S. M., effects of therapeutic agents on cyclic AMP metabolism *in vitro*, 1556
Weinstock, L. M., *see* Smith, G. B., 708
Weisleder, D., *see* Powell, R. G., 1227
Westlake, W. J., use of confidence intervals in analysis of comparative bioavailability trials, 1340
——*see* Caldwell, H. C., 984
White, A. I., *see* Kandeel, E. M., 1231
White, M., *see* Bowman, F. W., 532
White, S. E., *see* Hucker, H. B., 1490
Whitlock, H. W., Jr., *see* Digenis, G. A., 206
Whitworth, C. W., *see* Jun, H. W., 1160
Wiedhopf, R., *see* Sheth, K., 1819
Wiegand, R. G., and Chun, A. H. C., serum protein binding of erythromycin and erythromycin 2′-propionate ester, 425
Wiegert, P. E., *see* Valentine, J. L., 796
Wiley, R., *see* Pitman, I. H., 918
Wilham, W. L., *see* Thakkar, A. L., 1841
Wilken, L. O., Jr., *see* Crevar, G. E., 1336
Wilkin, R. E., *see* Stewart, J. T., 432
Willette, R. E., and Cammarato, L. V., phytochemical survey of Connecticut I: isolation of monocrotaline from *Crotalaria sagittalis* L. fruit, 122
Williams, C., *see* Wormser, H. C., 1168
Williams, E. J., and Smolen, V. F., determination of CMC from liquid junction potential measurements, 639
——*see* Smolen, V. F., 921
Williamson, G., *see* Batchelder, M., 252
Wilson, W. L., *see* Radecka, C., 430
Windheuser, J. J., and Jato, J., 5-fluorouracil and derivatives in cancer chemotherapy II: possible *in vivo* formation and stabilization of 5-fluoro-2′-deoxyuridine, 1669
——Sutter, J. L., and Auen, E., 5-fluorouracil and derivatives in cancer chemotherapy: determination of 5-fluorouracil in blood, 301
——Sutter, J. L., and Sarrif, A., analysis of scopolamine and its degradation products by GLC and liquid partition chromatography, 1311
——*see* Patel, S., 1794
Winkler, V. W., Regnier, F. E., Yoder, J. M., and Macy, L. R., GLC analysis of menadione bisulfite addition compounds by on-column pyrolysis to menadione, 1462
Witkop, B., *see* Waters, J. A., 321
Wittebort, R., *see* Notari, R. E., 1189
Wood, H. B., Jr., *see* Paull, K. D., 1481
Woodruff, C. W., and Nuessle, N. O., effect of processing variables on particles obtained by extrusion–spheronization processing, 787
——Peck, G. E., and Banker, G. S., dissolution of alkyl vinyl ether–maleic anhydride copolymers and ester derivatives, 1916
——Peck, G. E., and Banker, G. S., effect of environmental conditions and polymer ratio on water vapor transmission through free plasticized cellulose films, 1956
Wormser, H. C., Israsena, S., Meiling, M. S., Williams, C., and Perlman, D., synthesis and growth-promoting activity of *dl-cis*-hexahydro - 4 - (4 - carboxybutyl) - 2-cyclopentimidazolone: carbobiotin, 1168
Wright, G. E., and Tang, T. Y., photooxidation of reserpine, 299
Wright, N., *see* Gibson, P. F., 169
Wu, B., *see* Wade, A. E., 1205
Wu, M. T., and Lyle, R. E., new compounds: amino acid derivatives of nicotinic acid, 477
——and Lyle, R. E., new compounds: convenient preparation of nicotinoyl glycine derivatives, 141

X

Y

Yaffe, S. J., *see* Levy, G., 143
Yakatan, G. J., Juneau, R. J., and Schulman, S. G., phototautomerism of warfarin cation in lowest excited singlet state *via* an intramolecular hydrogen bridge, 749
Yalkowsky, S. H., and Zografi, G., calculation of partial molal volume in micellar systems, 793
——Flynn, G. L., and Amidon, G. L., solubility of nonelectrolytes in polar solvents, 983
——Flynn, G. L., and Slunick, T. G., importance of chain length on physicochemical and crystalline properties of organic homologs, 852
——*see* Flynn, G. L., 312, 838
——*see* Zografi, G., 651
Yamauchi, T. N., *see* O'Neill, H. J., 863, 1292
Yang, S. S., and Guillory, J. K., polymorphism in sulfonamides, 26
Yau, E. T., *see* Huang, C. L., 119
Yau, S. J., *see* Cammarata, A., 723
Yazdizadeh, K., *see* Aynehchi, Y., 292
Yeh, K. C., and Higuchi, W. I., influence of chain length on oil–water ion-pair partitioning behavior of *p*-alkylpyridinium chlorides, 1648
Yoder, J. M., *see* Winkler, V. W., 1462
Young, C. Y., *see* Schott, H., 182, 762
Yung, D. K., Lo, E. K. F., and Vohra, M. M., potential antiarrhythmic agents III: 2′-amino - *N* - [2 - (substituted amino)ethyl]-2,6-dimethylbenzamides, 1953

Z

Zagar, L. A., determination of residual ethylene oxide in methyl methacrylate polymer powders by GLC, 1801
Zaro, J. J., Jr., and Smith, W. E., technique for preparing simulated coated dosage forms and preliminary evaluation of sprayed and cast films, 814
Zatz, J. L., accumulation of organochlorine pesticides in man, 948
——penetration of polymer monolayers, 977
Zaylskie, R. G., *see* Tsai, C. S., 228
Zee-Cheng, K.-Y., and Cheng, C. C., practical preparation of coralyne chloride, 969
——*see* Cheng, C. C., 485
Zemer, R. E., *see* Schirmer, R. E., 428
Zheleva, A., Soine, T. O., and Bubeva-Ivanova, L., natural coumarins V: isolation of xanthalin and a new pyranocoumarin, peuarenine, from *Peucedanum arenarium* W.K., 1643
Zografi, G., and Yalkowsky, S. H., comments on the apparent shape of micelles, 651
——*see* Yalkowsky, S. H., 793
Zoorob, H., *see* Nabih, I., 967, 1327

SUBJECT INDEX

A

Absorbability, drugs—correlated with *in vitro* transfer across everted intestinal sac, 1361

Absorption, aspirin—relationship between salicylic acid concentration in saliva and plasma, man, 1219
buccal—*p*-*n*-alkyl phenylacetic, *p*-halogen phenylacetic, and toluic acids, application of partition coefficients, 1785
cyheptamide—effect of micronization, rats, 408
drug—three-phase (w/o/w) model investigated relative to pH–partition theory, 1931
drug—three-phase (w/o/w) model proposed to study pH–partition theory, 1922
gastric—sodium nitrite, mice, 1492
GI, sodium fusidate—effect of cholestyramine, rats, 735
GI—sulfameter polymorphs, man, 1615
GI, theoretical—effect of hydrostatic (or osmotic) flow and surface pH on drug transport, 192
inhibition—activated charcoal, *in vivo*, *in vitro* studies, 586
intestinal—effect of complex formation, prednisolone, rats, 367
in vivo—correlated to *in vitro* transport, three-phase model cell, sulfanilamides, liquid lipid barrier, 1656
kinetics—aspirin, oral aqueous solution, man, 379
oral—application of intravenous clearance concepts to calculate bioavailability, 70
oral—radiolabeled mepenzolate bromide, humans, 1663
percutaneous—salicylate in hydrophilic ointment, effect of pH, dimethyl sulfoxide, prior exposure, 172
—pralidoxime methanesulfonate after oral administration, compared to pralidoxime chloride, man, 1136
rate constants—effect of parallel first-order drug loss from site of action on calculated values, 135
rates, pseudoephedrine—effect of concurrent antacid administration, man, 903
riboflavin—enhanced with use of sodium alginate solutions for administration, 279
riboflavin—nonlinear pharmacokinetics, rats, 404
species dependent—methylene blue after oral administration, man, dog, 1086
spirolactones—disposition, metabolism, dogs, 1132
subcutaneous—local anesthetic amines, pH control in the absorption cell, 1263
water—effect on drug absorption rates in the intestine, 110

Abuse drugs—reliability of urine screening program, excretion data, validation of extraction and identification techniques, 305

Acetals—synthesis, evaluation as mosquito repellents, 577

***p*-Acetamidobenzoic acid** as *p*-aminobenzoic acid metabolite—renal metabolism and clearance, role of kidney reevaluated, 1288

2 - Acetamidoethyl (*p* - chlorophenyl)(*m*-trifluoromethylphenoxy)acetate (halofenate)—effect on binding of various drugs to human plasma proteins and on the plasma half-life of antipyrine in monkeys, 1490

***p*-Acetamidohippuric acid** as *p*-aminobenzoic acid metabolite—renal metabolism and clearance, apparent clearance, role of kidney reevaluated, 1288

Acetaminophen—complexation with methyl xanthines, particularly caffeine and theophylline, 1454
dosage forms—stability-indicating polarographic analysis, glassy carbon electrode, 1627
metabolism—effect of prior aspirin administration, enzyme systems involved, man, 1474
tablets and elixir—colorimetric analysis, as 2-nitro-4-acetamidophenol, 927

Acetaminophen–antipyrine complex—nature of complexation, 1661

Acetohydroxamic acid—from ethyl acetate, rate constants, hydroxide-ion effect, colorimetric assay, 244

***m*-Acetotoluide**—concentration gradients developed during dissolution from fused disks, column model, 214
dissolution—relationship between rate and solid–liquid interfacial energy in four organic solvents, 1478
—graphical determination of surface tension and particle size in equilibrium with saturated solution, 281

Acetoxymethylpyridine, methiodides—as acetylcholinesterase substrates, hydrolysis rates, 1735

Acetylcholine—colorimetric assay, 244
contractions—effect of local anesthetics, rat GI tract, 1141

Acetylcholinesterase, organophosphorus inhibited—structure–activity relationships of reactivators (hydroxyiminomethylimidazole quaternary salts), 631
—oxime acetates as substrates, 527
substrates—acetoxymethylpyridines, benzyl acetate, 1735

Acetyldigitoxin—separation from acetyldigoxin in *Digitalis lanata* extracts, 1320

Acetyldigoxin—separation from acetyldigitoxin in *Digitalis lanata* extracts, 1320

Acetylsalicylsalicylic acid in aspirin formulations—GLC analysis, 1794

Acid-dye technique—monitoring of hydrolysis rates of 5-aminodibenzo[*a*,*d*]-cycloheptanes, 1197

Acid hydrazides—nickel (II)-catalyzed hydroxamic acid formation, ferric hydroxamate colorimetric analysis, 211

Acridans—synthesis, oxidative fragmentation, 206

Acridine derivatives—GLC and TLC (fluorescent scanning) studies, analysis of 9-alkylaminoacridines in presence of their hydrolytic products, 1659
—formation by oxidative fragmentation of 9-aminomethylacridan, 206

Actinomycins—use in cancer chemotherapy, 485

Activated charcoal tablets—adsorption characteristics, *in vitro*, in man, 624

N^1 - Acyl - 4 - arylazopyrazoles—synthesis, screened for pharmacological activity, 130

Acyl dihydroxyacetone phosphates and related derivatives—synthesis for use as biosynthesis intermediates, 971

Adenosine-3′,5′-monophosphate metabolism, *in vitro*—effects of 158 compounds (49 classes of therapeutic agents), 1556

Adjuvant formulations—characterization of mannide monooleate emulsifier, 863
mineral oils—separation, UV and mass spectrometry characterization, 1292

α-Adrenergic blocking agents, potential—evaluation of 2-dialkylaminomethyl-1,4-benzoxathians, 228

β-Adrenergic blocking agents and metabolites—mass fragmentation patterns of trifluoroacetyl derivatives, 1728
blocking agents, cardioselective—practolol evaluation, 573
stimulants—effect of nylidrin on endotoxin-induced shock, 1844

Adriamycin—use in cancer chemotherapy, 485

Adsorbates, montmorillonite—nature of bonding, ion–dipole interaction hypothesized, 420

Adsorbents—used to increase dissolution rates of drugs, characterization of drug–excipient binding, 1435
—used to increase the dissolution rates of relatively insoluble drug powders, 1430

Adsorption characteristics—commercial activated charcoal tablets, *in vitro*, in man, 624
in vitro, activated charcoal—effect of pH, 586
of ionic surfactants on highly dispersed silicas—solvent effect, 700
organic compounds on montmorillonite—surface adsorption mediated by ion–dipole interaction, diazepam isotherms determined, 420

Aerosols—formulation of epinephrine maleate, malate, fumarate, and bitartrate, 219
inhalation—*in vitro* penetration efficiency evaluation, 262
occlusive dressing—evaluation of physical constants of polymeric films, kinetics of drug release proposed, 754

Agar diffusion technique—screening of 3-aminomethylbenzoxazoline-2-thiones as antibacterial agents, 112

Agkistrodon piscivorus, radiolabeled—distribution and excretion, rats, 119

Albumins, various human—binding of ^{99m}technetium, effect of albumin purity, dialysis and gel filtration, 1667

Alcohols, aliphatic—diffusivity and solubility in polyurethan films, thermogravimetric analysis, 1094

Alkaloids, biosynthesis—*Datura innoxia* root tissue, tropic acid pathways studied, 2006
cactus—chromatographic identification in seven Coryphantha species, 41
erythrina—isolation, identification, pharmacological evaluation of 11 constituents of *Erythrina variegata*, 1274
plant—isolation and identification of cathanneine from *Catharanthus lanceus*, 298
—structure of sanguidimerine isolated from *Sanguinaria canadensis*, 1846

Alkaloid–protein syntheses relationship—*Datura stramonium* L. var. *tatula*, 1257

9-Alkylaminoacridines—analysis in presence of their hydrolytic products, 1659

Alkyl *p*-aminobenzoates—effect of chain length on membrane diffusion, 838
—effect of chain length on melting point, solubilities, partition coefficients, crystalline properties, 852

3-Alkyl-3- and 4-alkyl-4-(*m*-methoxyphenyl)-pyrazolidines—synthesis, evaluation of analgesic activity, 188

***N*-Alkyl-*N*-[1-(2-bromopropionyl)]aniline** derivatives—prepared as selective antihistaminic agents, 974

1-*O*-Alkyl-3-*O*-phosphorylethanolamine-2-propanes—synthesis, characterization, ketal derivatives, 607

***p*-Alkylpyridinium** chlorides—influence of chain length on oil–water ion-pair partitioning behavior, 1648

Alkyltrimethylammonium salts—coacervation with amaranth, 502

Alkyl vinyl ether–maleic anhydride copolymers and partial esters—dissolution rates, related to use as timed-release coatings, 1916

Aluminum hydroxide gel—enhancement of pseudoephedrine absorption, man, 903

Amaranth—coacervation with alkytrimethylammonium salts, 502

Amide linkage—synthesis of homodetic cyclic peptides, review, 1345

Amides—synthesized from [(10,11-dihydro-5*H*-dibenzo[*a*,*d*]cycloheptan-5-yl)thio]-acetic acid, pharmacological screening, 978

Amine hydrochlorides—solubility as a function of pH, temperature, and solvent composition, 1896
salt injections—titrimetric assay with *p*-naphtholbenzein, compared to potentiometric method, 448

Amines, active—synthesized from anils, 1504
monobasic, and salts—phase solubility

analysis using solubility product relationships, theory, method, 1069
primary and secondary—comparative electron-capture sensitivity with various derivatives, 1235
primary—fluorescence measurement of cyclized 2-butylamino-1,3-thiazino-[4,5,6-*kl*]acridine, 273
Aminoacetals—synthesis, evaluation as mosquito repellents, 577
***p*-Aminoacetophenone**—diffusion across dimethylpolysiloxane membranes, 61
L-Amino acid decarboxylase transformation of levodopa to dopamine—analysis of D-dopa in levodopa formulations, 1460
Amino acid derivatives of nicotinic acid—synthesis, 477
—prediction of sweetness, molecular features, 1394
—synthesis of cyclic peptides, review, 1345
Aminoalkylnaphthols (heterocyclicamino)—synthesis as possible antimalarial agents, 1500
***p*-Aminobenzoic acid**—metabolism, disposition kinetics, reevaluation of contribution of kidney to clearance, 1288
5-Amino-10,11-dihydro-5*H*-dibenzo[*a,d*]-cycloheptane derivatives—synthesis, hydrolysis rates, acid-dye monitoring, 1197
2-(Aminoethanesulfonylamino)pyridine and nicotinoyl derivative—biopharmaceutical studies, rabbits, rats, 884
Aminoethanesulfonylphenetidine—effect on erythrocytolysis and methemoglobin production, plasma levels in rabbits, 1791
Aminoethanesulfonylpiperidine—blood levels, distribution, and excretion in animals, pharmacological activity, 198
***p*-Aminohippuric acid** as *p*-aminobenzoic acid metabolite—renal metabolism and clearance, apparent clearance, role of kidney reevaluated, 1288
9-Aminomethylacridan—synthesis, oxidative fragmentation, acetamide formation, 206
3-Aminomethylbenzoxazoline-2-thiones, substituted—screened as potential antibacterial agents, 112
α-Aminomethyl-9-phenanthrenemethanols—synthesis, 1297
3-Aminopropionates, methyl—synthesis, screened as potential hypotensive agents, 1739
3-Aminopropionohydroxamic acids—synthesis, screened as potential hypotensive agents, 1739
Aminopyrine plasma levels, barbital-induced enhancement—relationship to gastric emptying rates, phenol red transfer in duodenum, rabbits, 945
4-Amino-*N*-[2-(substituted amino) ethyl]-2,6-dimethylbenzamides—synthesized as potential antiarrhythmic agents, 1953
Amitriptyline oxidation, permanganate—identification of dibenzosuberone and anthraquinone as products, 986
Amobarbital–dextroamphetamine sulfate timed-release formulations—GLC separation, UV spectrophotometric analysis, 101
Amphetamine isomers—interactions with optically active and racemic mandelic and tartaric acids, thin-layer electrophoresis, molecular associations, 1325
Amphetamine–mandelic acid interaction—conductimetric study of optically active ions, 293
Amphetamines—detection procedures in urine screening programs, review, 655
methoxylated—UV spectra correlated with hallucinogenic potency, 480
Amphetamine sulfate isomer mixtures—determination of isomeric composition from melting point of monohydrogen succinate salt, 1976
Amphetamine–tartaric acid interaction—conductimetric study of optically active ions, 293
Amphoteric drug mixture (sulfapyridine–sulfadiazine)—release from inert matrix, solvent effects, equations, 1381
Ampicillin and hetacillin in solution—stability, equilibrium, ampicillin degradation, 906
—β-lactamase activity. rate of inactivation, pH-stat alkalimetric titration, compared to other penicillins, 1594
—polymorphic phase transition parameters determined from intrinsic dissolution rates, 868
—stability in aqueous solution, compared to hetacillin, mechanisms proposed for chemical alterations, 727
Ampuls, flame sealed—inadequacies of leakage test procedures demonstrated, 1609
Amyl nitrite ampuls—NMR stability assay, 428
α-Amyrin—isolated from *Bursera schlechtendalii*, 1992
β-Amyrin—TLC isolation, IR identification from *Euphorbia myrsinitis*, 292
Analgesic activity—determination by Nilsen method, compared to hot-plate procedure, 86
activity—determination, nonoxygenated phenylpyrazolidines, 235
activity—evaluation of oxygenated phenylpyrazolidines, 188
agents, potential—1,2-dialkyl-4-aryl and 1,2,4-trialkyl-4-aryl piperidazines, 1781
agents, potential—synthesis of 1,2-dialkyl- and 1,2,3-trialkyl-3-aryl piperidazines, screened, 1936
availability—effect of complexation, 1454
Analgesic/anti-inflammatory activity, evaluation—yeast paw edema method, comparison with aspirin, 75
Analgesics—simultaneous metabolism of aspirin and acetaminophen, man, 1474
Androstanes—photoreactions, review, 321
Anesthetic absorption, gaseous—effect of surfactant systems, 860
activity, local—(±)-2-(*N*-ethylpropylamino)-2′,6′-butyroxylidide, 1829
activity of aliphatic ethers—related to lipophilicity, correlated with hypnotics in solution, 589
amines, local—*in vitro* subcutaneous absorption, pH control, 1263
Anesthetics, local, containing primary aromatic amine—analysis, 9-chloroacridine, quenching fluorometry, 432
local—effect on acetylcholine-induced contraction of isolated rat GI tract segments, 1141
Angustibalin—isolation from *Balduina angustifolia*, structure identification, cytotoxic activity, 626
Anhydrotetracyclines—column chromatographic analysis, tetracycline base or hydrochloride, 615
Aniline, *N,N*-dialkylaminoalkyl derivatives—synthesis, designed to elicit selective antihistaminic activity, 974
—metabolism by liver homogenate of spironolactone-pretreated male rats, 296
substituted—effects of structure on permeability, from aqueous solution through polyethylene, correlated with hexane–water partition coefficients, 416
Anils—used for synthesis of active amines and amine salts, 1504
Anisotropine methylbromide—intestinal sorption, rats, 1223
Antacids—adsorption of belladonna alkaloids, desorption for analysis, 1458
dissolution rate—surface area term, Myhill–Piper equation, 2009
—effect on pseudoephedrine absorption, man, 903
Anthramycin—use in cancer chemotherapy, 485
Anthraquinone and dibenzosuberone—identification as oxidation products of amitriptyline, 986
Antiarrhythmic activity—evaluation and comparison of diphenylhydantoin, trimethadione, mephenytoin, ethotoin, methsuximide, and procainamide, 133
agents, decahydroisoquinolines—steric and physicochemical studies, structure–activity relationships, 637
agents, potential—synthesis of 4-amino-*N*-[2-(substituted amino)ethyl]-2,6-dimethylbenzamides, 1953
Antibacterial activity—correlated to metal-binding ability, heterocyclic thiones, 1209
agents, potential—substituted 3-aminomethylbenzoxazoline-2-thiones screened, 112
agents, potential—synthesis of carbamate derivatives of homosulfanilamide, 1856
agents—sulfonamides, mode of action, 142
Antibiotics, antineoplastic—review, 485
—automated bioassay readout, 449
combined—effect of erythromycin and lincomycin (Phase II) against *Escherichia coli*, 545
ophthalmic ointments—survey of microbial contamination in commercial preparations, 532
—pharmaceutical aspects, 989
—selected mushroom metabolites screened for antimicrobial activity, 1820
stability in aqueous solution—comparison of ampicillin and hetacillin, mechanisms proposed for chemical alterations, 727
Antibodies, polypeptide produced—specificity, 806, 1990
Anticholinergic agent (propantheline bromide)—effect on riboflavin absorption, man, 798
agents—synthesized, pharmacological screening, related to Ariëns' dual receptor site theory, 470
Anticholinesterase activity—pharmacological evaluation of naturally occurring and synthetic β-carbolines, mechanism of action, 808
intoxication therapy—kinetic comparison of toxogonin and pralidoxime, intravenous administration, man, 1765
Anticoagulants, coumarin—TLC separation and identification, 1303
(warfarin and dicumarol)—mathematical derivation of multiple-dose kinetic equations, pharmacological effects, 980
Anticonvulsant activity—evaluation of succinic semialdehyde, 1963
activity—1-substituted acetyl-3-aryl carbamides, correlated to inhibition of nicotinamide adenine dinucleotide-dependent pyruvic acid oxidation, 1366
activity—3,4,5-trimethoxybenzamides synthesized and screened, 1157
agents, potential—synthesis and evaluation of 2-alkyl substituted 1-(4′-benzhydrazide)aminomethylbenzimidazoles, 1322
drugs—evaluation as antiarrhythmic agents, 133
drugs—hydrogen binding to peptide bond, mode of action hypothesis, 1717
Antidiabetic agents, potential—synthesis and biological activity of N^1-phenylcarbamoyl-4-arylazo(3- and/or 5-substituted)pyrazoles, 957
Antidotes—adsorption, absorption characteristics of activated charcoal, 586
Antigenic polypeptides—immunochemical properties evaluated, 806
Antigens, polypeptide produced—conformation dependency to poly(L-tyrosyl-L-glutamyl-L-alanylglycyl)glycine-1-^{14}C ethyl ester, 1654
Antihistamines, potential—synthesis of aniline derivatives for increased receptor specificity, 974
potential—synthesis of sulfide amides, pharmacological screening, 978
Antihypertensive activity—1-(2,3-dihydro-5-methoxybenzo[*b*]furan-2-ylmethyl)-4-(*o*-methoxyphenyl)piperazine and salts, dogs, 1418
Anti-inflammatory agents, potential—synthesis of *p*-substituted 1,2-diphenylindolizines, pharmacological screening, 949
agents, screening program—correlation between *in vivo* carrageenin-induced edema and *in vitro* lysosomal-labilizing properties of *N,N,N′,N′*-tetramethylazoformamide, rats, 1450
drugs, nonsteroid—effect on blood glucose and carrageenin-induced pedal edema, compared to tolbutamide and tetrahydroalstonine, rats, 1202
properties—constituents of leaves of *Yucca schottii*, 1665
Anti-inflammatory/analgesic activity, evaluation—yeast paw edema method, comparison with aspirin, 75
Antileukemic alkaloids—process for the large-scale synthesis of coralyne chloride, 969
Antimalarial agents, potential—synthesis of (heterocyclicamino) aminoalkylnaphthols and reduced tetrahydro derivatives, 1500
Antimicrobial activity—eight thiocarbohydrazide-1,5-dicarboxylic acid diesters, 1486
activity—mushroom metabolites screened, 1820

Antimuscarinic activity—nonester antagonists prepared and evaluated, Ariëns' dual receptor site theory tested, 470
Antineoplastic agents, potential—inhibitors of t-RNA *O*-methyltransferase, 645
antibiotics—review, 485
Antipyrine half-life—effect of halofenate administration, 1490
Antipyrine–acetaminophen complex—nature of complexation, 1601
Antitumor activity—fagaronine, isolated from *Fagara zanthoxyloides*, 1858
activity—four plants studied, activity due to tannins, 1818
activity—isolation and structure determination of two lignans from *Bursera schlechtendali*, 1992
activity—mammein, related coumarin and phloroglucinol derivatives, 1599
agents—betulinic acid isolated from *Hyptis emoryi*, identified as the tumor-inhibiting constituent, 1819
agents, potential—constituents of *Balduina angustifolia*, 626
agents, potential—eupatolide, major constituent of *Eupatorium formosanum* HAY., 629
agents, potential—five cardenolides from *Cryptostegia grandiflora*, 570
agents, potential—pharmacological testing of a bufadienolide from *Bersama yangambiensis* Toussaint, 1165
agents—purification of stoichactin from sea anemone, pharmacological testing with Ehrlich ascites tumor, mice, 1814
agents, screening—simple, rapid microplate tissue culture method, 1960
alkaloids from *Cephalotaxus harringtonia*—structure, activity, 1227
alkaloids—isolation of leurosine from *Catharanthus lanceus*, 1840
Antiviral activity—cryptopleurine from *Boehmeria cylindrica*, 1508
Apomorphine-like activity, potential—nornuciferine derivatives screened, dogs, pigeons, mice, 813
Aporphines, pentamethoxy—synthesis of 9-(3,4-dimethoxyphenoxy)-1,2,10-trimethoxyaporphine, 1481
Arabinosylcytosine stability in aqueous solutions—pH profile, shelflife predictions, 1189
3-Aryl piperidazines, 1,2-dialkyl and 1,2,3-trialkyl—synthesized as potential analgesics, screened, 1936
Ascorbic acid—aerobic oxidation, pH–log rate profile, effect of disodium ethylenediaminetetraacetate, 556
deficiency—effect on kinetics of drug hydroxylation, guinea pig liver, 1205
in multivitamin dosage forms—analysis, tubular carbon electrode oxidation, 1301
—separation from 2-keto-L-gulonic acid, cation-exchange chromatography, 1333
L-Asparaginase of *Escherichia coli* B—reversible dissociation, conformational changes, activity, 791
Aspirin absorption—relationship between salicylic acid concentration in saliva and plasma, man, 1219
and codeine or propoxyphene formulations—GLC analysis of salicylic acid, 929
and ethanol—effect on gastric mucosa, rats, 815
—decomposition in polyethylene glycols at various temperatures, 1160
dissolution from tablets—effect of 11 buffering agents, 1370
formulations—GLC analysis, 1794
metabolism—effect of subsequent acetaminophen administration, enzyme systems involved, man, 1474
oral—absorption kinetics, aqueous solution, man, 379
***Atropa belladonna* L.**—effect of gibberellic acid on growth, flowering, and alkaloidal content, 1970
Automated analysis—turbidimetric microbiological assay, 449
Azaserine and related compounds—use in cancer chemotherapy, 485

B

Bacteria—electrokinetic studies, 182
Bactericidal activity—quaternary ammonium compounds, 390, 393
Balduina angustifolia (Pursh.) Robins—isolation, identification, of four cytotoxic constituents, 626
Balloon technique—recording of gastric contractions in conscious, unrestrained rats, 1357
Banisteriopsis quitensis, alkaloid extract—inhibition of rabbit ileal strip motility, effect of strip calcium content, 623
Barbital-induced enhancement of aminopyrine plasma levels—relationship to stomach emptying patterns, rabbits, 945
Barbiturate–cycloheptaamylose inclusion complexes—solubility and circular dichroism studies, 1841
Barbiturates—detection procedures in urine screening programs, review, 655
narcotics, and CNS stimulants—TLC identification, drug abuse urine screening program, 679
rapid identification—mass spectroscopy, 310
—separation, analysis, high pressure liquid chromatography, 1979
Barbituric acid derivatives—mechanism of butalbital degradation, ring cleavage, 1389
acids—rapid identification by mass spectroscopy, 310
Barium peroxide–sulfuric acid oxidation—analysis of methadone, 1397
Base strength of benzacridines and amino derivatives—relationship to electronic structure, molecular orbital calculations, 909
Basidiomycetes—metabolites screened for antimicrobial activity, 1820
Belladonna alkaloids—desorption from antacids for analysis, 1458
Benzacridines and amino derivatives—relationship between electronic structure and base strength, molecular orbital calculations, 909
Benzalkonium effect—phenylethanol-resistant and sensitive *Pseudomonas aeruginosa* cultures, 1075
***d,l*-α-Benzamido-4-hydroxy-3-methoxydihydrocinnamic acid**—resolution using dehydroabietylamine, 1506
Benzene, intraperitoneal administration—effect on rat liver ribonucleic acid, 465
1-(4′-Benzhydrazide)aminomethylbenz-imidazoles, 2-alkyl substituted—synthesis, evaluated as MAO inhibitors, anticonvulsant activity, 1322
Benzodiazepines, conjugated hydroxy—biliary excretion in rats, guinea pigs, mice, 965
—separation, analysis, high pressure liquid chromatography, 1797
Benzoic acid biotransformation to hippuric acid—kidney metabolism contribution contrasted to whole body, renal and apparent clearances, 1278
derivatives—solid-state decomposition, rate constants, 1112
dissolution in aqueous polysorbate 80 solutions—micellar diffusion coefficient calculated, constant and uncontrolled viscosity, determination of diffusion layer thickness, 592
dissolution rates—in sucrose, in methylcellulose, and in polysorbate 80 aqueous solutions, 175
Benzoic acid–salicylic acid mixture—release from inert matrix, effect of alkaline phosphate solvent, equations, 1374
ointments—colorimetric analysis, 1625
Benzophenone—UV analysis as methadone oxidation product, 1397
3,4-Benzpyrene—interaction with various molecular films, biological significance, 1065
Benzyl acetate—as acetylcholinesterase substrate, 1735
Benzylideneanilines, *p*-substituted—diethyl phosphonate addition kinetics, 114
Benzylisoquinoline alkaloids—isolation and identification of *N*-methylpalaudinium from *Thalictrum polygamum*, 295
***N*¹-Benzylphenyl-*N*²-(substituted phenyl)-urea** series—prepared and tested for antibacterial, antifungal, and antiviral activities, 125
Bersama yangambiensis Toussaint (Melianthaceae)—chemical and pharmacological characterization, isolation and identification of a bufadienolide, 1165
Betulinic acid—identified as the tumor-inhibiting constituent of *Hyptis emoryi*, 1819
Biguanides—analysis, bromthymol blue ion-pair extraction, urine, 1404
—analysis in biological fluids, ion-pair extraction, comparison of protein binding estimates, 1411
Biliary excretion—conjugated hydroxyl benzodiazepines in rats, guinea pigs, mice, 965
excretion—riboflavin absorption in man, 143
excretion—spirolactones, dogs, 1132
Binary drug systems—release from inert matrix, effect of alkaline phosphate solvent, equations, 1374
drug systems—release from inert matrix, solvent effects, equations, 1381
Binders—effect on granule and tablet physical properties, fluidized bed granulation, 618
Bioavailability—application of intravenous clearance concepts in the calculation of oral availability, 70
—*in vitro* transfer across everted intestinal sac correlated with *in vivo* absorbability, 1361
of incompletely absorbed drugs—effect of concurrent anticholinergic administration, 798
of sulfamethizole tablets—compared to dissolution rates, 746
polymorphs of an experimental antihypertensive—effect of recrystallization from different solvents on dissolution kinetics, 1423
—relationship between *in vivo* activated charcoal absorption inhibition of drugs and *in vitro* adsorption and physicochemical properties, 586
—reserpine–polyvinylpyrrolidone coprecipitates, *in vivo* absorption correlated with *in vitro* dissolution, rats, 400
—sulfameter polymorphs, GI absorption, man, 1615
—sulfisoxazole, intramuscular and oral administration, man, 773
trials, comparative—analysis, use of confidence intervals, 1340
Bioelectrometric determination—equilibrium and kinetics of sorption–desorption, hexachlorophene on human epidermis, compared to spectrophotometric determination, 1102
Biopharmaceutics—development of dosage forms, 1686
—drug metabolism in rats and dogs, design of pharmacological and safety tests, 1674
—drug properties, absorption, pharmacokinetics, 989
—general aspects, tablet timed release, dissolution rates, review, 1511
Biosynthesis and synthesis of prostaglandins—review, 1861
Biotransformation, disopyramide phosphate—species differences, rat, dog, man, 888
kinetics—benzoic acid to hippuric acid, kidney metabolism contribution, 1278
kinetics—salicylic acid to salicyluric acid, renal metabolism contribution, Rhesus monkey, 1284
of salicylic acid—capacity-limited salicyl phenolic glucuronide formation, man, 800
4-Biphenylyl *N*-methylcarbamate—hydrolysis, *in vitro* kinetics, *in vivo* urinary excretion, metabolites, 858
Bis(2-ethylhexyl) sebacate—GLC internal standard, determination of sorbitol in aqueous solutions, 103
4,5-Bis(*p*-methoxyphenyl)-2-phenylpyrrole-3-acetonitrile—correlation of plasma levels with biological activity, 1908
Bis[*N*-methyl(antipyrinyl)amino]methane—isolation, identification as dipyrone decomposition product, 386
Bisnorargemonine isomers—synthesis, NMR characteristics, 55
Bisnoryangonin—isolation, identification from *Pholiota squarroso-adiposa*, 318
Bisulfite–sulfite—inhibition of platelet aggregation, 1904
Bleomycins—use in cancer chemotherapy, 485

Blood distribution, erythrocyte sequestration—chlorpromazine metabolites, schizophrenic patients, 1753
fluorinated hydrocarbon content—analysis after propellant inhalation, dogs, 1445
glucose levels—effect of nonsteroid anti-inflammatory drugs, tolbutamide, and tetrahydroalstonine, rats, 1202
levels—guaiacol glyceryl ether mononicotinate, man, 1212
Boehmeria cylindrica (L.) Sw.—antiviral alkaloidal extract, 1508
Books
Actualities Pharmacologiques, 988
Advances in Biochemical Engineering, Volume I, 654
Advances in Drug Research, Volume 6, 1510
Advances in Pharmaceutical Sciences, Volume 3, 820
The Alkaloids, Volume I, A Specialist Periodical Report, 819
American Drug Index 1972, 983
Analysis of Biogenic Amines and Their Related Enzymes (Supplemental Volume), 150
Analytical Emission Spectroscopy, Vol. I, Part II, 2011
Analytical Metabolic Chemistry of Drugs (Medicinal Research Series, Vol. 4), 818
Anatomy of the Monocotyledons, Volume VI. Dioscoreales, 1174
The Anesthesiologists Handbook, 2012
Annual Drug Data Report, Volume I, 654
Antianginal Drugs, 988
The Bile Acids, Chemistry, Physiology, and Metabolism, Volume 1: Chemistry, 1344
Biochemical Preparations, Volume 13, 320
The Biochemistry of Functional and Experimental Psychoses, 819
Biopharmaceutics and Relevant Pharmacokinetics, 819
Birch Reduction of Aromatic Compounds, 820
British National Formulary—1971, 320
Bulletin Technique, Number 66, 2012
Carbohydrate Chemistry, Volume 4, 820
Cellular Biology and Toxicity of Anesthetics, 1174
Cellular Pharmacology—The Effects of Drugs on Living Vertebrate Cells *in vitro*, 988
Chelates in Analytical Chemistry, Volume 3, 988
Chelates in Analytical Chemistry, Volume 4, 988
Chemical Modification of Proteins, 819
Chemical Mutagens: Principles and Methods for Their Detection, 150
The Chemistry of Biosurfaces, Volume I, 484
Civilization & Science in Conflict or Collaboration? A Ciba Foundation Symposium, 2011
The Cobalamins (A Glaxo Symposium), 1174
Concise Medical Textbooks—Pharmacology, 820
Critical Micelle Concentrations of Aqueous Surfactant Systems, 319
Current Concepts in the Pharmaceutical Sciences: Biopharmaceutics, 319
Decision Making on the Efficacy and Safety of Drugs, 654
Depressive Illness, Some Research Studies, 2012
A Dictionary of Genetics, 820
Dispensing of Medication, 7th ed., 1173
Drogenkunde fur Pharmazeutisch-Technische Assistenten and Apotheker-Praktikanten, 1174
Drug Abuse in Today's Society (Proceedings of the Fifteenth Annual Ohio Pharmaceutical Seminar), 1510
Drug Abuse: Nonmedical Use of Dependence-Producing Drugs. Advances in Experimental Medicine and Biology, Volume 20, 2012
Drug Metabolism Reviews. Volume 1, Number 1, 2012
Drugs, Vol. 2, No. 1, Focus on Medrysone, 2012
Effects of Drugs on Cellular Control Mechanisms, A Symposium, 2012
Einfuhrung in die Verfahrenstechnik der Arzneifermung, 1174
Electron Microscopy and Plant Ultrastructure, 320
Encyclopedia of Industrial Chemical Analysis, Volume 13, 150
Encyclopedia of Industrial Chemical Analysis, Volume 14, 820
Encyclopedia of Industrial Chemical Analysis, Volume 15, 1344
European Pharmacopoeia, Volume II, 1344
Evaluation and Testing of Drugs for Mutagenicity: Principles and Problems, 1510
Experimental Pharmaceutical Technology, Third Edition, 484
Fluorocarbon and Related Chemistry, Volume I, A Review of the Literature Published during 1969–1970, 1510
Foreign Compound Metabolism in Mammals, Volume I, 150
Fourth International Congress on Pharmacology, Volumes I–V, 653
Fundamentals of Biochemical Pharmacology, 149
Hallucinogenic Drugs, 1344
Handbook of Experimental Pharmacology, Volume 28, Part 2, Concepts in Biochemical Pharmacology, 1859
Handbook of Obstetrical and Gynecological Data, 2012
Hazards of Medication—A Manual on Drug Interactions, Incompatibilities, Contraindications, and Adverse Effects, 320
Health of the Nation Conference Proceedings, March 21 through April 8, 1971, 1344
High Altitude Physiology: Cardiac and Respiratory Aspects (A Ciba Foundation Symposium), 820
Histochemistry of Nervous Transmission. Volume 34, Progress in Brain Research Series, 1174
Hormonal Contraception, 1344
Hormones and Resistance, 2012
Injectable Solutions and Additives (Compatibilities, Incompatibilities, Route of Administration), 150
International Nonproprietary Names for Pharmaceutical Substances: Cumulative List No. 3, 1971, 2012
Introduction to Biopharmaceutics, 654
Kidney International, 988
Laboratory Animals—An Annotated Bibliography of Informational Resources Covering Medicine-Science (Including Husbandry)-Technology, 1509
Laboratory Tests in Common Use, 820
Lactogenic Hormones (A Ciba Foundation Symposium), 988
Legal Medicine Annual: 1971, 1174
Limbic System Mechanisms and Autonomic Function, 1344
Luminescence Spectrometry in Analytical Chemistry, 1510
Manual of Medical Therapeutics, 20th Edition, 1344
Marijuana: The Second Trip, 484
Matiere Medicale, 820
Mechanisms of Homogeneous Catalysis from Protons to Proteins, 988
Mechanisms of Molecular Migrations, Volume 4, 320
Medicaments Organiques de Syntheses, Volume IV, 820
The Merck Manual of Diagnosis and Therapy, 2012
Methods of Biochemical Analysis, Volume 20, 484
Microbial Pathogenicity in Man and Animals, Twenty-Second Symposium of the Society for General Microbiology Held at Imperial College London, 1344
Monographs on Drugs—Drugs and Driving, 1344
Narcotic Drugs—Biochemical Pharmacology, 319
Neurohypophysial Hormones. (Ciba Foundation Study Group No. 39), 988
Neurotransmitter Receptor Interactions, 484
Newer Trace Elements in Nutrition, 320
The Nitrile Oxides: Versatile Tools of Theoretical and Preparative Chemistry, Volume 13, 150
Organic Compounds in Aquatic Environments, 150
Organic Reactions in Steroid Chemistry, Volumes I and II, 2011
Organophosphorous Chemistry, Volume 2, Specialist Periodical Reports, 150
Organophosphorus Chemistry, Volume 3, Specialist Periodical Reports, 1344
Oxidation: Techniques and Applications in Organic Synthesis, Volume 2, 150
Peptides 1969, 484
Personality and Science (A Ciba Foundation Blueprint), 988
Perspectives in Neuropharmacology, A Tribute to Julius Axelrod, 1344
Pharmacology for Medical Students, 988
Pharmacology of the Cerebral Circulation, 2012
Practical Catalytic Hydrogenation: Techniques and Applications, 319
The Primitive Therapeutic Use of Natural Products: A Bibliography, 1510
Problèms Actuels de Biochimie Appliquée, 1344
Procedures in Clinical Chemistry, 820
Progress in Medicinal Chemistry 7, 320
The Psychodynamic Implications of the Physiological Studies on Psychomimetic Drugs, 320
Qualitative Organic Analysis, 320
Recent Advances in Studies on Cardiac Structure and Metabolism, Volume I: Myocardiology, 2012
The Relationship of Magnesium to Disease in Domestic Animals and in Humans, 820
The Rising Cost of Hospital Care, 820
Rodd's Chemistry of Carbon Compounds, Volume III, Part A, 150
Search for New Drugs, Volume 6, Medicinal Research Series, 1174
Seminars in Drug Treatment, 1344
Simplified Circuit Analysis, 1174
Solvent Extraction Reviews, Volume I, 150
Specifications for the Quality Control of Pharmaceutical Preparations. Second Edition of the International Pharmacopoeia, Supplement 1971, 150
Statistics: A Guide to the Unknown, 2012
Strategy of the Viral Genome (A Ciba Foundation Symposium), 820
Subcellular Organization and Function in Endocrine Tissues (Memoirs of the Society for Endocrinology No. 19), 150
Surgical Dressings and Wound Healing, 820
Synthetic Methods of Organic Chemistry, Volume 25, Yearbook 1971, 150
Terpenoids and Steroids, Volume I, 150
Thermomicroscopy in the Analysis of Pharmaceuticals, 819
Tobacco: Experimental and Clinical Studies, Supplement II, 320
The Use of Cannabis, 1509
Uses of Marijuana, 150
Water Pollution: Disposal and Reuse, Volume 1, 320
Water Pollution: Disposal and Reuse, Volume 2, 820
X-Ray Spectrometry, 988
Boric acid toxicity—*in vivo* effect of riboflavin, rats, guinea pigs, chicks, 1081
Bradykinin—pressor-induced release of norepinephrine in perfused human placenta, 878
Bromine solution—used as titrant in analysis of sulfanilic acid and sulfonamides, 779
3-Bromo-2-phenyltetrahydropyran—stereochemistry determined, 963
Bromthymol blue ion-pair extraction—analysis, biguanides in urine, 1404
ion-pair extraction—biguanides from biological fluids, 1411
Bronchodilators, aerosol—*in vitro* penetration efficiency, *in vivo* comparison, 262
Buccal absorption—*p-n*-alkyl phenylacetic, *p*-halogen phenylacetic, and toluic acids, application of partition coefficients, 1785
Bufadienolides—isolation from *Bersama yangambiensis* Toussaint, pharmacological testing for cardiotonic and antitumor properties, 1165
Bufexamac—absorption, metabolism, urinary excretion rates, man, 164
Buffering agents—effect on aspirin dissolution from tablets, 1370
Buformin—analysis, bromthymol blue ion-pair extraction, urine, 1404
—analysis in biological fluids, ion-pair extraction, protein binding estimates, 1411

Bursera schlechtendalii (Burseraceae)—isolation and structure determination of two new lignans, 1992

Butalbital—intermediates, products of barbiturate-ring decomposition, 1389

4-*n*-Butoxyphenylacethydroxamic acid (bufexamac)—absorption, metabolism, urinary excretion rates, man, 164

***N*-Butyl-*N'*-(9-acridinyl)thiourea**—photochemical cyclization, isolation, characterization, structure identification of product, 273

2-Butylamino-1,3-thiazino[4,5,6-*kl*]acridine—isolation, characterization, structure identification as photochemical cyclization product of *N*-butyl-*N'*-(9-acridinyl)thiourea, 273

C

^{45}Ca binding to *in vitro* bovine gangliosides—effects of morphine and nalorphine, 1471

Cacodylate injections—NMR analysis, compared to NF X and atomic absorption spectrophotometry methods, 1635

Cactus alkaloids—isolation and identification of (−)-normacromerine from *Coryphantha macromeris*, 147

Caffeine metabolites, possible—mass spectrometric identification of methylxanthines and methyluric acids, 1822

Caffeine–acetaminophen complexes—isolation, solubility, dissolution rates, stability constants, 1454

Calcium (radiolabeled) binding to *in vitro* bovine gangliosides—effects of morphine and nalorphine, 1471

Calliactis polypus (sea anemone)—toxicology, pharmacology, 66

Cancer chemotherapy—*in vitro* formation and stabilization of 5-fluoro-2′-deoxyuridine, 1669

chemotherapy—review, 485

Cannabidiol—photoreactions, 1994

Cannabidivarin—GLC and mass spectroscopic identification as constituent of *Cannabis sativa*, 1476

Cannabinoids—presence, activity in 43-year-old Cannabis fluidextract, 144

propyl homologs—identified as constituents of *Cannabis sativa*, GLC, mass spectroscopy, 1476

Cannabis constituents—photochemical study, 1994

fluidextract—stability of 43-year-old sample, 144

***Cannabis sativa* L.**—identification of cannabidivarin and tetrahydrocannabivarin, GLC, mass spectroscopy, 1476

Cannulated everted intestinal sac—absorbability screening, drugs in solution, 1361

Canrenoate–canrenone—lactonization, hydrolysis, equilibrium constants, solubility studies, 717

Canrenone and potassium canrenoate, fluorescent and tritium labeled—disposition, metabolism, dogs, 1132

and potassium canrenoate—fluorometric analysis, biological fluids, 1126

and potassium canrenoate—plasma levels after intravenous administration, fluorometric analysis, dogs, 1129

Canscora decussata (Gentianaceae)—pharmacological study of xanthone constituents, 1838

Capsules, chloral hydrate—NMR analysis, compared to compendial method, 613

Carbamates, derivatives of homosulfanilamide—synthesized as possible antibacterial agents, 1856

Carbamazepine in plasma—GLC determination, trimethylsilyl derivative formation, 284

oral administration—identification, characterization of carbamazepine-10,11-epoxide metabolite in urine, man, 1144

Carbamazepine-10,11-epoxide—identification as carbamazepine metabolite in human urine, mass spectrometric characterization, 1144

Carbamides, 1-substituted acetyl-3-aryl—synthesis, *in vitro* (mouse and rat brain homogenates) inhibition of respiratory activity, *in vivo* anticonvulsant activity, 1366

1-Carbethoxy-4-cyano-4-phenylpiperidine—synthesized as intermediate for preparation of meperidine, 1316

Carbobiotin [*dl-cis*-hexahydro-4-(4-carboxybutyl)-2-cyclopentimidazolone]—synthesized and evaluated for growth-promoting activity, 1168

Carbolines—as MAO inhibitors, review, 821

β-Carbolines, natural and synthetic—as cholinesterase inhibitors, pharmacological evaluation, mechanism of action, 808

Carboxamide acetals and esters–synthesis, evaluation as mosquito repellents, 577

Carcinogenic hydrocarbons—interaction of 3,4-benzpyrene with various monomolecular films, biological significance, 1065

Cardenolides—analysis, mass spectroscopy, 765

—isolation from *Cryptostegia grandiflora*, identification, cytotoxic activity, 570

Cardiac steroid aglycones, cardenolides—analysis, mass spectroscopy, 765

Cardiotonics, potential—pharmacological testing of a bufadienolide from *Bersama yangambiensis* Toussaint, 1165

Cardiovascular agents, potential—piperidinecarboxamides synthesized and screened, 127

Catabolism, cyheptamide—effect of drug-metabolizing enzyme, rats, 408

Cathanneine—a new alkaloid isolated from *Catharanthus lanceus*, identification, 298

Catharanthus lanceus—isolation and identification of a new alkaloid, cathanneine, 298

—isolation of leurosine from a previously inactive fraction, an antitumor alkaloid, 1840

Cation-exchange resin—electrometric determination of fixed-charge density, compared to atomic absorption spectrophotometry, 921

Cell, three-phase model—*in vitro* transport–*in vivo* absorption correlations, sulfanilamides, 1656

Cellulose films, plasticized—effects of environment and hydroxypropyl methylcellulose–ethylcellulose ratio on water vapor transmission, 1956

Central vagal stimulation—vagosympathetic pressor reflex, dogs, 1507

Cephalexin and related compounds—colorimetric estimation, 1647

Cephalin interaction with quaternary ammonium bactericides—*in vivo* literature review, *in vitro* conductometric study, 390

Cephalin–gliadin and gliadin monolayers—interaction of quaternary ammonium bactericides, presence and absence of protamine, 393

Cephaloglycin and related compounds—colorimetric estimation, 1647

Cephalotaxus harringtonia alkaloids—structure, antitumor activity, 1227

Cetrimide–salicylic acid system—effect of anionic surfactants on viscosity, 642

Cetylpyridinium chloride—effect of polysorbate 80 on bactericidal activity against *Escherichia coli*, 1163

Cetyl sulfate and cetrimonium ions—interactions with dipalmitoyl lecithin and dipalmitoyl glycerol monolayers, kinetics, mechanisms, 1720

Cetyltrimethylammonium bromide—growth inhibition of *Streptococcus faecalis*, 762

Chain length effect—melting point, solubilities, partition coefficients, and crystalline properties of alkyl *p*-aminobenzoates, 852

effect—membrane diffusion of alkyl *p*-aminobenzoates, 838

—influence on oil–water ion-pair partitioning behavior of *p*-alkylpyridinium chlorides, 1648

Charcoal, activated—as *in vivo* absorption inhibitor of aspirin, salicylamide, and phenylpropanolamine, prediction from *in vitro* adsorption studies and physicochemical properties, 586

tablets, activated commerical—drug adsorption efficacy *in vitro*, in man, 624

Chemotherapy, cancer—review, 485

Chloral hydrate soft gelatin capsules—NMR analysis, compared to compendial method, 613

Chloramphenicol palmitate—polymorphic phase transition parameters determined from intrinsic dissolution rates, 868

Chlordiazepoxide administered concurrently with furosemide—effect on diuresis and skeletal muscle relaxation, rats, 562

metabolites—biotransformation of orally administered radiolabeled demoxepam, urinary and fecal metabolites, man, 123

Chlorhexidine effect—phenylethanol-resistant and sensitive *Pseudomonas aeruginosa* cultures, 1075

Chlormadinone acetate—GLC analysis, plasma, monkeys, 1441

Chloroacetaldehyde—toxicity, compared to ethylene chlorohydrin, 19

9-Chloroacridine—analysis of sulfonamides and local anesthetics containing primary aromatic amine, quenching fluorometry, 432

***N*-*p*-Chlorobenzyl-*N*-methylaminoethyl carbanilate** series—prepared and tested for antibacterial, antifungal, and antiviral activities, 125

7-Chloro-1,3-dihydro-5-(2,6-difluorophenyl)-2*H*-1,4-benzodiazepin-2-one—synthesis, potency compared to chlordiazepoxide and diazepam, mice, 275

***N*-Chloro-*N*-methylbenzenesulfonamide**—formation and hydrolysis rate constants in water, 371

Chlorophenothane (*p,p'*-DDT), radiolabeled—distribution, excretion, rats, 1912

1-(*o*-Chlorophenyl)-1-(*p*-chlorophenyl)-2,2-dichloroethane—metabolism, metabolite identification, 314

2-Chloro-1-phenylindene—synthesis from *trans*-stilbene and sodium trichloroacetate in diglyme and tetrachloroethylene *via* 1,1-dichloro-*trans*-2,3-diphenylcyclopropane, 1216

***N*-Chloroquinuclidinium** ion—formation and hydrolysis rate constants in water, 371

***N*-Chlorosuccinimide**—formation and hydrolysis rate constants in water, 371

Chlorpromazine metabolism—determination of 11 nonconjugated metabolites in the blood of schizophrenic patients, TLC, fluorometry, 581

metabolism—disposition of free and conjugated metabolites in blood fractions of schizophrenic patients, 1753

Cholestanes—photoreactions, review, 321

Cholesterol, membrane transport—uptake by Burkitt lymphoma cells in suspension, baseline procedures, 1618

solubility and incorporation of radioactive acetate—effect of guaiacol glyceryl ether mononicotinate, 1212

transfer—oil/water interface, ionic surfactant system, interfacially controlled, 375

Cholesteryl esters—phase transitions in binary mixtures, 1762

Cholestyramine effect—GI absorption of sodium fusidate, rats, 735

Cholestyramine–sodium fusidate *in vitro* binding—effects of temperature, organic and inorganic electrolytes, 730

Cholinesterase inhibitors—pharmacological evaluation of naturally occurring and synthetic β-carbolines, mechanism of action, 808

Chromatography—analysis, drug abuse screening programs, review, 655

partition—versatile solvent system for corticosteroids, prediction of elution curves, 689

with cation-exchange resins—separation of ascorbic acid and 2-keto-L-gulonic acid, 1333

Chymotrypsin—inhibition of adenosine 5′-triphosphate-induced muscular contraction, effect of ultrasonication on physicochemical and pharmacological properties, 352

Cinnamides, di—synthesis, potential hypocholesterolemic agents, 610

substituted—synthesis, relationship between MAO inhibition and anticonvulsant activity, 78

Circular dichroism—analysis of cycloheptaamylose–barbiturate inclusion complexes, 1841

Clinical equivalence of drug formulations—use of confidence intervals in analysis of comparative bioavailability, 1340

Clinical pharmacologists—evaluation of new drugs, 1690

CMC—polysorbate 20, surface tension method, 1334

surfactants—determined from diffusion potential measurements (liquid junction), 639

CNS activity—succinic semialdehyde, 1963
agents, potential—conversion of anils to active amines and amine salts, 1504
agents, potential—piperidinecarboxamides synthesized and screened, 127
depressants, potential—synthesis and preliminary pharmacological testing of substituted hippuramides, 1331
depression—ethanol and pentobarbital in goldfish, 1401
drugs—hypothesis and model for binding to peptide bond, 1717
stimulants, narcotics, and barbiturates—TLC identification, drug abuse, urine screening program, 679
Coacervation, amaranth–alkyltrimethylammonium salts—determination by extraction, surface tension, viscosity, light scattering, microscopy, spectroscopy, microelectrophoresis, phase studies, 502
complex—microencapsulation of stearyl alcohol in gelatin–acacia system, 1586
Coatings—evaluation of free unsupported polymer films, method and apparatus, 106
solutions—method and apparatus for preparing both cast and sprayed free films, 814
Cocculus carolinus D.C. (Menispermaceae)—isolation and identification of chemical constituents, 1825
Codeine–aspirin formulations—GLC analysis of salicylic acid, 929
Cohesive energy density—method of calculation for nonpolar substances, values for some drugs and excipients, 723
Colloid fixed-charge density, cation-exchange resin—electrometric determination, compared to atomic absorption spectrophotometry, 921
Color stability of tablets—rapid determination, fadeometer, 1811
Colorimetry—analysis, acetaminophen in tablets and elixir, as 2-nitro-4-acetamidophenol, 927
—analysis, acid hydrazides, 211
—analysis, cyheptamide metabolites, 408
—analysis, ethchlorvynol, 169
—analysis, levodopa, 924
—analysis, salicylic acid–benzoic acid ointments, 1625
—determination of *p*-hydroxyphenoxyacetic acid separated from phenoxymethyl penicillin fermentations, 933
—estimation of cephalexin, cephaloglycin, and related compounds, 1647
—monitoring, assay, hydroxamic acids, 244
Column chromatography—analysis, polymyxin B sulfate, 1803
partition—analysis, tetracycline base or hydrochloride, evaluated as potential compendial method, 615
—purification of *meso*-tetraphenylporphine and derivatives, 307
—separation of D-dopa and dopamine, 1460
—separation of methyl *p*-hydroxybenzoate from *p*-hydroxybenzoic acid, compared to compendial method, 252
Compartment elimination—general equations for linear mammillary models, first- or zero-order input process, 536
Complex formation—acetaminophen with methyl xanthines, 1454
formation, prednisone/prednisolone–dialkylpropionamide—effect on transfer through artificial lipoid barrier, 356
formation, prednisone/prednisolone–dialkylpropionamide—enhancement of intestinal drug absorption, rats, 362
formation, prednisone/prednisolone–*N*,*N*-di-*n*-propylpropionamide—structural requirements, 649
reactions—significance of coupling terms in passive transport, Fick's law, equations, 2001
formation—transport rates, method for predicting enhancement or reduction, equations, 894
inclusion—cycloheptaamylose–barbiturate, solubility and circular dichroism studies, 1841
—studies of complexation of acetaminophen–antipyrine, 1661
Compression force and tablet hardness—effect on tablet disintegration, review, 1695
tablets—preliminary testing, rotary tableting machine simulation device, 1313
Computer simulation—dose-dependent decline of pharmacological effects of drugs with linear pharmacokinetic characteristics, 567
of salicylic acid biotransformation—compared to experimental studies in man, 800
—particle dissolution, disappearance, 223
—time-optimal control of drug input, 1941
Concentration gradients, during dissolution of a solid—mathematical interpretation, analyzed, compared with diffusion layer theory, 214
Conductivity changes—optically active ions, amphetamine with mandelic and tartaric acids, ionic associations, 293
Conductometric studies—interaction of cephalin with quaternary ammonium bactericides, 390
Confidence intervals—analysis of comparative bioavailability trials, 1340
Conformation changes—L-asparaginase of *Escherichia coli B*, reversible dissociation, activity, 791
sulfanilamides—NMR evidence for stabilization by *o*-methyl groups, 1670
Content uniformity, tablets—migration during drying of water-soluble drug in wet granulations, evaluation of additive inhibitors, 1121
Convulsants—hydrogen binding to peptide bond, mode of action hypothesis, 1717
Copper complexation—with phenethyl-β-D-glucopyranosiduronic acid, 810
Copper (II)–glycine chelates—effect on penicillin hydrolysis, 82
Coprecipitates, reserpine–polyvinylpyrrolidone—effect on *in vivo* absorption, correlation with *in vitro* dissolution, rats, 400
Coralyne chloride—procedure adaptable for large-scale synthesis, 969
Corticoids—photoreactions, review, 321
Corticosteroids creams and ointments—analysis, high pressure liquid chromatography, 444
—separation by partition chromatography, versatile solvent system, prediction of elution curves, 689
Coryphantha, seven species—chromatographic isolation and identification of β-phenethylamine alkaloids, spectroscopic identification of two new alkaloids and structures proposed, synephrine found in all seven species, 41
Coryphantha macromeris var. *runyonii*—isolation and identification of (−)-normacromerine, 147
Coumarin anticoagulants—TLC separation and identification, 1303
chromeno and dihydrofurano formation—oxidation of mammein and mammeisin, 1603
natural—isolation of xanthalin and peuarenine from *Peucedanum arenarium*, 1643
Counterion independency—interrelationship between ion-pair extraction and group contribution, tricyclic amine antidepressants, 1967
Creep analysis—viscoelastic materials, using rising sphere rheometer, 783
Crotalaria sagittalis L. fruit—isolation of monocrotaline, 122
Crotalus adamanteus, radiolabeled—distribution and excretion, rats, 119
Crotalus atrox, radiolabeled—distribution and excretion, rats, 119
Cryptopleurine—isolation from *Boehmeria cylindrica*, antiviral activity, 1508
Cryptostegia grandiflora (Roxb.) R. Br.—isolation, identification, of five cytotoxic cardenolides, 570
Cyclacillin—β-lactamase activity, rate of inactivation, pH-stat alkalimetric titration, compared to other penicillins, 1594
Cyclase activity—49 classes of therapeutic agents, 1556
Cyclic AMP metabolism, *in vitro*—effects of 158 compounds (49 classes of therapeutic agents), 1556
Cyclization of peptides—homodetic and heterodetic, review, 1345
Cycloheptaamylose–barbiturate inclusion complexes—solubility and circular dichroism studies, 1841
Cyclomammein formation—oxidation of mammein, 1603
Cyclophosphamide—GLC analysis in raw materials and formulations, 97
Cyclopropylamines—as MAO inhibitors, review, 821
Cyheptamide—absorption, catabolism, metabolites (colorimetric analysis), rats, 408
Cynarin analogs, dicinnamoyl esters—synthesis, screened as potential hypocholesterolemic agents, 802
Cytidine—solvolysis, deamination mechanisms, pH-rate profiles, 1052
Cytosine—solvolysis, deamination mechanisms, pH-rate profiles, 1052
Cytotoxicity—constituents of *Balduina angustifolia*, 626
—eupatolide, major constituent of *Eupatorium formosanum* HAY., 629
—five cardenolides from *Cryptostegia grandiflora*, 570
screening, large scale—simple, rapid microplate tissue culture method, 1960

D

Datura innoxia—biosynthesis of tropic acid, studied using various radiolabeled precursors, 2006
Datura stramonium L. var. *tatula*—protein synthesis–alkaloid synthesis relationship, 1257
Daunorubicin—use in cancer chemotherapy, 485
Decahydroisoquinolines, 5-substituted, diastereoisomers—distribution coefficients calculated, correlated with antiarrhythmic activity, acid dissociation constants determined, 637
Decomposition—aspirin in polyethylene glycols, effect of temperature, 1160
rates of solid compounds—*p*-substituted benzoic acid derivatives, 1112
Degradation, penicillin—effect of ionic strength on chemical stability, 202
Dehistaminization—biological extracts, 960
Dehydroabietylamine—used to resolve *d*,*l*-α-benzamido-4-hydroxy-3-methoxydihydrocinnamic acid, a precursor of *l*-3,4-dihydroxyphenylalanine, 1506
Demoxepam, radiolabeled—biotransformation, urinary and fecal metabolites, man, 123
Densitometry, direct—analysis, erythromycins, 430
Derivation—resolution of diffusion layer control, barrier flux, 312
Dermal toxicity—silver-containing pharmaceuticals, method to determine chemical nature of silver tissue deposits, rabbits, 1488
Descending column dissolution model—effective interfacial concentration verification during solid dissolution, 1589
Desmosterol transfer—oil/water interface, ionic surfactant system, interfacially controlled, 375
Desorption, belladonna alkaloids—from antacids, analysis, 1458
Deuterium isotope effect—hydrocortisone aqueous degradation, 918
Development of new drugs—evaluation of metabolism, bioavailability, drug interactions, role of clinical pharmacology, 1690
of new drugs—use of drug metabolism studies by medicinal chemists, 1678
Dexamethasone phosphate and bisulfite—equilibration kinetics in aqueous solution, 708
Dexoxadrol hydrochloride—solubility profile, 1896
Dextroamphetamine sulfate—determination in amphetamine sulfate mixtures from melting point of monohydrogen succinate salt, 1976
interaction with spray-dried lactose—ethanol mediated, mechanism and rate of discoloration, 1770
Dextroamphetamine sulfate–amobarbital timed-release formulations—GLC separation, UV spectrophotometric analysis, 101
2-Dialkylaminomethyl-1,4-benzoxathians—synthesis, evaluation as α-adrenergic blocking agents (rat vas deferens), 228
1,2-Dialkyl-4-aryl piperidazines—synthesis, screened for analgesic activity, 1781
Dialkylpropionamides—effect of complex formation on steroid drug absorption,

transfer through artificial lipoid barrier, 356
Dialysis, peritoneal—short-term lavage with dioctyl sodium sulfosuccinate used to achieve increased urea and phosphate clearance rates, 475
—separation of 5-fluorouracil from blood components, GC determination, 301
—used to study binding of ^{99m}technetium to various human albumins, 1667
Diazepam and *N*-demethyldiazepam—biliary excretion in rats, guinea pigs, mice, 965
—isotherms determined, nature of montmorillonite binding, surface adsorption and ion–dipole interaction suggested, equations, 420
Dibenzosuberone and anthraquinone—identification as oxidation products of amitriptyline, 986
***N,N*-Dibenzylaminoethyl carbanilate** series—prepared and tested for antibacterial, antifungal, and antiviral activities, 125
***o,p'*-Dichlorodiphenyl acetic acid**—mitotane metabolite, isolation, characterization, GLC, TLC, 314
1,1-Dichloro-*trans*-2,3-diphenylcyclopropane—intermediate in the formation of 2-chloro-1-phenylindene from *trans*-stilbene and sodium trichloroacetate in diglyme and tetrachloroethylene, 1216
***o,p'*-Dichlorodiphenyldichloroethane**—metabolism, metabolite identification, 314
Dichlorodiphenyltrichloroethane—pharmacokinetic relationships used to quantify accumulation in man, 948
Dicinnamides—synthesis, potential hypocholesterolemic agents, 610
Dicinnamoyl esters—synthesis, as cynarin analogs, screened as potential hypocholesterolemic agents, 802
Dieldrin—pharmacokinetic relationships used to quantify accumulation in man, 948
1,2-Diethyl-4-phenylpyrazolidine—synthesis, analgesic activity, 235
Diethyl phosphonate—reaction with *p*-substituted benzylidene portion of Schiff bases, mechanism of action, 114
Differential scanning calorimetry—determination of polymorphic transformation of sulfathiazole form I in presence of form II, kinetics, 1318
—preformulation screening, multicomponent drug systems, compared to differential thermal analysis, 1806
Differential thermal analysis—characterization of drug—excipient binding, 1435
—compared to differential scanning calorimetry, preformulation screening, multicomponent drug systems, 1806
—determination, menadione bisulfite pyrolysis to menadione, 1460
Diffuse reflectance spectroscopy—characterization of drug–excipient binding, 1435
—monitoring, discoloration of dextroamphetamine sulfate–spray-dried lactose mixtures, 1770
Diffusion coefficient, micellar—calculated for dissolution of benzoic acid in aqueous polysorbate 80 solutions, constant and uncontrolled viscosity, 592
coefficients of aliphatic alcohols—polyurethan films, thermogravimetric analysis, 1094
coefficients—used in computing transport rates, influence of complex formation, 894
layer control—mathematical derivation, 312
model—solute transport in three-phase (w/o/w) system, relationship to pH–partition theory, 1922, 1931
potential measurements, liquid junction—determination of CMC of surfactants, transport numbers, 639
2,6-Difluorobenzodiazepinone—synthesis, potency compared to chlordiazepoxide and diazepam, mice, 275
Digestive and interdigestive contractions—atraumatic balloon technique, conscious, unrestrained rats, 1357
Digitalis lanata extracts—separation of acetyldigoxin from acetyldigitoxin, 1320
[(10,11-Dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5-yl)thio]acetic acid—used as a starting material for synthesis of sulfide amides, products tested for pharmacological activity, 978
10,11-Dihydro-10,5-(epoxymethano)-5*H*-dibenzo[*a,d*]cycloheptene-13-one—as cycloheptamide metabolite, colorimetric analysis, 408
1-(2,3-Dihydro-5-methoxybenzo[*b*]furan-2-ylmethyl)-4-(*o*-methoxyphenyl)piperazine and salts—dissolution properties, comparative antihypertensive activity in dogs, 1418
hydrochloride polymorphs—dissolution kinetics, thermodynamic parameters, 1423
Dihydroxyacetone phosphates (acyl) and related derivatives—synthesis for use as biosynthesis intermediates, 971
2,8-Dihydroxy-3,9-dimethoxy-*N*-methylpavinane—synthesis, NMR characteristics, 55
3,9-Dihydroxy-2,8-dimethoxy-*N*-methylpavinane—synthesis, NMR characteristics, 55
***l*-3,4-Dihydroxyphenylalanine**—resolution of a precursor, *d,l*-α-benzamido-4-hydroxy-3-methoxydihydrocinnamic acid, using dehydroabietylamine, 1506
2,5- and 3,5-Diiodobenzoic acids—formation from microbial degradation of 2,3,5-triiodobenzoic acid, 804
2,5-Dimethoxyamphetamine—identification in illicit drug seizures, NMR spectroscopy and mass spectroscopy, 1851
9-(3,4-Dimethoxyphenoxy)-1,2,10-trimethoxyaporphine—synthesis, 1481
3,4-Dimethoxyphenylacetamide—hypocholesterolemic and hyperglycemic activity, compared to 20,25-diazacholesterol, rats, 1611
***N,N*-Dimethyl-9-aminomethylacridan**—synthesis, oxidative fragmentation, acetamide formation, 206
Dimethylpolysiloxane membranes—diffusion of *p*-aminoacetophenone, 61
Dimethyl sulfoxide—as a solvent for sulfa drugs in high speed liquid chromatography, 254
effect—salicylate absorption from hydrophilic ointment, 172
—interactions with lipid, protein, and lipid–protein monolayer films, surface pressure–surface area curves, 1098
Dioctyl sodium sulfosuccinate—short-term lavage prior to peritoneal dialysis, increased urea and phosphate clearance rates, 475
1,2-Diphenylindolizines, *p*-substituted—synthesized and screened as potential anti-inflammatory agents, 949
2-Diphenylmethylene-1-acyl-1-alkyl hydrazines—synthesis, potential psychotropic agents, 1571
***N,N*-Di-*n*-propylpropionamide**—effect on intestinal drug absorption of seven compounds, rats, 473
—effect on prednisolone absorption, rat small intestine, 367
Dipyrone solutions—oxidative decomposition, hydrolysis products identified, 386
Direct compression tableting—effect of moisture on excipients, 939
Discoloration of dextroamphetamine sulfate–spray-dried lactose mixtures—ethanol mediated, effect of storage and temperature, 1770
of tablets—rapid determination of color stability, 1811
Disease—as related to stress, environmental stimuli, 1175
Disintegrants, tablet—mechanism of action, comparative effects, review, 1695
tablets—mechanism of action, correlation of tablet mean pore diameter and porosity, 303
Disintegration of uncoated tablets designed for rapid release—review, 1695
Disopyramide phosphate biotransformation—species differences, rat, dog, man, 888
Dissociation, thermal, tolbutamide and related sulfonylureas—in alcohols, water, and amines, mechanism, 602
Dissolution, antacids—surface area term, Myhill–Piper equation, 2009
equipment—review of tablet disintegration procedures, 1695
hydrocortisone—effect of low concentrations of nonionic surfactant, 1732
kinetics—polymorphs of an experimental antihypertensive, effect of recrystallization from different solvents, 1423
mechanisms—concentration gradients, *m*-acetotoluide from fused disks, ascending and descending conditions, column model, mathematical interpretation, 214
mechanisms—experimental determination of surface tension of a solid, 281
of aspirin tablets—effect of 11 buffering agents, 1370
of solids, descending column model—determination of effective interfacial concentration, 1589
profiles, capsules and tablets—magnetic basket dissolution apparatus and method, 1152
profiles—free base and salts of an experimental antihypertensive, 1418
rate (*m*-acetotoluide)—relationship to solid–liquid interfacial energy in organic solvents, 1478
rate—effect of total solubility and viscosity, 175
rates, alkyl vinyl ethers–maleic anhydride copolymers and partial esters—determination, related to use as timed-release coatings, 1916
rates, intrinsic—determination of thermodynamic parameters for polymorphic phase transitions, 868
rates, isosorbide dinitrate tablets—modified column-type apparatus, compared to official methods, 1985
rates, kinetics—2-naphthol in cyclohexane or cyclohexane with additives, modified film theory model tested using concentration jump technique, solute–solvent complexation reaction effects, 695
rates—micronized (minuscular) drug dispersed on adsorbents, characterization of binding forces, 1435
rates—micronized (minuscular) drug dispersed on microparticulate adsorbents, 1430
rates of sulfamethizole tablets—compared to bioavailability parameters, 746
rates—patterns of log-normally distributed powders, 223
rates, salicylic acid tablets—effect on starch formulation, 239
rates, slightly water-soluble powders—prediction from simple mathematics, 811
rates, tablets—correlation with disintegration times, review, 1695
sulfathiazole—*in vivo* inhibition by water-soluble dye, man, 1857
testing, USP/NF method—corrosion of basket apparatus, replacement of official fluids with phosphate buffer, 460
tests—effect of vessel shape (concavity), compendial dissolution vessels, modified vessel, 1638
Distribution coefficients—5-substituted decahydroisoquinolines, correlated wih antiarrhythmic activity, 637
***N,N*-Disubstituted 9-phenanthreneglyoxylamides**—synthesis, reduction, 1297
Disulfide linkage—synthesis of heterodetic cyclic peptides, review, 1345
Disulfiram tablets—analysis, pulse polarography using a dropping mercury electrode, 249
DNA interaction with isophosphamide—effect of microsomal activation, 2009
D-Dopa—analysis in levodopa formulations, levodopa biotransformation to dopamine, separation, fluorometry, 1460
Dopamine, biotransformation product of levodopa—analysis of D-dopa in levodopa formulations, 1460
Dosage form development—role of drug metabolism group and pharmaceutical chemist, 1686
Dose-dependent decline of pharmacological effects—multicompartment systems, computer simulations, 567
Dose–effect curves—used to transform pharmacological response intensity into biophasic drug levels, equations, 467
Dose–plateau drug levels relationship—drugs eliminated by parallel first-order and capacity-limited kinetics, 541
Dragendorff reagent, modified—determination of homatropine methylbromide in formulations with antacids, 1630
Drop volume surface tension measurements—automated apparatus, 781
Drug absorption, complex formation—effect of *N,N*-di-*n*-propylpropionamide on prednisolone absorption, rat small intestine, 367

absorption—concurrent loss of water, in rat intestine, 110
absorption—effect of *N,N*-di-*n*-propylpropionamide on seven compounds, rats, 473
absorption—effect of tonicity and net water transfer, *in situ* rat intestine, 1061
absorption, prednisone and prednisolone—effect of steroid–dialkylpropionamide complex formation on transfer through artificial lipoid barrier, 356
absorption, prednisone and prednisolone—effect of steroid–dialkylpropionamide complex formation, rats, 362
absorption, prednisone, prednisolone—structural requirements for enhancement by *N,N*-di-*n*-propylpropionamide complex formation, 649
abuse screening programs—detection procedures, development costs, and field tests, review, 655
abuse urine screening program—identification techniques, validity, excretion data, 305
abuse urine screening program—TLC identification, narcotics, barbiturates, and CNS stimulants, 679
delivery system—micronized (minuscular) drug dispersed on microparticulate adsorbents, 1430
delivery systems—release of progesterone-type steroids from silicone polymer, equations, 46
distribution and elimination—relationship in multicompartment systems, effect on apparent volume of distribution, 952
formulations, comparison—use of confidence intervals in analysis of comparative bioavailability trials, 1340
hydroxylation kinetics—effect of ascorbic acid deficiency, guinea pig liver, 1205
input dynamics—relationship of input functions to time variations of multiple pharmacological effects, computer simulation, 1941
interactions at air/water or monolayer/-water interfaces—correlated with biological activity, review, 151
levels (biophasic), dose, effect, and time—relationship, equations, 467
loss, parallel first order—effect on calculated values for absorption rate constants, 135
metabolism—role in drug research and development, symposium, 1674, 1678, 1682, 1686, 1690
metabolism—role of kidney in *p*-aminobenzoic acid metabolism reevaluated from analysis of clearance data, 1288
mixtures, solid (benzoic–salicylic acids)—release rates from inert matrixes, effect of alkaline solvent, equations, 1374
mixtures, solid (sulfapyridine–sulfadiazine)—release from inert matrix, solvent effects, equations, 1381
release—from polymeric film formulated as aerosol dressing, 754
release rates—effect of lipase on timed-release lipase–lipid–sulfamethizole tablets, blood levels, dogs, 900
transfer—linear two-compartment open model, erroneous assignment of nonlinear data, 552
transfer rates—variability over time, rat everted small intestine, 116
transport—cholesterol in suspension cultures of mammalian cells, permeability and partition coefficients, 1618
transport—effect of hydrostatic (or osmotic) flow and surface pH in the GI tract, theoretical, 192
transport—effect of solvent and solubility, *p*-aminoacetophenone across dimethylpolysiloxane membranes, 61
transport—functional integrity, rat everted small intestine, passive transfer, 116
transport—role of complex formation, method for predicting enhancement or reduction, equations, 894
Drug–anionic-exchange resin interactions—effect of cholestyramine on GI absorption of sodium fusidate, rats, 735
interactions—sodium fusidate and cholestyramine binding, 730
Drug–excipient binding—dissolution characterization of micronized (minuscular) drug dispersed on adsorbents, 1435
Drug–protein binding—sulfonylureas, 89
plasma binding, *in vitro*—pentylenetetrazol, rabbits, 652
Dyes, water soluble—*in vivo* inhibition of sulfathiazole dissolution, man, 1857

E

Edema, carrageenin-induced pedal—effect of nonsteroid anti-inflammatory drugs, tolbutamide, and tetrahydroalstonine, 1202
Editorials
Bioavailability Goes Public (June)
Bioavailability Testing: Principles and Ethics (March)
A Call for Moderation (January)
Clinical Pharmacology vis-à-vis Clinical Pharmacy (August)
Closing the Loopholes (October)
Consistency in the Literature (July)
Ethics and Morality in Drug Research (December)
Informing Responsibly (November)
Open Forum Page: New Opportunity for Communication (September)
Providing for the Future (May)
Reference Standards (February)
The Sorry State of Medical Dictionaries (April)
Electrical circuits—simulation of multiple-dosing kinetics, 1468
Electrokinetics—bacteria, 182
—cetyltrimethylammonium bromide effect on ζ-potential of *S. faecalis*, 762
Electrometric determination—fixed-charge density of cation-exchange resins, compared to atomic absorption spectrophotometry, 921
Electron impact fragmentation patterns—β-adrenergic blocking agents and metabolites, GC–mass spectroscopy, 1728
Electron-capture detection—comparison of various derivatives of primary and secondary amines, 1235
Electrophoresis—bacteria, 182
thin layer—interactions of amphetamine isomers with optically active and racemic mandelic and tartaric acids and inactive salicylic acid, molecular associations, 1325
Elimination and drug distribution—relationship in multicompartment systems, effect on apparent volume of distribution, 952
effects—two-compartment open-model parameters, 1270
kinetics, parallel first order and capacity limited—relationship between drug dose and plateau levels, 541
Emulsifying agents—characterization of mannide monooleate commercial formulation, 863
Emulsions, liquid petrolatum–water—effect of age stability, ultracentrifugation, 769
mineral oil–surfactant–water—effect of ultrasound, HLB, surfactant, and power parameters, 1567
Endotoxin shock—effect of intravenously administered nylidrin, 1844
Entropy of solution—correlated with solubilities of *N*-substituted sulfanilamides, 94
Environmental pharmacology—interaction of drugs and environment, 1175
stimuli—physiological effects, review, 1175
Enzyme induction of organic nitrates—nitroglycerin, rabbits, mice, 1267
kinetics—oxime acetates as substrates for acetylcholinesterase, 527
4-Epianhydrotetracycline—column chromatographic analysis, tetracycline base or hydrochloride, 615
Epichlorohydrin—toxicity profile, 1712
Epidermis, human—equilibrium and kinetics of hexachlorophene sorption–desorption, bioelectrometric determination, compared to spectrophotometric determination, 1102
Epinephrine salts (maleate, malate, fumarate, bitartrate)—synthesis, partition coefficients, formulation of aerosol dosage forms, 219
4-Epitetracycline—column chromatographic analysis, tetracycline base or hydrochloride, 615
Erythrina variegata—isolation, identification, pharmacological evaluation of eight spiroamine alkaloids and three carboxylated indole-3-alkylamines, 1274
Erythrocyte sequestration—disposition of free and conjugated metabolites of chlorpromazine in blood of schizophrenic patients, 1753
Erythromycin—absorption, half-life, tissue levels, serum protein binding, compared to propionyl ester, 425
and erythromycin estolate formulations—analysis, direct densitometry after TLC separation, 430
—effect on lincomycin and lincomycin 7(S)-chloro analogs (phase II) against *Escherichia coli*, 545
enteric-coated tablets—GLC analysis, 1633
Erythromycin 2′-propionate ester—absorption, half-life, tissue levels, protein serum binding, compared to erythromycin, 425
Escherichia coli, electrophoretic mobility—effect of nature, ionic strength, and pH of buffer solutions, 182
B—reversible dissociation, conformational changes, and activity of L-asparaginase, 791
Ethanol and aspirin—effect on gastric mucosa, rats, 815
depressant activity—goldfish overturn, compared to pentobarbital, 1401
Ethchlorvynol poisoning—metabolism, chemical and GLC determination in blood, urine, and hemodialysate, 169
Ethinyl estradiol tablets—fluorometric analysis, Liebermann–Burchard reaction, 1306
Ethyl acetate—hydroxylaminolysis rate constants, hydroxide-ion effect, colorimetric assay, 244
Ethylcellulose films—*in vitro* release rates, effect of thickness, composition, drying process, 412
Ethylene glycol—GC analysis, reversible adsorption on column, ghosting, 1339
Ethylene oxide residues in methyl methacrylate polymer powders—GLC analysis, 1801
(±)-2-(*N*-Ethylpropylamino)-2′,6′-butyroxylidide—local anesthetic activity and acute toxicity, 1829
Etoxadrol hydrochloride—solubility profile, 1896
Eupatolide—isolation, structure identification, cytotoxic activity, 629
Eupatorium formosanum HAY.—isolation, structure identification of eupatolide, cytotoxic activity, 629
Euphorbia millii—phytochemical investigation, isolation and identification of constituents, 954
Euphorbia myrsinitis—chemical examination, isolation, identification of nonacosane, octacosanol, β-amyrin, and taraxerol, 292
Eutectic temperature—effect of additives, preformulation screening, multicomponent drug systems, differential scanning calorimetry–differential thermal analysis results compared, 1806
Everted small intestine, rat—functional integrity with respect to passive transfer, 116
Excipients, direct compression—effect of moisture on tablet formulations, 939
—effect on tablet disintegration, 1695
tablet formulation—review of active drug substance, diluents, binders, glidants, lubricants, disintegrants, colorants, coating materials, surfactants, 1511
Excretion data—abuse drugs, 305
rates, urinary—4-*n*-butoxyphenylacethydroxamic acid (bufexamac), man, 164
riboflavin—nonlinear pharmacokinetics, rats, 404
studies—radiolabeled chlorophenothane, rats, 1912
Extraction constants, *p*-alkylpyridinium chlorides—chloroform–water and octanol–water systems, 1648
—using ion-exchange chromatography, 960
Extrusion–spheronization processing—effect of processing variables on particles, 787

F

Fagara zanthoxyloides Lam.—isolation, identification of fagaronine, antitumor activity, 1858
Fagaronine—isolation, identification from *Fagara zanthoxyloides* Lam., antitumor activity, 1858
Falling sphere viscometer—compared to rising sphere rheometer, 783

Fatty acids—*Ludwigia alternifolia* content examined, relationship to antimicrobial activity, 1336
Fenoprofen glucuronide—major urinary metabolite of fenoprofen, man, 739
—urinary and plasma kinetics compared after oral and intravenous administration, major urinary metabolites identified, man, 739
Ferric hydroxamate complex formation—in spectrophotometric analysis of acid hydrazides, 211
Films compositions, timed-release—effect of thickness, composition, drying process on release rates, 412
free, unsupported—method and apparatus for spray formation, evaluation, 106
plasticized cellulose—effects of environment and hydroxypropyl methylcellulose–ethylcellulose ratio on water vapor transmission, 1956
polyethylene—permeation of aromatic organic compounds from aqueous solutions, hexane–water partition coefficients, permeability constants, 1775
polymeric—physical constants and kinetics of drug release, formulation of aerosol dressing, 754
sprayed and cast, from the same coating solution—method, apparatus, 814
Flocculated suspensions, sedimentation kinetics—effect of ζ-potential, 1999
systems—use in coarse suspensions, structure, 268
Fluidized bed granulation—effects of binder and binder concentration on granule and tablet physical properties, 618
Flumethasone pivalate cream and ointment—analysis, high pressure liquid chromatography, 444
Fluorescence, pamaquine—effect of intramolecular hydrogen bonding, acidity dependence, 1576
Fluorescent probe technique—used to study phenylbutazone–warfarin binding, binding constants, proposed mechanism, 1835
Fluorinated hydrocarbon propellants—analysis in blood after inhalation, dogs, 1445
5-Fluoro-2′-deoxyuridine—*in vivo* formation from 5-fluorouracil in presence of nucleosides, stabilization, 1669
Fluorometry—analysis, chlorpromazine metabolites in blood, 581
—analysis, D-dopa, 1460
quenching—analysis, primary aromatic amine compounds with 9-chloroacridine, 432
5-Fluorouracil—dialysis separation, GC determination from blood, 301
—*in vivo* conversion to 5-fluoro-2′-deoxyuridine in presence of nucleosides, 1669
Flux, drug—method of computation, influence of complex formation on drug transport, 894
mucosal to serosal—determined for solutes as a function of time, rat everted small intestine, 116
—significance of coupling terms for drugs affected by complex formation reactions, simplified Fick's law, equations, 2001
Formulations—effect of additives, preformulation screening, multicomponent drug systems, determination of eutectic temperature, lyophilization conditions, defined, 1806
—effect of solvents on marijuana constituent stability, biological evaluation, vehicle toxicity, 1106
pharmaceutical—polysorbate 80–cetylpyridinium chloride interaction, effect on bactericidal activity, 1163
***syn*-3- and *syn*-4-Formyl-1-methylpyridinium iodide oximes**, acetate derivatives—configuration confirmation by NMR, acetylcholinesterase substrates, 527
Free-radical ionic intermediates—photochemical formation, steroids, 321
Freeze drying—definition of lyophilization, preformulation screening, multicomponent drug systems, differential scanning calorimetry–differential thermal analysis results compared, 1806
Functional group contribution in ion-pair extraction—tricyclic amine antidepressants, 1967
Furazolidone—metabolites in urine, chickens, 1495
Furosemide and concurrent administration of tubocurarine, succinylcholine, or chlordiazepoxide—effects on diuresis and skeletal muscle relaxation, rats, 562

G

Gangliosides (bovine)—*in vitro* binding of radiocalcium, effects of morphine and nalorphine, 1471
Gastric emptying rates—relationship to barbital induced increase of aminopyrine plasma levels, rabbits, 945
motility—atraumatic balloon technique, conscious, unrestrained rats, 1357
mucosa irritation—effect of aspirin and ethanol, rats, 815
GC—analysis, ethylene glycol, reversible adsorption on column, ghosting, 1339
—determination of 5-fluorouracil in blood, 301
electron-capture detector—analysis, fluorinated hydrocarbons, blood, dogs, 1445
—isolation and identification of *Euphorbia millii* constituents, 954
–mass spectroscopy—determination, menadione bisulfite pyrolysis to menadione, 1460
–mass spectroscopy—electron impact fragmentation patterns, β-adrenergic blocking agents and metabolites, 1728
—separation of mineral oil components, 1292
Gel filtration—used to study binding of ^{99m}technetium to various human albumins, 1667
Ghosting of ethylene glycol—GC analysis, reversible adsorption on column, 1339
GI motor activity—effect of local anesthetics on acetylcholine-induced contraction of isolated rat GI tract segments, 1141
Gibberellic acid—effect on growth, flowering, and alkaloidal content of *Atropa belladonna* L., 1970
Glass dissolution vessels—effect of shape (concavity) on dissolution rates, compendial vessels, modified vessel, 1638
GLC—analysis, 9-acridine derivatives, 1659
—analysis, aspirin, salicylic acid, and acetylsalicylsalicylic acid, 1794
—analysis, cyclophosphamide, 97
—analysis, erythromycin enteric-coated tablets, 1633
—analysis, ethchlorvynol, 169
—analysis, ethylene oxide residues in methyl methacrylate polymer powders, 1801
—analysis, iodochlorhydroxyquin and related halogenated 8-hydroxyquinolines, 1147
—analysis, menadione bisulfite *via* pyrolysis to menadione, 1460
—analysis, meprobamate, carisoprodol, and mebutamate, 1974
—analysis, meprobamate in solution *via* hydrolysis and silylation, compared to direct GLC method, 1341
—analysis, mycophenolic acid and glucuronide in plasma, 1750
—analysis, pentylenetetrazol binding to rabbit plasma proteins, 652
—analysis, salicylic acid in analgesic formulations, 929
—analysis, scopolamine and degradation products, 1311
—analysis, sulthiame in plasma, 1252
—assay, carbamazepine, 284
—determination of griseofulvin in skin, 634
—determination of pentylenetetrazol in various samples, 1651
—determination of sorbitol and mannitol in aqueous solutions, 1831
—determination, sorbitol in aqueous irrigating solutions, 103
electron capture—analysis, chlormadinone acetate in plasma, monkeys, 1441
electron-capture detection—analysis, microquantities of primary and secondary amines, 1235
—isolation, identification, 314
—isolation of methotrimeprazine and its metabolites from urine, 914
–mass spectroscopy—identification of β-(2-methoxyphenoxy)lactic acid as major metabolite of glyceryl guaiacolate, 1997
—methyl esters of fatty acids of *Ludwigia alternifolia*, 1336
—prostaglandins, review, 1861
—quantitative determination of methadone in human urine, 796
—separation, amobarbital–dextroamphetamine, 101
Gliadin and gliadin–cephalin monolayers—interaction with quaternary ammonium bactericides, presence and absence of protamine, 393
Glucophores—prediction of sweetness, three structural features, 1394
Glucose metabolism, isolated dog brain *in situ*—effect of lysergide and nimergoline, 348
D-Glucuronic acid—synthesis of phenethyl alcohol glucuronide, 810
Glucuronides—direct synthesis of phenethyl-β-D-glucopyranosiduronic acid, 810
Glyceryl guaiacolate—identification of β-(2-methoxyphenoxy)lactic acid as major metabolite, human urine, GLC–mass spectroscopy, 1997
Goldfish—comparative depressant (overturn) activity of ethanol and pentobarbital in tromethamine, 1401
Granulation—effect of spheronization on flow rate and particle-size distribution, compared to conventional wet method, 1466
fluidized bed—effects of binder and binder concentration on granule and tablet physical properties, 618
Granules, form—extrusion–spheronization process, effect of processing variables, 787
Griseofulvin—GLC determination in skin, spectrophotofluorometric determination in plasma and sweat, 634
Growth-promoting activity—synthesis and evaluation of carbobiotin, 1168
Guaiacol glyceryl ether mononicotinate—effect on solubility of cholesterol and incorporation of radioactive acetate, blood levels and urinary metabolites in man, 1212

H

Half-life, antipyrine—effect of halofenate administration, monkeys, 1490
—orally administered aspirin, first-order kinetics, man, 379
Hallucinogenic activity of methoxylated amphetamines—correlated with UV spectra, 480
Hallucinogens—identification by NMR spectroscopy and mass spectroscopy of 2,5-dimethoxyamphetamine in illicit drug seizures, 1851
Halofenate—effect on binding of various drugs to human plasma proteins and on the plasma half-life of antipyrine in monkeys, 1490
Haloperidol-^{3}H, intravenous, man—effect of volume of distribution on plasma levels of total radioactivity, atypical profile discussed, 1170
Harringtonine, isoharringtonine, homoharringtonine, deoxyharringtonine—antitumor activity, 1227
Hemodialysis—removal of ethchlorvynol poisoning, man, 169
Hetacillin solutions—stability dependence on hetacillin–ampicillin equilibrium and ampicillin degradation, 906
—stability in aqueous solution, compared to ampicillin, mechanisms proposed for chemical alterations, 727
(Heterocyclicamino)aminoalkylnaphthols and reduced tetrahydro derivatives—synthesis as possible antimalarial agents, 1500
Heterocyclic thiones—metal-binding constants, correlated to antibacterial activity, 1209
Hexachlorophene—equilibrium and kinetics of sorption–desorption on human epidermis, bioelectrometric determination, compared to spectrophotometric determination, 1102
1-*O*-Hexadecyl-3-*O*-phosphorylethanolamine-2-propanone—synthesis, characterization, ketal derivative, 607
***dl*-*cis*-Hexahydro-4-(4-carboxybutyl)-2-cyclopentimidazolone** (carbobiotin)—synthesized and evaluated for growth-promoting activity, 1168
Hexobarbital—metabolism by liver homogenate of spironolactone-pretreated rats, 296

High altitude stress—effects of decompression and hypoxia, 1175
High pressure liquid chromatography—analysis, corticosteroid creams and ointments, 444
—analysis, ketazolam, diazepam, nitrazepam, oxazepam, 1797
—separation, analysis, barbiturates, 1979
High speed liquid chromatography—separation of sulfa drugs (sulfonamides), 254
Hippuramides, substituted—synthesis and preliminary pharmacological testing, 1331
Hippuric acid from benzoic acid biotransformation—kidney metabolism contrasted to whole body, renal and apparent clearances, 1278
Homatropine methylbromide formulations with antacids—extraction, iodobismuthate (modified Dragendorff reagent) complexation, UV analysis, compared to silver nitrate titration, 1630
Homologous alkyl series, *p*-aminobenzoates—effect of chain length on melting point, solubilities, partition coefficients, crystalline properties, 852
alkyl series, *p*-aminobenzoates—effect of chain length on membrane diffusion, 838
Homosulfanilamide—carbamate derivatives synthesized as possible antibacterial agents, 1856
Hydrazides—as MAO inhibitors, review, 821
Hydrazines—as MAO inhibitors, review, 821
2 - diphenylmethylene - 1 - acyl - 1 - alkyl—synthesis, potential psychotropic agents, 1571
Hydrocarbon solvents—suggested for use in standard-state analyses of drug molecules, 816
Hydrochlorides, organic—solubility as a function of pH, temperature, and solvent composition, equations, 1896
Hydrocortisone aqueous degradation—effect of C-21-dideuterio substitution, 918
cream—analysis, high pressure liquid chromatography, 444
dissolution—effect of low concentrations of nonionic surfactant (*n*-alkyl polyoxyethylene), 1732
Hydrogen bonding—CNS drugs to peptide bond, hypothesis, 1717
Hydrolysis, butalbital—mechanism, intermediates, products, 1389
dipyrone—isolation, identification of decomposition products, 386
in vitro, in vivo—salicylanilide and 4-biphenyl *N*-methylcarbamates, 858
of 5-aminodibenzo[*a,d*]cycloheptanes—dilute aqueous acid, 1197
rate constants—*N*-chlorinated molecules, 371
rate constants—2-, 3-, and 4-monohexanoates of lincomycin, alkaline media, 287
rates, enzymatic, nonenzymatic—acetoxymethylpyridines, 1735
Hydrophobic binding—effect on drug activity, 1
Hydroxamic acids—formation by hydroxylaminolysis, hydroxide-ion effect, colorimetric assay, 244
2-Hydroxybenzenethiol—reactant in the formation of 2-dialkylaminomethyl-1,4-benzoxathians, 228
17-Hydroxycorticosterone plasma levels—effect of chronic levodopa treatment, dogs, 481
4-Hydroxycoumarin—pH and Hammett acidity dependence of fluorescent spectra, 749
4′-Hydroxyfenoprofen glucuronide—major urinary metabolite of fenoprofen, man, 739
Hydroxyiminomethylimidazoles, quaternary salts—structure–activity relationships, 631
4 - (2 - Hydroxy - 3-isopropylaminopropoxy)-acetanilid (practolol)—evaluation as cardioselective β-adrenergic blocking agent, 573
9-Hydroxymethylacridan—synthesis, 206
3 - Hydroxy - 1 - nitrophenyl - 1*H* - pyrazolo-[4,3-*c*]pyridines—synthesis, inhibition of xanthine oxidase, 179
***p*-Hydroxyphenoxyacetic acid**—from phenoxymethyl penicillin fermentations, TLC separation, colorimetric determination, 933
Hydroxypropyl methylcellulose films—*in vitro* release rates, effect of thickness, composition, drying process, 412
8-Hydroxyquinolines, halogenated—rapid GLC analysis, 1147
Hyperglycemic activity—3,4-dimethoxyphenylacetamide, 1611
Hypocholesteremic activity—guaiacol glyceryl ether mononicotinate, 1212
Hypocholesterolemic agents, potential—dicinnamides, 610
agents, potential—dicinnamoyl esters, 802
agents, potential—3,4-dimethoxyacetamide, compared to 20,25-diazacholesterol, 1611
Hypoglycemic agents, potential—synthesis and pharmacological screening of pyrazine derivatives, 1483
Hypotensive agents, potential—synthesis, screening of methyl 3-aminopropionates and 3-aminopropionohydroxamic acids, 1739
Hyptis emoryi (Labiatae)—identification of betulinic acid as tumor-inhibiting constituent, 1819

I

Indolealkylamines—as MAO inhibitors, review, 821
Indolizines, *p*-substituted 1,2-diphenyl—synthesized and screened as potential anti-inflammatory agents, 949
Inhalation aerosols—*in vitro* penetration efficiency evaluation, 262
therapy—synthesis and formulation of aerosol epinephrine salts, 219
Inhibition of platelet aggregation—saline bisulfite–sulfite, 1904
of pyruvic acid oxidation in absence/presence of nicotinamide adenine dinucleotide—1-substituted acetyl-3-aryl carbamides, correlated to anticonvulsant activity, 1366
Injectable solutions—design of a nonprecipitating potassium canrenoate solution, solubility and stability factors, 717
Injections, amine salt—titrimetric assay, 448
Interactions—cycloheptaamylose with phenobarbital, pentobarbital, amobarbital, and barbital, 1841
—phenylbutazone–warfarin–protein binding constants, proposed mechanism, 1835
Interfacial concentration—determination during descending column dissolution, five solids, 1589
drug accumulation—correlation between surface and biological activities, review, 151
energy, solid–liquid—relationship to dissolution rates of *m*-acetotoluide in four organic solvents, 1478
Intestinal absorption, *in situ*, rat—effect of tonicity and net water transfer, 1061
absorption, prednisone, prednisolone—structural requirements for enhancement by dialkylpropionamide complex formation, 649
drug absorption—effect of prednisone/prednisolone–dialkylpropionamide complex formation, rats, 362
drug absorption, rats—role of *N,N*-di-*n*-propylpropionamide on rate of seven compounds, 473
sorption—anisotropine methylbromide, rats, 1223
transit, riboflavin—decreased by use of sodium alginate solutions, increased vitamin absorption, 279
Intrazole—solvolysis, pH–rate profile, 1579
Iodochlorhydroxyquin and related 8-hydroxyquinolines—rapid GLC analysis, 1147
Ion-exchange chromatography—analysis of nifurpipone in urine, 1502
Ionic strength—effect on chemical stability of potassium penicillin G, 202
Ion-pair drug extraction—biguanides from biological fluids, 1411
extraction of drugs with bromthymol blue—analysis of biguanides in urine, 1404
extraction of tricyclic amine antidepressants—functional group contribution, linear free energy relationships, 1967
partitioning behavior, oil–water—influence of chain length using *p*-alkylpyridinium chlorides, 1648
IR spectrophotometry—identification, analysis, methotrimeprazine and its metabolites from urine, 914
Isomer mixtures, amphetamine sulfate—determination of components, 1976
Isomerization rate constants—2-, 3-, and 4-monohexanoates of lincomycin, alkaline media, 287
Isonicotinic acid hydrazide—reagent in colorimetric analysis of levodopa, 924
Isophosphamide interaction with DNA—effect of microsomal activation, 2009
Isosorbide dinitrate tablets—dissolution rates, modified column-type apparatus, compared to official methods, 1985
Isotope dilution method—analysis, morphine in opium, 1118
Itobarbital—intermediates, products of barbiturate-ring decomposition, 1389

J

K

Kelvin equation—importance of interfacial tension and particle size for the solubility of small particles, 479
Ketazolam—half-life, separation from diazepam, analysis, high pressure liquid chromatography, 1797
2-Keto-L-gulonic acid—separation from ascorbic acid, cation-exchange chromatography, 1333
Keto phospholipids—synthesis, characterization, 607
Kinetics, dissolution—solute–solvent complexation reaction effects, film theory model tested using concentration jump technique, 695
—sulfite addition to dexamethasone phosphate in aqueous solution, 708

L

β-Lactamase activity, penicillins, ampicillin, cyclacillin—determination, pH-stat alkalimetric titration, 1594
Lactic acid formation, isolated dog brain *in situ*—effect of lysergide and nimergoline, 348
Lactose, spray dried, interaction with dextroamphetamine sulfate—ethanol mediated, mechanism and rate of discoloration, 1770
Lampropeltis getulus, radiolabeled—distribution and excretion, rats, 119
Leakage procedures for flame-sealed ampuls—inadequacies demonstrated, 1609
Leucomethylene blue, as major methylene blue metabolite—UV assay in blood, urine, tissue, 598
Leurosine—anomalous isolation from a previously inactive fraction of *Catharanthus lanceus*, 1840
Levodopa—analysis, colorimetric reaction with isonicotinic acid hydrazide, 924
biotransformation to dopamine—separation, fluorometric analysis of D-dopa, 1460
—chronic treatment, effect on plasma levels of 17-hydroxycorticosterone, dogs, 481
Light stability of tablets containing dyes—rapid determination, 1811
Lignans—isolated from *Bursera schlechtendalii*, structure determination, 1992
Lincomycin and lincomycin 7(S)-chloro analogs (phase II)—against *Escherichia coli*, effect of erythromycin, 545
monoesters—kinetics of alkaline isomerization and hydrolysis, 287
Linear free energy relationships—tricyclic amine antidepressants, 1967
Lipase effect—blood levels of dogs following administration of timed-release lipase–lipid–sulfamethizole tablets, 900
Lipid monolayer films—interactions with dimethyl sulfoxide, surface pressure–surface area curves, 1098
Lipid–protein monolayer films—interactions with dimethyl sulfoxide, surface pressure–surface area curves, 1098
Lipolysis activity—49 classes of therapeutic agents, 1556
Lipophilicity of aliphatic ethers—related to anesthetic activity, correlated with hypnotics in solution, 589

Lipophilicity–biological activity linear relationships—review, 1
Liquid–liquid partition chromatography—analysis, scopolamine and degradation products, 1311
Liquid petrolatum–water emulsions—effect of age on stability, ultracentrifugation, 769
Lithium borohydride reduction in tetrahydrofuran—determination of conjugated ketosteroids, differential UV spectrophotometry, 148
Lithium carbonate tablets and capsules—comparison of *in vitro* dissolution rates, magnetic basket apparatus, 1152
Loliolide—isolated and identified from *Cocculus carolinus* D.C., 1825
Lubricants, tablet—evaluation of magnesium lauryl sulfate, 984
Ludwigia alternifolia L.—fatty acid content examined, 1336
Lysergide—effect on glucose metabolism in isolated dog brain *in situ*, 348

M

Mafenide—carbamate derivatives synthesized as possible antibacterial agents, 1856
Magnesium lauryl sulfate—evaluation as tablet lubricant, 984
Magnesium trisilicate—adsorption of belladonna alkaloids, desorption for analysis, 1458
Magnetic basket dissolution apparatus—dissolution rates of both tablets and capsules, 1152
Magnoflorine—isolated and identified from *Cocculus carolinus* D.C., 1825
Maleic anhydride–alkyl vinyl ether copolymers and partial esters—dissolution rates, related to use as timed-release coatings, 1916
Mammalian cells, suspension cultures—cholesterol transport, baseline procedures, 1618
Mammea americana **L.**—isolation, identification of constituents, antitumor activity, 1599
—oxidation of mammein and mammeisin, 1603
Mammein and mammeisin—oxidation, isolation and characterization of cyclomammein, chromeno and dihydrofurano coumarins, 1603
related coumarin and phloroglucinol derivatives—structure identification, antitumor activity, 1599
Mammillary models (linear), with first- or zero-order input process—equations, general treatment, 536
Mangiferin—xanthone from *Canscora decussata*, pharmacological activity, 1838
Mannide monooleate commercial emulsifier—fractionation, characterization, 863
Mannitol—GLC determination from aqueous solutions, 1831
Manometry (Warburg)—determination of MAO activity, cinnamides, 78
MAO inhibitors, cinnamides—synthesis, correlation to anticonvulsant activity, 78
potential—synthesis and evaluation of 2-alkyl substituted 1-(4′-benzhydrazide)-aminomethylbenzimidazoles, 1322
—review of recent research, 821
Marijuana constituents—oral and parenteral formulation, stability in various solvents, biological evaluation of formulations, vehicle toxicity, 1106
constituents—photochemical study, 1994
—identification of cannabidivarin and tetrahydrocannabivarin, GLC, mass spectroscopy, 1476
Mass spectroscopy—analysis, cardenolides, 765
—characterization of carbamazepine-10,-11-epoxide, 1144
—characterization of mineral oils, 1292
—identification, 318
—identification, analysis, methotrimeprazine and its metabolites from urine, 914
—identification, mammein and mammeisin oxidation products, 1603
—identification of 2,5-dimethoxyamphetamine, 1851
—identification of β-(2-methoxyphenoxy)lactic acid as major metabolite of glyceryl guaiacolate, 1997
—identification of methylxanthines and methyluric acids as possible metabolites of caffeine, 1822
—rapid identification of barbiturates, 310
Medicinal chemists—use of drug metabolism studies to design and synthesize potential new drugs, 1678
Medicinal plants—antitumor activity found due to tannins in four plants, 1818
—*Canscora decussata* xanthones, pharmacological activity, 1838
—chemical and pharmacological characterization of *Bersama yangambiensis* Toussaint, 1165
—constituents of *Mammea americana* L., antitumor activity, 1599
—isolation and identification of betulinic acid from *Hyptis emoryi* as antitumor agent, 1819
—isolation, identification of fagaronine from *Fagara zanthoxyloides* Lam., antitumor activity, 1858
—isolation, identification, pharmacological evaluation of 11 constituents of *Erythrina variegata*, 1274
—isolation of cryptopleurine from *Boehmeria cylindrica*, antiviral activity, 1508
—preliminary phytochemical investigation of *Euphorbia millii*, 954
—*Salmalia malabarica* flowers, chemical characterization, 807
—*Yucca schottii* leaves, constituents, anti-inflammatory properties, 1665
Membrane diffusion—cholesterol in suspension cultures of mammalian cells, permeability and partition coefficients, 1618
diffusion—effect of hydrostatic (or osmotic) flow and surface pH on GI drug absorption, theoretical, 192
diffusion—maximum steady-state flux as a function of homolog size, alkyl *p*-aminobenzoates, 838
diffusion—thermodynamic activity of the diffusing compound in the applied phase, 61
permeability—equations describing diffusion layer control, 312
Menadione bisulfite addition products—GLC analysis, on-column pyrolysis to menadione, thermal decomposition confirmed by differential thermal analysis and GC–mass spectroscopy, 1462
Mepenzolate bromide, radiolabeled—oral absorption, humans, 1663
Meperidine—intermediate of 1-carbethoxy-4-cyano-4-phenylpiperidine synthesis, 1316
Meprobamate—analysis in solution *via* hydrolysis and silylation, compared to direct GLC method, 1341
—GLC analysis in powder and tablets, 1974
Mercury—analysis in pharmaceutical products, neutron activation analysis, 936
lamp—photochemical steroid reactions, 321
Mescaline amino acid analogs—synthesis of mescaloxylic and mescaloruvic acids, 1172
Mescaloruvic acid—synthesized as amino acid analog of mescaline, 1172
Mescaloxylic acid—synthesized as amino acid analog of mescaline, 1172
Metabolism, drug—species dependence, design of pharmacological and safety tests, 1674
—naproxen, animals, man, 703
of prostaglandins—animal and human systems, review, 1861
Metabolites formation—effect on drug metabolism, 1682
of β-adrenergic blocking agents—mass fragmentation patterns of trifluoroacetyl derivatives, 1728
Metabolizing enzymes, drug—inhibition, induction, effect on drug metabolism, 1682
Metal binding to cupric, aluminum, and ferric ions—heterocyclic thiones, binding constants, 1209
Metformin—analysis, bromthymol blue ion-pair extraction, urine, 1404
—analysis in biological fluids, ion-pair extraction, protein binding estimates, 1411
Methacholine—colorimetric assay, 244
Methacrylate polymer powders—GLC analysis, ethylene oxide residues, 1801
Methadone in biological specimens—liquid–liquid extraction, barium peroxide–sulfuric acid oxidation, UV analysis, 1397
in human urine—quantitative GLC determination, 796
Methotrimeprazine and metabolites—isolation, analysis, in urine of psychiatric patients, 914
(+)-6-Methoxy-α-methyl-2-naphthaleneacetic acid—absorption, distribution, metabolism, and excretion in animals, man, 703
β-(2-Methoxyphenoxy)lactic acid—identification as major metabolite of glyceryl guaiacolate in human urine, GLC–mass spectroscopy, 1997
3- and 4-(*m*-Methoxyphenyl)pyrazolidines—synthesis, evaluation of analgesic activity, 188
Methoxy-*meso*-tetraphenylporphine—preparation, purification, 307
***N*-Methylaminoantipyrine**—isolation, identification as dipyrone decomposition product, 386
3-Methylamino-2-phenyltetrahydropyran, *cis* and *trans*—synthesis, configuration established by NMR, 963
1-Methyl-4-[4-(7-chloro-4-quinolylamino)benzoyl]piperazine (WR 4809)—evaluation of spasmolytic activity, 482
Methylene blue and leucomethylene blue—UV assay in blood, urine, tissue, 598
—dog plasma and rat tissue concentrations after intravenous administration, pharmacokinetics, 1090
—species-dependent absorption, metabolism, and excretion after oral administration, man, dog, 1086
***trans*-3-Methyl-2-hexenoic acid**—schizophrenic sweat component, synthesis, 316
Methyl *p*-hydroxybenzoate—separation from *p*-hydroxybenzoic acid, UV analysis, compared to compendial methods, 252
Methyl orange ion-pair formation—monitoring of hydrolysis rates of 5-aminodibenzo[*a,d*]cycloheptanes, 1197
***N*-Methylpalaudinium chloride**—isolation and identification from *Thalictrum polygamum*, 295
Methyltestosterone in plasma or serum—spectrophotofluorometric analysis, 1746
Methyl-*meso*-tetraphenylporphine—preparation, purification, 307
Methyluric acids—mass spectrometric identification, possible metabolites of caffeine, 1822
Methylxanthines—mass spectrometric identification, possible metabolites of caffeine, 1822
Micellar diffusion coefficient—calculated for dissolution of benzoic acid in aqueous polysorbate 80 solutions, constant and uncontrolled viscosity, 592
solutions—dissolution rate, effect of viscosity and solubilization, 175
systems—calculation of partial molal volume of surfactant, 793
Micelles formation, sodium glycocholate—determination of CMC, solubilization of testosterone, 1757
—spherical shape, 651
Michaelis constants—acetoxymethylpyridines, 1735
Microbial contamination of ophthalmic ointments—survey of commercial preparations, 532
degradation in soil—2,3,5-triiodobenzoic acid, 804
Microbiological assay—automated turbidimetric readout system, 449
contamination of topical dosage forms—evaluation of commercial sterilizing techniques, 1078
Microdissociation constants—determination, two methods for analyzing spectral data, 232
Microencapsulation of waxy solid (stearyl alcohol) by complex coacervation—effect of colloid concentration and particle size, 1586
Microplate tissue culture method—large-scale cytotoxicity screening, 1960
Microscopy—visualization of starch grain deformation, 455
Microsomal activation—effect on isophosphamide interaction with DNA, 2009
Migration of drugs in wet granulations—evaluation of additive inhibitors, 1121
Mineral oils, adjuvant—separation, UV and mass spectrometry characterization, 1292
Miosis—prolonged-acting pilocarpine alginate flakes, 985

Mithramycin—use in cancer chemotherapy, 485
Mitomycins—use in cancer chemotherapy, 485
Mitotane—metabolism, metabolite identification, 314
Model, open, classical linear two compartment—equations relative to erroneous assignment of nonlinear data, 552
Moisture effect—direct compression tablet excipients, 939
—effect on tensile strength of fine particle-size materials with varying inherent coherence, 342
—effect on tensile strength of variable particle-size sodium chloride, bulk solids, 256
Molar attraction constants—method of calculation for nonpolar substances, 723
Molecular associations—interactions of amphetamine isomers with optically active and racemic mandelic and tartaric acids, thin-layer electrophoresis, 1325
estimates—molar attraction constants, semiempirical method of calculation, 723
orbital calculations—used to determine the relationship between electronic structure and base strength of benzacridines and amino derivatives, 909
theory of sweetness—structural features, relationship between polarizability parameter and sweetness level, 1394
Monocrotaline—isolation from *Crotalaria sagittalis* L. fruit, 122
Monolayers, dipalmitoyl lecithin and dipalmitoyl glycerol—interactions with cetyl sulfate and cetrimonium ions, kinetics, mechanisms, 1720
lipid and protein—interactions with dimethyl sulfoxide, surface pressure–surface area curves, 1098
polyvinylpyrrolidone copolymers—interaction with benzoic acid and *p*-hydroxybenzoic acid, orientation of polymer at interface, effect on penetration, 977
Monomolecular films—interaction of 3,4-benzpyrene with various cholesterol, phospholipid, protein, and lipid–protein films, biological significance, 1065
Montmorillonite, adsorbates—bonding as an ion–dipole interaction, diazepam isotherms determined, equations, 420
—solvation, comparison of liquid and vapor, number of layers in interlaminar spacing, 139
Morphine—effect on *in vitro* ^{45}Ca binding to bovine gangliosides, 1471
in opium—analysis, isotope dilution method, 1118
Mosquito repellents, topical, potential—acetals, aminoacetals, carboxamide acetals, and esters, 577
Multiparticulate dispersion technique—sterols across oil/water interface, ionic surfactant systems, 375
Multiple-dose kinetics—pharmacological effects, indirect anticoagulants, 980
kinetics—simulation, electrical circuits, 1468
Multivitamin dosage forms—analysis, ascorbic acid, tubular carbon electrode oxidation, 1301
Muscarinic activity—2-trimethylammonium-7-oxabicyclo[2.2.1]heptane iodide epoxides and 2-trimethylammoniumbicyclo[2.2.1]-heptane iodides, 1640
Muscular contraction, adenosine 5′-triphosphate induced—inhibition by chymotrypsin, 352
effects—*Banisteriopsis quitensis* extract, rabbit ileal strips, 623
Mushroom metabolites—screened for antimicrobial activity, 1820
Mycophenolic acid and glucuronide—GLC and fluorometric analyses, human plasma, 1750

N

Nalorphine—effect on *in vitro* ^{45}Ca binding to bovine gangliosides, 1471
***p*-Naphtholbenzein**—indicator in assay of amine salt injections, 448
1-Naphthylamine-4-sulfonic acid—blood level–time relationships after intravenous administration, pharmacokinetic parameters, rate constants, rabbits, 524
Naproxen—absorption, distribution, metabolism, and excretion in animals, man, 703
Narcotics, barbiturates, and CNS stimulants—TLC identification, drug abuse urine screening program, 679
—detection procedures in urine screening programs, review, 655
Neutron activation analysis—mercury in pharmaceutical products, 936
Nickel (II)-catalyzed hydroxylaminolysis—in spectrophotometric analysis of acid hydrazides, 211
Nicotinic acid—synthesis of amino acid derivatives, azide method, 477
Nicotinic anhydride and methyl glycinate—convenient preparation of nicotinoyl glycine derivatives, 141
Nicotinoylaminoethanesulfonylpheneti dine—effect on erythrocytolysis and methemoglobin production, blood levels in rabbits, rats, mice, 1791
Nicotinoyl glycine derivatives—convenient preparation, anhydride method, 141
Nicotinoyltauraminopyridine—rabbit serum protein binding, presence in rat organs, 884
Nicotinoyltaurinophenetidine—effect on erythrocytolysis and methemoglobin production, blood levels in rabbits, rats, mice, 1791
Nifurpipone—isolation from urine, analysis, 1502
Nilsen method for determination of analgesic activity—compared to hot-plate procedure, 86
Nimergoline—effect on glucose metabolism in isolated dog brain *in situ*, 348
Ninhydrin—analysis, polymyxin B sulfate after column chromatography, 1803
Niridazole—structure–schistosomicidal activity, biological studies, compared to thiamine, 1327
Nitrite/nitrate levels—sodium nitrite absorption, metabolic pathways, mice, 1492
2-Nitro-4-acetamidophenol—colorimetric derivative of acetaminophen, analysis in tablets and elixir, 927
5-Nitrofuraldehyde-*N′*-methylpiperazinoacetylhydrazone—isolation from urine, analysis, 1502
Nitrofuran compounds—turbidimetric assay in urine and serum, using *S. faecalis* as test organism, 462
Nitrofurans—furazolidone metabolites determined in urine, chickens, 1495
Nitroglycerin—enzyme induction, rabbits, mice, 1267
1-Nitroso-2-naphthol—determination of medicinal phenolic compounds, UV spectrophotometry, 146
1-(5′-Nitro-2′-thiazolyl)-2-imidazolidinone—structure–schistosomicidal activity, biological studies, compared to thiamine, 1327
Nitrous acid—oxidation of acridans, 206
NMR spectroscopy—analysis, cacodylate injections, 1635
—analysis, chloral hydrate soft gelatin capsules, 613
—analysis, pentylenetetrazol tablets and injectables, 1309
—characteristics of bisnorargemonine isomers, 55
—characterization, synthetic amino acid analogs of mescaline, 1172
—configuration confirmation of *cis*- and *trans*-3-methylamino-2-phenyltetrahydropyran, 963
—configuration identification, 527
—determination, hydrogen bonding of drugs to peptide bond, 1717
—determination, stereochemistry of 4,4-disubstituted 1,2,3,4-tetrahydro-2-naphthoic acids, 1231
—identification, Cephalotaxus alkaloids, 1227
—identification, classification scheme, sulfonamides, 434
—identification, 2-dialkylaminomethyl-1,4-benzoxathians, 228
—identification, mammein and mammeisin oxidation products, 1603
—identification of 2,5-dimethoxyamphetamine, 1851
—identification of reserpine photooxidation products, 299
—stability assay, amyl nitrite ampuls, 428
—stabilization of sulfanilamides, 1670
—structure identification, 708
Nonacosane—TLC isolation, IR identification from *Euphorbia myrsinitis*, 292
Nonelectrolyte solubility—polar solvents, 983
Nonlinear regression analysis—applied to microdissociation constant determinations, 232
Norepinephrine—release by bradykinin in perfused human placenta, 878
(−)-Normacromerine—isolated from *Coryphantha macromeris*, 147
Nornuciferine derivatives—screened for apomorphine-like activity, dogs, pigeons, mice, 813
Nylidrin—effect on endotoxin-induced shock, 1844

O

Octacosanol—TLC isolation, IR identification from *Euphorbia myrsinitis*, 292
1-*O*-Octadecyl-3-*O*-phosphorylethanolamine-2-propanone—synthesis, characterization, ketal derivative, 607
Ointments, benzoic and salicylic acids—colorimetric analysis, 1625
Ophthalmic ointments—survey of microbial contamination in antibiotic and non-antibiotic commercial preparations, 532
prolonged-acting dosage forms—pilocarpine alginate flakes, cul-de-sac deposition, compared to pilocarpine hydrochloride solutions, 985
Opium alkaloids—analysis of morphine in opium by isotope dilution, 1118
Optically active ions—amphetamine with mandelic or tartaric acid, conductivity changes, 293
Optimal drug input functions—relationship to time variations of multiple pharmacological effects, computer simulation, 1941
Organic aromatic compounds—permeation from aqueous solutions through polyethylene films, 1775
Organochlorine pesticides—accumulation in man, pharmacokinetic relationships, quantification, 948
Organomercurials—mercury analysis, neutron activation analysis, 936
Oxazepam and *N*-methyloxazepam—biliary excretion in rats, guinea pigs, mice, 965
Oxidation, aerobic, ascorbic acid—pH–log rate profile, effect of disodium ethylenediaminetetraacetate, 556
dipyrone—isolation, identification of decomposition products, 386
of mammein and mammeisin—isolation and characterization of products, 1603
Oximes, pralidoxime methanesulfonate—plasma levels and pharmacokinetic parameters after oral administration, compared to pralidoxime chloride, man, 1136

P

Packaging materials—toxicity profile of epichlorohydrin, 1712
Palmatine—isolated and identified from *Cocculus carolinus* D.C., 1825
3-PAM acetate—reaction with isonitrosoacetone, substrate for acetylcholinesterase, 527
4-PAM acetate—configuration, substrate for acetylcholinesterase, 527
Pamaquine—fluorescence, intramolecular hydrogen bonding, acidity dependence, 1576
Pan-coating method—polyvinylpyrrolidone film-coating formulations, 265
Partial molal volume—calculation, surfactants in the micellar state, 793
Particle dissolution, sink conditions—powder, log-normal distribution, rate patterns, computer, simulation, 223
form—extrusion–spheronization process, effect of processing variables, 787
size of bulk solids—effects of moisture on tensile strength, 256
size of bulk solids, fine—effect of moisture on tensile strength, 342
solubility—importance of interfacial tension and particle size as indicated by the Kelvin equation for small particles, 479
solubility—thermodynamic aspects for small particles, surface enthalpy and surface entropy, 478

Partition chromatography, 17 corticosteroids —versatile solvent system, prediction of elution curves from partition coefficients, substituent effect, 689
Partition coefficients, *p*-alkylpyridinium chlorides—chloroform–water and octanol–water systems, 1648
—application to buccal absorption, 1785
—comparison between epinephrine maleate, malate, fumarate, and bitartrate in octyl or hexadecyl alcohol–water systems, 219
—determination of linear relationships between lipophilicity and biological activity, 1
dodecane—correlated with goldfish test system data, structure–toxicity relationships of substituted phenothiazine derivatives, 1498
hexane–water—used to study permeation of aromatic acids, alcohols, amines, esters, aldehydes, and ketones in aqueous solutions through polyethylene films, 1775
Passive transport—significance of coupling terms, complex formation reactions, Fick's law, equations, 2001
Penetrability—interaction of polyvinylpyrrolidone copolymer monolayers with benzoic acid and *p*-hydroxybenzoic acid, orientation of polymer at interface, 977
Penicillin, hydrolysis to penicilloic acid—effect of copper (II)–glycine chelates, mechanism, 82
Penicillin G, potassium—effect of ionic strength on chemical stability, 202
Penicillins—β-lactamase activity, rate of inactivation, pH-stat alkalimetric titration, 1594
Pentachlorophenol, radiolabeled—excretion and tissue distribution studies, rats, 2004
Pentobarbital, sodium, depressant activity—goldfish overturn, compared to ethanol, 1401
Pentylenetetrazol—GLC determination from various samples, 1651
—*in vitro* binding to plasma proteins, GLC analysis, rabbits, 652
—NMR analysis in tablets and injectables, 1309
Peptides, cyclic—synthesis, homodetic and heterodetic, review, 1345
mono—synthesis of amino acid derivatives of nicotinic acid, 477
Peritoneal dialysis—accelerated using dioctyl sodium sulfosuccinate, 475
Permeability constants, substituted anilines—from aqueous solution through polyethylene, effects of different aniline structures, correlated with hexane–water partition coefficients, 416
epidermal—effect of surfactants, rabbits, 1329
parameters across everted intestinal sac—correlated with *in vivo* absorbability, 1361
Permeation—aromatic organic compounds from aqueous solutions through polyethylene films, 1775
of water vapor through plasticized cellulose films—effects of environment and hydroxypropyl methylcellulose–ethylcellulose ratio, 1956
water vapor—cast and sprayed polymer films, factors involved, 1645
Pesticides, organochlorine—pharmacokinetic relationships used to quantify accumulation in man, 948
Peuarenine—isolated from *Peucedanum arenarium*, 1643
Peucedanum arenarium—isolation of xanthalin and peuarenine, 1643
Peyote alkaloids—synthesis of new amino acid analogs of mescaline, mescaloxylic and mescaloruvic acids, 1172
pH effect—salicylate absorption from hydrophilic ointment, 172
profile—arabinosylcytosine stability in aqueous solutions, 1189
pH–log rate profile—aerobic oxidation of ascorbic acid, 556
pH–partition theory—effect of transport rates in three-phase (w/o/w) system, 1922
theory—effect on transport rates in three-phase (w/o/w) system, 1931
pH–rate profiles—cytosine and cytidine solvolysis, 1052
pH–solubility profiles—organic hydrochlorides (dexoxadrol and etoxadrol hydrochlorides), 1896
pH–solvolysis rate profile—intrazole, 1579
pH-stat alkalimetric titration—measurement of β-lactamase activity, rate of inactivation, penicillins, 1594
Pharmaceutical chemists—selection of dosage forms for preclinical and phase I studies, 1686
Pharmaceutical sciences—1971 literature review of pharmaceutics, 989
Pharmacokinetics, aspirin, oral aqueous solution—absorption kinetics, calculations, half-life, plasma concentration–time curves, two-compartment model, 379
—comparison of toxogonin–pralidoxime, intravenous administration, man, volume of distribution terms reviewed and compared, 1765
—dose–plateau levels relationship, parallel first-order and capacity-limited elimination kinetics, 541
—drug input optimization, computer simulation, 1941
—general treatment of linear mammillary models with elimination from any compartment, 536
models—erroneous assignment of nonlinear data to classical linear two-compartment open model, equations, 552
multicompartment systems—dose-dependent decline of pharmacological effects, computer simulations, 567
multiple-dose and pharmacological effects —calculations regarding behavior and optimal regimen for indirect anticoagulants, 980
1-naphthylamine-4-sulfonic acid, sulfanilic acid—after intravenous administration, rabbits, 524
nonlinear—absorption, excretion of riboflavin, rats, 404
of highly ionized drugs—methylene blue, dogs, rats, 1090
of highly ionized drugs—species-dependent absorption, metabolism, and excretion of methylene blue, man, dog, 1086
of highly ionized drugs—UV assay for methylene blue and leucomethylene blue in blood, urine, tissue, 598
species differences—disopyramide phosphate biotransformation, rat, dog, man, 888
sulfamethazine, sulfisomidine, sulfathiazole—after intravenous administration, rabbits, 518
—sulfisoxazole, man, 773
two-compartment open model—effects of changes in elimination, 1270
Pharmacological response, intensity—basis for transforming into biophasic drug levels at any time by any route, equations, 467
toxicological activity—effects of binding, hepatic drug-metabolizing enzymes, formation of active metabolites, 1682
Pharmacology, environmental—interaction of drugs and environment, 1175
—succinic semialdehyde, 1963
Phase solubility analysis—monobasic amines and their salts in aqueous solution, theory, method, 1069
transitions—binary mixtures of cholesteryl esters, 1762
Phenanthrenemethanols—synthesis, 1297
9-Phenanthryllithiums—reactant, synthesis of α-aminoethyl-9-phenanthrenemethanols, 1297
β-Phenethylamine alkaloids—chromatographic isolation and/or identification from seven Coryphantha species, 41
Phenethyl-β-D-glucopyranosiduronic acid—direct synthesis, complexation with copper, 810
Phenformin—analysis, bromthymol blue ion-pair extraction, urine, 1404
—analysis in biological fluids, ion-pair extraction, protein binding estimates, 1411
Phenolic compounds, medicinal—determinations with 1-nitroso-2-naphthol, UV spectrophotometry, 146
Phenothiazine derivatives, substituted—structure–toxicity relationships, goldfish test system data correlated with dodecane partition coefficients, 1498
Phenoxymethyl penicillin fermentations—determination of *p*-hydroxyphenoxyacetic acid, TLC separation, colorimetric determination, 933
***d,l*-2-(3-Phenoxyphenyl)propionic acid**—urinary and plasma kinetics compared after oral and intravenous administration, major urinary metabolites identified, man, 739
Phenylacetic acids, *p*-*n*-alkyl and *p*-halogen—application of partition coefficients to buccal absorption, 1785
Phenylbutazone–warfarin binding—studies using fluorescent probe technique, binding constants, proposed mechanism, 1835
***N*¹-Phenylcarbamoyl-4-arylazo(3- and/or 5-substituted)pyrazoles**—synthesis as potential antidiabetic agents, biological activity, 957
Phenylethanol-resistant and sensitive *Pseudomonas aeruginosa* cultures—effect of benzalkonium, chlorhexidine, phenylmercuric nitrate, 1075
Phenylmercuric nitrate effect—phenylethanol-resistant and sensitive *Pseudomonas aeruginosa* cultures, 1075
Phenylpyrazolidines, nonoxygenated—synthesis, analgesic activity, 235
Pholiota squarroso-adiposa—isolation, identification of bisnoryangonin, 318
Phosphodiesterase activity—49 classes of therapeutic agents, 1556
Phospholipids, keto—synthesis, characterization, 607
monolayers—interaction with long-chain surfactants, kinetics, mechanisms, 1720
Photooxidation products, reserpine—isolation, identification from chloroform solutions, 299
Photoreactions of steroids—rearrangements, additions, reductions, oxidation, 321
Phototautomerism—warfarin cation in the lowest excited singlet state, 749
Phthalates—embryo-fetal toxicity, teratogenic effects, rats, 51
esters—identification in adjuvant mineral oils, 1292
Physical constants—polymeric films, considerations for an aerosol formulation, 754
Physical pharmacy—dissolution, solubility, permeability, complexation, surface phenomena, 989
Physiological effects of environmental stimuli—review, 1175
effects of prostaglandins—reproductive, GI, respiratory, and cardiovascular systems, review, 1861
Phytochemical survey of Connecticut—monocrotaline isolation from *Crotalaria sagittalis*, 122
Picrate salts—phase solubility analysis using solubility product relationships, theory, method, 1069
Pilocarpine—colorimetric assay, 244
Piperidazines, 1,2-dialkyl-4-aryl and 1,2,4-trialkyl-4-aryl—synthesis, screened for analgesic activity, 1781
3-substituted—syntheses of series of 1,2-dialkyl and 1,2,3-trialkyl substituted, screened as possible analgesics, 1936
Piperidinecarboxamides—synthesized and screened as potential CNS and cardiovascular agents, 127
Placenta perfusates—norepinephrine release by bradykinin, 878
Plant growth regulators—effect of gibberellic acid on *Atropa belladonna* L., 1970
growth regulators—microbial degradation of 2,3,5-triiodobenzoic acid, 804
Plasma concentration–time curves—effects of protein binding of drugs on area under curve, pharmacokinetics of inhibitor, equations, 138
levels, 4,5-bis(*p*-methoxyphenyl)-2-phenylpyrrole-3-acetonitrile—correlated with biological activity, 1908
levels—carbamazepine, GLC determination, 284
levels, 17-hydroxycorticosterone—effect of chronic levodopa treatment, dogs, 481
levels, methylene blue—intravenous administration, dogs, 1090
levels, methyltestosterone—spectrophotofluorometric analysis, 1746
levels—pralidoxime methanesulfonate after oral administration, man, 1136
levels—spironolactone, canrenone, and potassium canrenoate after intravenous administration, dogs, 1129
profile of radioactivity—atypical appearance after intravenous haloperidol-³H administration, man, effect of volume

of distribution, 1170
protein binding—effect of halofenate on various drugs, 1490
Plasticizers—possible leaching of phthalates, teratogenic effects, rats, 51
Plastics—effect of aniline structure on its permeability, hexane–water partition coefficient correlated with structure of aniline, 416
Platelet aggregation—inhibition by saline bisulfite–sulfite, 1904
PMR spectroscopy—identification, 2-chloro-1-phenylindene, 1216
—stabilization of sulfanilamides, 1670
Poisoning, ethchlorvynol—metabolism, determination in biological fluids, 169
Polarizability—used in calculating molar attraction constants, 723
Polarography, glassy carbon electrode—stability-indicating analysis, acetaminophen dosage forms, 1627
—metal complexes of thiouracils, 1241
Polyethylene—effects of structure of substituted anilines on permeability, correlated with hexane–water partition coefficient, 416
films—permeation of aromatic organic compounds from aqueous solutions, hexane–water partition coefficients, permeability constants, 1775
Polyethylene glycols—effect of temperature on aspirin decomposition, 1160
Polymer films, free—factors affecting water vapor transmission, 1645
films—method and apparatus for spray formation, evaluation, 106
films—physical constants and kinetics of drug release, formulation of aerosol dressing, 754
Polymorphism—effect of structure and recrystallization from different solvents on dissolution kinetics, 1423
—evaluation of 16 sulfonamides, hydrogen-bonding arrangements, crystal compactness, 26
sulfameter—GI absorption, man, related to dissolution rates, 1615
thermodynamics—phase transition parameters from intrinsic dissolution rates, 868
Polymyxin B sulfate—analysis, column chromatography and ninhydrin, compared to microbiological method, 1803
Polypeptides, linear, antigenic—immunochemical properties evaluated, 806, 1990
linear—synthesis, immunochemical properties, 1654
Polysorbate 20—determination of CMC by surface tension method, 1334
Polysorbate 80—effect on bactericidal activity of cetylpyridinium chloride against *Escherichia coli*, 1163
Poly(L-tyrosyl-L-glutamyl-L-alanylglycyl)glycine-1-^{14}C ethyl ester—synthesis, conformation dependency of antibodies, 1654
Polyurethan films—diffusivity and solubility of aliphatic alcohols, thermogravimetric analysis, 1094
Polyvinylpyrrolidone copolymers—monolayer interaction with benzoic acid and *p*-hydroxybenzoic acid, orientation of polymer at interface, effect on penetration, 977
film-coated tablets—addition of ethylcellulose and shellac to eliminate tackiness, dissolution, 265
Polyvinylpyrrolidone–reserpine coprecipitates—enhanced reserpine absorption, correlation with *in vitro* dissolution rates, rats, 400
Pore diameter (mean), tablets—correlated with porosity, 303
Porosity, tablets—correlated with tablet mean pore diameter, 303
Potassium canrenoate—design of a nonprecipitating injectable solution, stability factors, 717
Potassium penicillin G—effect of ionic strength on chemical stability, 202
Potentiometric titration—metal complexes of thiouracils, 1241
Powders, dissolution under sink conditions—rate patterns, (approximate) numerical solution of log-normal distribution integrals, 223
slightly water soluble—dissolution rates predicted from simple mathematics, 811
Practolol—evaluation as cardioselective β-adrenergic blocking agent, 573
Pralidoxime methanesulfonate—plasma levels and pharmacokinetic parameters after oral administration, compared to pralidoxime chloride, man, 1136
Pralidoxime–toxogonin—kinetic comparison after intravenous administration, man, 1765
Prednisolone absorption—effect of *N,N*-di-*n*-propylpropionamide, rat small intestine, 367
Prednisolone–dialkylpropionamide complex formation—effect on intestinal drug absorption, rats, 362
complex formation—effect on transfer through artificial lipoid barrier, 356
Prednisone–dialkylpropionamide complex formation—effect on intestinal drug absorption, rats, 362
complex formation—effect on transfer through artificial lipoid barrier, 356
Pregnanes—photoreactions, review, 321
Procainamide—antiarrhythmic activity evaluation, comparison with five anticonvulsant drugs, 133
Processing of tablets—review of particle-size reduction, mixing, granulating, drying, compressing, coating, 1511
Progesterone-type steroids—*in vitro* release from silicone polymer, 46
L-Proline-U-^{14}C—incorporation into alkaloid and trichloroacetic acid-precipitable proteins, *Datura stramonium* L. var. *tatula*, 1257
Propantheline bromide—effect on riboflavin absorption after concurrent oral administration, 798
Propargylamines—as MAO inhibitors, review, 821
Propellants, fluorinated hydrocarbon—analysis in blood after inhalation, dogs, 1445
Propoxyphene–aspirin formulations—GLC analysis of salicylic acid, 929
Prostaglandins—review of biosynthesis, chemistry, analytical methods, metabolism, biology, 1861
Protamine—effect on interaction of quaternary ammonium bactericides with gliadin and gliadin–cephalin monolayers, 393
Protein binding—effects on area under plasma concentration–time curve, conservation-of-mass treatment, equations, 138
binding estimates—buformin, metformin, phenformin, dog and human plasma, 1411
binding, human serum—radiolabeled sulfonylureas, relationship between inhibition and hypoglycemia potentiation, 89
monolayer films—interactions with dimethyl sulfoxide, surface pressure–surface area curves, 1098
Protein–alkaloid syntheses relationship—*Datura stramonium* L. var. *tatula*, 1257
Pseudoephedrine absorption—effect of concurrent administration of antacid, man, 903
Pseudomonas aeruginosa cultures, phenylethanol resistant and sensitive—effects of benzalkonium, chlorhexidine, phenylmercuric nitrate, 1075
Psychotropic agents, potential—2-diphenylmethylene-1-acyl-1-alkyl hydrazines synthesized, 1571
Pulse polarography—analysis, disulfiram tablets, 249
Puromycin inhibition of protein synthesis—*Datura stramonium* L. var. *tatula*, 1257
Pyrazine derivatives—synthesized and screened as potential hypoglycemic agents, 1483
Pyrazinoyl - 4 - ethylthiosemicarbazide—synthesis, tested as potential hypoglycemic agent, 1483
Pyrazole derivatives—synthesis of N^1-acyl-4-arylazopyrazoles, screened for pharmacological activity, 130
Pyrazoles, N^1-phenylcarbamoyl-4-arylazo(3- and/or 5-substituted)—synthesis as potential antidiabetic agents, biological activity, 957
Pyrazolidines, hydroxy- and alkoxyphenyl substituted—synthesis, evaluation of analgesic activity, 188
nonoxygenated phenyl—synthesis, analgesic activity, 235
Pyridines—as MAO inhibitors, review, 821
Pyridinium oximes—kinetic comparison of toxogonin and pralidoxime, intravenous administration, man, 1765
Pyrimidines, substituted—synthesized as potential schistosomicidal agents, biological activity, 967
Pyrolysis, menadione bisulfite to menadione—GLC analysis of menadione bisulfite addition products, thermal decomposition confirmed by differential thermal analysis and GC–mass spectroscopy, 1460
Pyruvic acid formation, isolated dog brain *in situ*—effect of lysergide and nimergoline, 348
oxidation inhibitors—synthesis of 3,4,5-trimethoxybenzamides, 1157

Q

Quality control, tablets—review of drug content, organoleptic properties, weight variation, disintegration test, mechanical strength, stability, 1511
Quaternary ammonium bactericides—interaction with cephalin, *in vivo* literature review, *in vitro* conductometric study, 390
bactericides—interaction with gliadin and gliadin–cephalin monolayers, presence and absence of protamine, 393
(+)-Quercitol—isolated and identified from *Cocculus carolinus* D.C., 1825

R

Radiolabeled chlorophenothane (*p,p'*-DDT)—distribution, excretion, rats, 1912
haloperidol—effect of volume of distribution on plasma levels, atypical profile discussed, intravenous administration, man, 1170
spirolactones—disposition, metabolism, dogs, 1132
Radiolabeling—^{14}C-pentachlorophenol excretion and tissue distribution studied in rats, 2004
—preparation of ^{14}C-mepenzolate bromide, 1663
Radiopharmaceuticals—pharmaceutical aspects, 989
Receptor sites, Ariëns' dual theory—tested, nonester antagonists prepared, evaluated for antimuscarinic activity, 470
theory—cyclopropyl rigid ring system, geometric isomers of stilbene, isolation and identification of 2-chloro-1-phenylindene, 1216
Refractometry, immersion—determination of dissolution rates, alkyl vinyl ether–maleic anhydride copolymers, 1916
Release rates, ethylcellulose and hydroxypropyl methylcellulose films—effect of thickness, composition, drying process, 412
of solid drug mixture (benzoic–salicylic acids) embedded in inert matrix—effect of alkaline solvent, equations, 1374
of solid drug mixture (sulfapyridine–sulfadiazine) embedded in inert matrix—effect of reactive solvents, equations, 1381
Renal metabolism—biotransformation of salicylic acid to salicyluric acid, renal and apparent clearances, Rhesus monkey, 1284
metabolism—contribution to biotransformation of benzoic acid to hippuric acid, contrasted with whole body, renal and apparent clearances, 1278
Repellency, insects—relationship between volatility and topical activity, 577
Reproductive systems—effects of prostaglandins on organs, labor induction, therapeutic abortion, review, 1861
Reserpine, absorption—from reserpine–polyvinylpyrrolidone coprecipitates, correlation with *in vitro* dissolution rates, rats, 400
—photooxidation products, isolation, identification of 3,4,5,6-tetradehydroreserpine, 299
Resins—preparation, capacitance, regeneration, efficacy, comparison, 960
Review Articles
Disintegration of Tablets, 1695
Drug Abuse Screening Programs: Detection Procedures, Development Costs,

Street-Sample Analysis, and Field Tests, 655
Linear Relationships between Lipophilic Character and Biological Activity of Drugs, 1
Monoamine Oxidase Inhibitors, 821
Pharmaceutical Sciences—1971: Literature Review of Pharmaceutics, 989
Photochemistry of Steroids, 321
Physiological Effects of Environmental Stimuli, 1175
Prostaglandins, 1861
Relationships between Surface Activity and Biological Activity of Drugs, 151
Some Antineoplastic Antibiotics, 485
Synthesis of Cyclic Peptides, 1345
Tableting Research and Technology, 1511
Rheological master curve—shear rate variation, spreadability of lipophilic topical preparations, 335
Riboflavin absorption after oral administration—effect of concurrent administration of anticholinergic agent (propantheline bromide), man, 798
—absorption and excretion after oral administration of riboflavin-5′-phosphate, nonlinear pharmacokinetics, rats, 404
absorption—biliary excretion, man, 143
enhanced intestinal absorption—using sodium alginate solutions, man, 279
—*in vivo* effect on boric acid toxicity, *in vitro* serum protein binding, 1081
Riboflavinuria—borate-treated rats, guinea pigs, chicks, 1081
Rising sphere rheometer—compared to falling sphere viscometer, 783
RNA, rat liver—effect of intraperitoneal administration of benzene on sucrose density sedimentation and soluble species, 465
t-RNA ***O*-methyltransferase** inhibitors—as potential antineoplastic agents, 645
Rotary tableting machine—stimulation device for preliminary tablet compression testing, 1313
Rotating-basket dissolution method—corrosion of basket, replacement of official fluids with phosphate buffer, 460
Rotenone—isolation from *Balduina angustifolia*, cytotoxic activity, 626

S

Salicylanilide ***N*-methylcarbamate**—hydrolysis, *in vitro* kinetics, *in vivo* urinary excretion, metabolites, 858
Salicylate absorption—hydrophilic ointment, 172
Salicylic acid biotransformation in man—capacity-limited formation of salicyl phenolic glucuronide, compared to computer simulations, 800
biotransformation to salicyluric acid—renal metabolism contribution, renal and apparent clearances, Rhesus monkey, 1284
in analgesic formulations—GLC analysis, 929
in aspirin formulations—GLC analysis, 1794
levels after aspirin administration—relationship between saliva and plasma concentrations, man, 1219
tablets—effect of starch excipient on dissolution rate, 239
Salicylic acid–benzoic acid ointments—colorimetric analysis, 1625
Salicylic acid–cetrimide system—effect of anionic surfactants on viscosity, 642
Salicyluric acid from salicylic acid biotransformation—renal metabolism contribution, renal and apparent clearances, Rhesus monkey, 1284
Salivary excretion—relationship between salicylic acid concentration in saliva and plasma after aspirin administration, man, 1219
Salmalia malabarica—chemical constituents of flowers, 807
Sanguidimerine, alkaloid from *Sanguinaria canadensis*—structure, 1846
Sanguinaria canadensis (Papaveraceae)—structure elucidation of sanguidimerine, 1846
Saponins—from *Yucca schottii* leaves, separation, potential anti-inflammatory agents, 1665
Schiff bases—rate of disappearance used to study kinetics of diethyl phosphonate addition to *p*-substituted benzylideneanilines, 114
Schistosomicidal agents, potential—synthesis and biological activity of pyrimidine moiety with 5-nitrothiazole or 2-imidazolidinethione, 967
agents, thiazole type—1-(5′-nitro-2′-thiazolyl)-2-imidazolidinone, structure–activity, compared to thiamine, biological studies, 1327
Schizophrenics' chlorpromazine blood distribution—disposition of free and conjugated metabolites, erythrocyte sequestration, 1753
chlorpromazine blood levels—determination of 11 nonconjugated metabolites, TLC, fluorometry, 581
sweat, malodorous component—synthesis of *trans*-3-methyl-2-hexenoic acid, 316
Scopolamine and degradation products—analysis, GLC and liquid–liquid partition chromatography, 1311
Screening programs, anti-inflammatory agents—correlation between *in vivo* carrageenin-induced edema and *in vitro* lysosomal-labilizing properties of *N*,*N*,-*N*′,*N*′-tetramethylazoformamide, rats, 1450
urine—for abuse drugs, reliability and validity of extraction and identification techniques, 305
Sea anemone—toxicology, pharmacology, 66
Sedimentation kinetics—flocculated suspensions, effect of ζ-potential, 1999
Sensory scaling procedures—ordinal, preference, ratio, 335
Serum levels, methyltestosterone—spectrophotofluorometric analysis, 1746
protein binding—erythromycin and erythromycin 2′-propionate ester, 425
protein binding to riboflavin—effect of serum dialysis against borate buffer, 1081
Sesquiterpene lactones—cytotoxicity, microplate tissue culture method, 1960
Silicas, highly dispersed—solvent effect on adsorption of ionic surfactants, 700
Silicone polymer—release of steroids, matrix-boundary diffusion layer model equations, effect of filler, 46
Silver deposits in tissue—method of determining chemical nature of salts or complexes, rabbits, 1488
Simulated coated dosage forms—free films, method and apparatus, 814
Simulation of multiple-dosing kinetics—electrical circuits, 1468
Single-pan chemical balance—used as a rheometer, Newtonian fluids and viscoelastic materials, 783
Singlet and triplet states—photochemical formation, steroids, 321
Sinoacutine—isolated and identified from *Cocculus carolinus* D.C., 1825
Skeletal muscle relaxants—pharmacology of concurrent administration of furosemide, rats, 562
Skin permeability, rabbits—effect of surfactants, water desorption rates, 1329
Snake serum and venoms (king and pit viper), radiolabeled—tissue distribution, urinary and fecal excretion, rats, 119
Sodium alginate solutions—role in promoting intestinal absorption of riboflavin, man, 279
Sodium cacodylate injections—NMR analysis, compared to NF X and atomic absorption spectrophotometry methods, 1635
Sodium fusidate, GI absorption—effect of cholestyramine, rats, 735
Sodium fusidate–cholestyramine *in vitro* binding—effects of temperature, organic and inorganic electrolytes, 730
Sodium glycocholate—micellar properties, determination of CMC, solubilization of testosterone, 1757
Sodium 1,2-naphthoquinone-4-sulfonate—oxidation of acridans, 206
Sodium nitrite—gastric absorption and metabolism, mice, 1492
Sodium warfarin tablets—additive inhibition of drug migration in wet granulations, 1121
Solid dissolution, descending model—determination of effective interfacial concentration, 1589
surface tension—graphical determination, 281
Solid-state decomposition—*p*-substituted benzoic acid derivatives, 1112
Solubility—nonelectrolytes in polar solvents, 983
of organic hydrochlorides—pH profiles, temperature dependence, species equilibrium, 1896
of small particles—importance of interfacial tension and particle size as indicated by the Kelvin equation, 479
of small particles—thermodynamic aspects, surface enthalpy and surface entropy, 478
studies, canrenone—for development of a nonprecipitating potassium canrenoate injectable solution, 717
—*N*′-substituted sulfanilamides, related to entropy of solution, 94
Solubility–diffusion coefficient–dissolution rate—relationship at constant viscosity, benzoic acid–aqueous polysorbate 80 solutions, 592
Solubilization, micelle formation—possible mechanism of gaseous anesthetic absorption, 860
—testosterone by sodium glycocholate, 1757
Solute transport—three-phase (w/o/w) system, experimental considerations, 1931
transport—three-phase (w/o/w) system, theoretical considerations, 1922
Solute–solvent complexation reactions—effects on dissolution kinetics, model tested using concentration jump technique, dissolution rates of 2-naphthol in cyclohexane or cyclohexane with additives, 695
Solvation—montmorillonite, comparison of number of layers in interlaminar spacing when equilibrated with liquid and vapor, 139
Solvent effect—adsorption of ionic surfactants on highly dispersed silicas, 700
Solvolysis—cytosine and cytidine, mechanisms, 1052
Sorbitol—GLC determination from aqueous solutions, 1831
irrigating solutions—GLC determination, compared to USP XVIII column chromatographic method, 103
Sorption, intestinal—anisotropine methylbromide, rats, 1223
Sorption–desorption equilibrium and kinetics—hexachlorophene on human epidermis, 1102
Spasmolytic activity—1-methyl-4[4-(7-chloro - 4 - quinolylamino)benzoyl]piperazine on guinea pig ileum, 482
Spectrophotofluorometry—analysis, 4,5-bis-(*p* - methoxyphenyl) - 2 - phenylpyrrole-3-acetonitrile in plasma, 1908
—analysis, ethinyl estradiol tablets, Liebermann–Burchard reaction, 1306
—analysis, methyltestosterone in plasma or serum, 1746
—analysis, mycophenolic acid and glucuronide in plasma, 1750
—analysis, spirolactones, 1129, 1132
—analysis, spironolactone, canrenone, potassium canrenoate, and metabolites in biological fluids, 1126
—analysis, warfarin and 4-hydroxycoumarin, 749
—determination of griseofulvin in plasma and sweat, 634
—determination of MAO activity, cinnamides, 78
—pamaquine fluorescence, acidity dependence, 1576
Spectrophotometric titration—analysis of sulfonamides and sulfanilic acid, 779
Spectrophotometry—determination of microdissociation constants, two methods for analysis of data, 232
Spheronization—preparation of spherical particles for tablet compression, compared to conventional wet granulation method, 1466
Spheronized materials—compared to nonpareil beadlets and conventionally produced granulation, 787
Spiroamine alkaloids—isolated, identified from *Erythrina variegata*, 1274
Spirolactones, fluorescent and tritium labeled—disposition, metabolism, dogs, 1132
—plasma levels after intravenous ad-

ministration, fluorometric analysis, dogs, 1129
Spironolactone, fluorescent and tritium labeled—disposition, metabolism, dogs, 1132
—fluorometric analysis, biological fluids, 1126
—plasma levels after intravenous administration, fluorometric analysis, dogs, 1129
pretreatment—effects on aniline and hexobarbital metabolism, liver homogenates, male rats, 296
Spreadability of lipophilic topical preparations—sensory tests, rheology, 335
Stability of liquid petrolatum–water emulsions—age effect, 769
pharmaceutical preparations—design of nonprecipitating potassium canrenoate solution, 717
Starch as tablet disintegrant—effect of moisture and pressure on starch grain deformation, 455
various, in salicylic acid tablets—effect on dissolution rate, 239
Stereochemistry of 4,4-disubstituted 1,2,3,4-tetrahydro-2-naphthoic acids—determination, NMR spectroscopy, 1231
Sterility of ophthalmic ointments—survey of commercial preparations, 532
Sterilization by ethylene oxide—determination of residues in polymethacrylate powders, 1801
techniques—evaluation of methods used for manufacturing various topical dosage forms, effect on formulation, 1078
Steroid–dialkylpropionamide complexes—structural requirements for formation, 649
Steroidogenesis activity—49 classes of therapeutic agents, 1556
Steroids, conjugated keto—identification *via* lithium borohydride reduction in tetrahydrofuran, differential UV determination, 148
C-17-dihydroxyacetone side chain—deuterium isotope effect on aqueous degradation of hydrocortisone, 918
—factors affecting release from silicone polymer, effects of steroid structure, 46
—photochemistry, review, 321
***trans*-Stilbene** reaction with sodium trichloroacetate—isolation, PMR identification of 2-chloro-1-phenylindene, 1216
Stoichactin—identification and pharmacological studies as an antitumor agent, mice, 1814
Stoichactis kenti—isolation and purification of stoichactin, a potent antitumor agent, pharmacological testing, mice, 1814
Stomach emptying pattern—relationship to aminopyrine plasma level enhancement by barbital, rabbits, 945
Streptococci, oral—mechanism of antibacterial sulfonamides, 142
Streptococcus faecalis electrophoretic mobility—effect of nature, ionic strength, and pH of buffer solutions, 182
—growth inhibition by cetyltrimethylammonium bromide, 762
Streptonigrin—use in cancer chemotherapy, 485
Streptozotocin—use in cancer chemotherapy, 485
Stress reaction—relationship to environmental stimuli, 1175
Structure of molecules—prediction of sweetness, 1394
Structure–activity relationships—cinnamides, MAO inhibition, 78
—diastereoisomers of 5-substituted decahydroisoquinolines, 637
—dicinnamides and hypocholesterolemic activity, 610
—2 - diphenylmethylene - 1 - acyl - 1-alkyl hydrazines as potential psychotropic agents, 1571
drugs—suggested thermodynamic standard state for comparison, 816
—effect of alkyl chain length on membrane diffusion, *p*-aminobenzoate esters, 838
—effect of alkyl chain length on physicochemical and crystalline properties, *p*-aminobenzoate esters, 852
—free base and salts of an experimental antihypertensive, 1418
—heterocyclic thione metal-binding ability, correlated to antibacterial activity, 1209
—hypothesis for binding of CNS drugs to proteins, 1717
—lipophilicity and anesthetic activity, aliphatic ethers, 589
—methoxylated amphetamines, 480
—nonoxygenated phenylpyrazolidines, 235
—pyruvic acid oxidation inhibitors with anticonvulsant activity, 1157
quaternary salts of hydroxyiminomethylimidazoles—reactivators of organophosphorus-inhibited acetylcholinesterase, 631
—sesquiterpene lactones as antitumor agents, 626, 629
—sulfonamides, 872
—thiouracil–metal complexes, correlations among complex stability, thiouracil structure, and biological activity, 1241
—volatility and topical insect repellency, 577
Structure–toxicity relationships—substituted phenothiazine derivatives, goldfish test system data correlated with dodecane partition coefficients, 1498
Subcutaneous absorption—local anesthetic amines, pH control in the absorption cell, 1263
Succinic acid—amphetamine sulfate salt formation, determination of isomeric composition, 1976
Succinic semialdehyde—pharmacology, 1963
Succinylcholine administered concurrently with furosemide—effect on diuresis and skeletal muscle relaxation, rats, 562
Sucrose density patterns—effect of benzene on RNA *in vitro*, 465
Sulfa drug formulations dissolution—corrosion of rotating basket, proposed use of phosphate buffer, 460
drugs—crystallography, relationship to biological activity, 872
drugs—separation, high speed liquid chromatography, 254
Sulfadiazine—solubility in normal alcohols, function of entropy of solution, 94
Sulfadiazine-containing agar medium—growth of oral streptococci, 142
Sulfadimethoxine—crystallography, relationship to biological activity, 872
—solubility in normal alcohols, function of entropy of solution, 94
Sulfadoxine—crystallography, relationship to biological activity, 872
Sulfameter polymorphs—GI absorption, man, related to dissolution rates, 1615
Sulfamethazine—blood level–time relationships after intravenous administration, pharmacokinetic parameters, rate constants, rabbits, 518
Sulfamethizole tablets—comparison of bioavailability parameters with dissolution rates, 746
Sulfamethoxazole tablet dissolution—corrosion of rotating basket, proposed use of phosphate buffer, 460
Sulfanilamides—conformational stabilization by *o*-methyl groups, NMR, PMR spectroscopy, 1670
—correlations between *in vitro* transport in three-phase model cell and *in vivo* absorption, 1656
Sulfanilic acid—blood level–time relationships after intravenous administration, pharmacokinetic parameters, rate constants, rabbits, 524
sulfonamides—determined by spectrophotometric titration using bromate–bromide solution, comparison with official method, 779
Sulfapyridine–sulfadiazine mixture—release from inert matrix, solvent effects, equations, 1381
Sulfathiazole—blood level–time relationships after intravenous administration, pharmacokinetic parameters, rate constants, rabbts, 518
dissolution—*in vivo* inhibition by water-soluble dye, man, 1857
form I—quantitative method for determining form I in presence of form II, kinetics of polymorphic transformation, differential scanning calorimetry, 1318
Sulfisomidine—blood level–time relationships after intravenous administration, pharmacokinetic parameters, rate constants, rabbits, 518
—solubility in normal alcohols, function of entropy of solution, 94
Sulfisoxazole—crystallography, relationship to biological activity, 872
—pharmacokinetic parameters following intravenous, intramuscular, and oral administration, man, 773
tablet dissolution—corrosion of rotating basket, proposed use of phosphate buffer, 460
Sulfite addition—aqueous solutions of dexamethasone phosphate, kinetics, 708
Sulfonamides—antibacterial mechanism, 142
—characterization by TLC, using metal ions, 277
containing primary aromatic amine—analysis, 9-chloroacridine, quenching fluorometry, 432
—crystallography, relationship to biological activity, 972
—NMR identification, classification scheme, 434
—separation, high speed liquid chromatography, 254
—studied for polymorphism, correlation of frequency of occurrence with chemical structure, X-ray diffraction patterns compared to IR spectra, entropy and enthalpy comparisons, 26
sulfanilic acid—determined by spectrophotometric titration using bromate–bromide solution, comparison with official method, 779
Sulfonylureas—binding to human serum proteins, relationship between inhibition and hypoglycemia potentiation, 89
—thermal dissociation in alcohols, water, and amines, mechanism, 602
Sulthiame—GLC analysis in plasma, 1252
Surface activity–biological activity relationships—at air/water or monolayer/water interfaces, review, 151
adsorption — montmorilionite – diazepam bonding, ion–dipole interaction hypothesized, 420
area—effect on dissolution rate, antacids, Myhill–Piper equation, 2009
tension measurement—automated drop volume apparatus, 781
tension method—determination of CMC for polysorbate 20, 1334
tension, solids—graphical determination, *m*-acetotoluide, 281
Surfactants, anionic—effect on salicylic acid–cetrimide system viscosity, 642
—determination of CMC using diffusion potential measurements (liquid junction), 639
effect—absorption of gaseous anesthetics, 860
effect, nonionic—hydrocortisone dissolution, 1732
—effect on epidermal permeability in rabbits, water desorption rates, 1329
—effect on tablet disintegration, 1695
—formation of spherical micelles, 651
in the micellar state—calculation of partial molal volume, 793
ionic, adsorption on silicas—solvent effect, 700
long chain—interaction with phospholipid monolayers, kinetics, mechanisms, 1720
Suspensions, coarse—stability, physical properties, structure-controlling factors, 268
Sweetness of molecules—molecular theory, three structural features, 1394
Synephrine—identified in seven Coryphantha species, 41

T

Tablet compression—preliminary testing, simulation of double-acting compression cycle of a rotary tableting machine, 1313
disintegrants—mechanism of action, correlation of tablet mean pore diameter and porosity, 303
disintegration—effect of starch grain deformation on mechanism of action, 455
disintegration—uncoated tablets designed for rapid release, review, 1695
dissolution, aspirin—buffering agent effect, 1370
formulations—effect of moisture on direct compression excipients, 939
granulations—spheronization method compared to conventional wet granulation, hardness, disintegration times, 1466

lubricants—evaluation of magnesium lauryl sulfate, 984
Tableting research and technology—review, 1511
Tablets and capsules—magnetic basket dissolution apparatus and method, 1152
containing dyes—rapid determination of color stability, 1811
content uniformity—migration during drying of water-soluble drug in wet granulations, evaluation of additive inhibitors, 1121
enteric coated, erythromycin—GLC analysis, 1633
film coated—elimination of tackiness in polyvinylpyrrolidone coatings, 265
Tannins—found responsible for antitumor activity in certain plants, 1818
Taraxerol—TLC isolation, IR identification from *Euphorbia myrsinitis*, 292
Tauraminopyridine and nicotinyl derivative—biopharmaceutical studies, rabbits, rats, 884
Taurinophenetidine—effect on erythrocytolysis and methemoglobin production, plasma levels in rabbits, 1791
Taurinopiperidine—blood levels, distribution, and excretion in animals, pharmacological activity, 198
^{99m}Technetium—binding to human serum albumins, effect of variations in albumin, dialysis and gel filtration, 1667
Technology, pharmaceutical—sterility, dosage forms packaging equipment, 989
Temperature effect—solubility of two amine hydrochlorides, 1896
Tensile strength, bulk solids—effect of moisture on fine particle-size materials with varying inherent coherence, 342
bulk solids—effect of moisture on variable particle-size sodium chloride, 256
Teratogenicity—phthalates, rats, 51
Testosterone—solubilization by sodium glycocholate, 1757
Tetracycline base or hydrochloride—column chromatographic analysis for tetracycline and impurities, evaluated as potential compendial method, 615
3,4,5,6-Tetradehydroreserpine — isolation, identification as final product of reserpine photooxidation, 299
Tetrahydroalstonine—effect on blood glucose and carrageenin-induced pedal edema, compared to nonsteroid anti-inflammatory drugs and tolbutamide, rats, 1202
Tetrahydrocannabinols—photoreactions, 1994
—stability in various solvents, biological evaluation of formulations for long-term oral and parenteral administration, vehicle toxicity, 1106
Tetrahydrocannabivarin—GLC and mass spectroscopic identification as constituent of *Cannabis sativa*, 1476
1,2,3,4-Tetrahydro-2-naphthoic acids, 4,4-disubstituted—synthesis, stereochemistry, 1231
Tetralins, substituted—synthesis, stereochemistry of 4,4-disubstituted 1,2,3,4-tetrahydro-2-naphthoic acids, 1231
***N,N,N′,N′*-Tetramethylazoformamide** lysosomal-labilizing properties—effect of anti-inflammatory agents, screening program, rats, 1450
***meso*-Tetraphenylporphine**, derivatives—preparation, purification, 307
Textural profile of topical preparations—sensory tests, rheology, 335
Thalictrum cytotoxic alkaloids, synthetic precursor—synthesis of 9-(3,4-dimethoxyphenoxy) - 1,2,10 - trimethoxyaporphine, 1481
Thalictrum polygamum—isolation and identification of *N*-methylpalaudinium, 295
Theophylline—polymorphic phase transition parameters determined from intrinsic dissolution rates, 868
Theophylline–acetaminophen complexes—isolation, solubility, dissolution rates, stability constants, 1454
Thermal microscopy, visual—determination, phase transitions in mixtures of cholesteryl esters, 1762
Thermodynamics analysis—suggested standard state for comparing drug molecules in structure–activity studies, 816
solution—solubilities of sulfadiazine, sulfisomidine, sulfadimethoxine, 94
Thermogravimetric analysis—diffusivity and solubility of aliphatic alcohols in polyurethan films, 1094
Thiamine—effect on oral administration of 1 - (5′ - nitro - 2′ - thiazolyl) - 2 - imidazolidinone, structure relationships, 1327
Thiazole-type schistosomicidal agents—1-(5′ - nitro - 2′ - thiazolyl) - 2 - imidazolidinone, structure–activity, compared to thiamine, biological studies, 1327
Thiocarbohydrazide-1,5-dicarboxylic acid diesters—synthesis, evaluation of antimicrobial activity, 1486
Thiones, heterocyclic—metal-binding constants, correlated to antibacterial activity, 1209
Thiouracil–metal complexes—polarography, correlations among complex stabilities, thiouracil structures, and biological activities, 1241
Thixotropy measurements—using a weight-actuated viscometric method, bentonite magmas measured, concentration and shelflife effects, 1848
Three-phase (water-oil-water) system—solute transport, experimental considerations, 1931
(water-oil-water) system—solute transport, theoretical considerations, 1922
Timed-release dosage forms, ophthalmic—pilocarpine alginate flakes, compared to pilocarpine hydrochloride solutions, 985
films—*in vitro* release rates, effect of thickness, composition, drying process, 412
formulations, amobarbital–dextroamphetamine sulfate—separation and analysis, 101
lipase–lipid–sulfamethizole tablets—effect of lipase, blood levels, dogs, 900
Tissue distribution—radiolabeled chlorophenothane, rats, 1912
levels, methylene blue—intravenous administration, rats, 1090
Titration, spectrophotometric—analysis of sulfonamides and sulfanilic acid, 779
Titrimetry—assay of amine salt official injections with *p*-naphtholbenzein, compared to potentiometric method, 448
TLC—analysis, drug abuse screening programs, review, analysis of street samples and field tests, 655
—characterization of 15 sulfonamides using metal ions, 277
—evaluation of additives for inhibition of sodium warfarin migration in wet granulations, 1121
—fluorescent scanning analysis of 9-acridine derivatives, 1659
—identification, deamination products of cytosine and cytidine, 1052
—identification, narcotics, barbiturates, and CNS stimulants, drug abuse urine screening program, 679
—isolation, 318
—isolation, identification, 314, 386
—isolation of reserpine photooxidation products, 299
—prostaglandins, review, 1861
—separation, 581
—separation, erythromycins, 430
—separation, identification of coumarin anticoagulants, 1303
—separation of *p*-hydroxyphenoxyacetic acid from phenoxymethyl penicillin fermentations, 933
Tolbutamide and related sulfonylureas—thermal dissociation in alcohols, water, and amines, mechanism, 602
—effect on blood glucose and carrageenin-induced pedal edema, compared to nonsteroid anti-inflammatory drugs and tetrahydroalstonine, rats, 1202
tablet dissolution—use of phosphate buffer in rotating-basket method, 460
Toluic acids—application of partition coefficients to buccal absorption, 1785
Topical dosage forms—evaluation of commercial sterilizing techniques, effect of sterilization techniques on various dosage forms, 1078
drug availability—thermodynamic control, 61
formulations—spreadability, rheological conditions, 335
Toxicity, acute—(±)-2-(*N*-ethylpropylamino)-2′,6′-butyroxylidide, 1829
—*C. polypus* (sea anemone), 66
—chloroacetaldehyde, compared to ethylene chlorohydrin, 19
—commercial mannide monooleate formulation, 863
drugs—dose–plateau levels relationship, elimination kinetics, 541
profile—epichlorohydrin, 1712
vehicle—stability of marijuana constituents in various solvents, biological evaluation of formulations for long-term oral and parenteral administration to laboratory animals, 1106
Toxicological activity of drugs—effects of binding, hepatic drug-metabolizing enzymes, formation of active metabolites, 1682
Toxicology—silver deposits in tissue after dermal application of silver-containing pharmaceuticals, method to determine chemical nature of deposits, rabbits, 1488
Toxogonin–pralidoxime—kinetic comparison after intravenous administration, man, 1765
Transformation kinetics—sulfathiazole form I and form II, quantitative differential scanning calorimetric method, 1318
Transmission (water vapor) through plasticized cellulose films—effects of environment and hydroxypropyl methylcellulose–ethylcellulose ratio, 1956
Transport kinetics—interface controlled, sterols across oil/water interface in ionic surfactant systems, 375
numbers—determined using diffusion potential measurements (liquid junction), surfactants, 639
of solutes—three-phase (w/o/w) system, experimental considerations, 1931
of solutes—three-phase (w/o/w) system, theoretical considerations, 1922
1,2,4-Trialkyl-4-aryl piperidazines—synthesis, screened for analgesic activity, 1781
Tricyclic amine antidepressants—ion-pair extraction, functional group contribution to ion-pair extraction, linear free energy relationships, 1967
2,3,5-Triiodobenzoic acid—microbial degradation in soil, identification of metabolites, 804
3,4,5-Trimethoxybenzamides, substituted—synthesized as pyruvic acid oxidation inhibitors, correlated with anticonvulsant structure–activity relationships, 1157
2 - Trimethylammoniumbicyclo[2.2.1]heptane iodides—synthesized and screened for muscarinic activity, 1640
2 - Trimethylammonium - 7 - oxabicyclo-[2.2.1]heptane iodide epoxides—synthesized and screened for muscarinic activity, 1640
***N*-Trimethylsilylimidazole**—silylating reagent for rapid GLC analysis of halogenated 8-hydroxyquinolines, 1147
Tropic acid—biosynthesis in *Datura innoxia* root tissue, studied using various radiolabeled precursors, 2006
Tubocurarine administered concurrently with furosemide—effect on diuresis and skeletal muscle relaxation, rats, 562
Tubular carbon electrode—oxidative analysis, ascorbic acid in multivitamin preparations, 1301
Turbidimetric assay—nitrofuran compounds, in urine and serum, using *S. faecalis* as test organism, 462
microbiological assay—automated readout system, 449
Two-compartment open model—effect of changes in elimination on pharmacokinetic parameters, 1270
Tybamate—internal standard for GLC analysis of meprobamate, carisoprodol, and mebutamate, 1974

U

Ultracentrifugation—determination of stability of liquid petrolatum–water emulsions, 769
Ultrasonication—effect on physicochemical and pharmacological properties of chymotrypsin, 352
Ultrasound—effect on mineral oil–surfactant–water emulsions, HLB, surfactant, and power parameters, 1567
Urinary excretion—disopyramide phosphate biotransformation, rat, dog, man, 888
excretion—hydrolysis of salicylanilide and 4-biphenylyl *N*-methylcarbamates, metabolites, 858

excretion—pralidoxime methanesulfonate after oral administration, man, 1136
excretion rates—sulfisoxazole following intravenous, intramuscular, and oral administration, man, 773
excretion, riboflavin—effect of boric acid administration, 1081
kinetics, fenoprofen—compared to plasma kinetics, major metabolites identified, man, 739
metabolites—guaiacol glyceryl ether mononicotinate, man, 1212
UV irradiation—steroids, rearrangement, addition, reduction, and oxidation reactions, 321
UV spectrophotometry—analysis, amobarbital and dextroamphetamine in combination, 101
—analysis, biguanides in urine, ion-pair formation, 1404
—analysis, ethchlorvynol, 169
—analysis, homatropine methylbromide, Dragendorff reagent complex, 1630
—analysis, methadone *via* oxidation to benzophenone, 1397
—analysis, methyl *p*-hydroxybenzoate, compared to compendial method, 252
—assay, methylene blue and leucomethylene blue in blood, urine, tissue, 598
—characterization of mineral oils, 1292
—determination of phenolic compounds after reaction with 1-nitroso-2-naphthol, 146
differential—determination of conjugated ketosteroids *via* lithium borohydride reduction, 148
—monitoring, cytosine and cytidine deamination, 1052

V

Vagosympathetic pressor reflex—response to central vagal stimulation, sympathetic efferents *versus* vagal afferents, dogs, 1507
Vasodilation, nitroglycerin—enzyme induction, rabbits, mice, 1267
Vessels for dissolution testing—effect of shape (concavity) on dissolution rates, compendial vessels, modified vessel, 1638
(−)-viburnitol—isolated and identified from *Cocculus carolinus* D.C., 1825
Viscometry—weight-actuated viscometric method proposed for thixotropic measurements, bentonite magmas measured, 1848
Viscosity effect—enhanced riboflavin absorption using sodium alginate solutions, man, 279
—effect on dissolution rate in micellar solutions, 175
of Newtonian fluids—determined using a single-pan chemical balance, 783
—role of anionic surfactants in salicylic acid–cetrimide system, 642
—weight-actuated viscometer, used for thixotropic measurements of bentonite magmas, 1848
Voltammetry, glassy carbon electrode—stability-indicating analysis, acetaminophen dosage forms, 1627
Volume of distribution, apparent—considerations relative to drug distribution and elimination relationship in multicompartment systems, 952
—effect on plasma levels of total radioactivity, intravenous haloperidol-^{3}H, man, 1170
—review of definitions and interrelationships of various terms, 1765

W

Warfarin—pH and Hammett acidity dependence of fluorescent spectra, phototautomerism, 749
Warfarin–phenylbutazone binding—studied using fluorescent probe technique, binding constants, proposed mechanism, 1835
Water absorption, rat intestine—effect on drug absorption profiles, 110
vapor transmission—free polymer films, factors involved, 1645
Waxy solids, encapsulation by complex coacervation—stearyl alcohol in gelatin–acacia system, effect of colloid concentration and particle size, 1586
Wet granulations—inhibition of water-soluble drug migration, evaluation of additives, 1121

X

Xanthalin—isolated from *Peucedanum arenarium*, 1643
Xanthine oxidase—inhibition by 3-hydroxy-1 - nitrophenyl - 1*H* - pyrazolo[4,3 - *c*]-pyridines, 179
Xanthones from *Canscora decussata*—pharmacological studies, 1838
X-ray crystallography—characterization of drug–excipient binding, 1435
—sulfonamides, structure–activity relationships, 872

Y

Yucca schottii (Liliaceae)—phytochemical investigation, saponin fraction constituents, potential anti-inflammatory agents, 1665

Z

Zeta-potential—effect on sedimentation kinetics of flocculated suspensions, 1999
of *S. faecalis*—effect of cetyltrimethylammonium, 762